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Abstract 
 
Background 
 
Parasitic infection is one of the major causes of human diseases and distress in most 
tropical countries in the world.  Among the most common parasitic infections worldwide are 
Soil-Transmitted Helminthiasis (STHs) infections, transmitted by eggs that are present in 
human feces which contaminate the soil in areas where sanitation is poorly practiced. The 
World Health Organization (WHO) has classified STH infections as Neglected Tropical 
Diseases (NTDs), for not being prioritized in terms of investment or research funding for 
greater control or treatment, despite the health and economic impact of the disease to 
people living in less developed or developing countries.   
 
Parasitic diseases are predominant in the Philippines, a tropical country in Southeast Asia in 
the Western Pacific Ocean.  In 2009, a very high prevalence of STH infections, wherein 
38.6% for A. Lumbricoides, 38.5% for T. Trichiura and 3.8% for Necator americanus, was 
reported among pupils examined in selected endemic Local Government Units (LGUs) of the 
country.   
 
Although a number of economic evaluations of helminth control have been conducted in 
various parts of the world, none has been done for the Philippines.  Evaluations of 
interventions in neighboring countries show that these constitute low treatment costs, but 
they are not comprehensive in that cost-effectiveness was not estimated and some did not 
consider the economic or opportunity costs of delivering the programme.   Where full 
evaluations have been undertaken, it was found out that the mass treatment strategy was 
more cost-effective compared to no control and targeted treatment strategies.  However, 
such findings are sensitive to coverage achieved by mass treatment which was found to be 
typically low in the Philippines. In addition, a multi-parasite infection control is also preferred 
since it can present efficiency and cost-effectiveness benefits especially in areas where 
different parasitic infections are co-endemic.   
 
It should also be noted that costs and effectiveness of intervention can differ even within a 
country, making it improbable to have a universally applicable single estimate of cost-
effectiveness.  This intra-country (i.e., subregional) variations may occur for several reasons 
such as differences in relative costs of inputs, technical efficiency, and factors associated 
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with economies of scale as well as differences with respect to the demography and 
epidemiology of disease, availability of health care resources and system of health care 
delivery.  With this intra-country variation of costs and cost-effectiveness, helminth control 
policies that vary subnationally may likely be more effective and efficient than a blanket 
national policy.    
 
Objectives 
 
The general objective of this research is to conduct a cost-effectiveness analysis of multi-
parasite control strategies for the Philippines, and then identify the strategy option that gives 
the best value for money. Specifically, this research has the following detailed objectives: 
 
1. To determine the financial and economic costs associated with each of the 
competing control strategies; 
2. To estimate the health outcomes of each of the competing control strategies looking 
at Disability Adjusted Life Years (DALYs) averted and number of infections and 
reinfections averted; 
3. To estimate the cost-effectiveness of each of the competing parasite control 
strategies in the Philippines, with uncertainty from parameters included; 
4. To establish the optimal parasite control strategy in terms of frequency (i.e., annual 
vs. biannual) and mode of delivery (i.e., mass vs. targeted) and identify whether this 
varies subnationally or among the three island groups: Luzon, Visayas, and 
Mindanao; and  
5. To establish whether a blanket national policy is more efficient relative to a multi-
regional/subnational tailored helminth control strategy in the Philippines. 
 
Methods 
 
A comprehensive literature review relating to economic evaluation of intervention strategies 
to control parasitic diseases (i.e., STH and schistosomiasis) was conducted to assess their 
value and usefulness in guiding programme managers and policymakers choose which 
among the competing intervention strategies has the best value for the money.  These 
studies have also been critiqued in terms of their significance to equip future researchers 
with a deeper understanding of the economics of controlling these parasitic diseases.  In the 
process, some key economic evaluation factors and good practice guidelines in conducting 
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economic evaluation have been considered. 
 
This research involved the standard techniques of cost-effectiveness analysis, and the main 
outcome measures are considered as the cost per DALYs averted and cost per number of 
infections and reinfections averted.  Primary cost data collected from a multi-level sources 
given the country’s devolved setting, and secondary data or estimates based on different 
assumptions, to estimate scaled-up cost of a round of mass treatment and to predict costs 
for the other intervention strategies were used.  
 
To estimate the respective DALYs (i.e., YLLs and YLDs) caused by a particular STH 
infection for each intervention strategy,  a simple spreadsheet was developed incorporating 
the findings from relevant studies such as the disability weights from the Global Burden of 
Disease (GBD) study as assumptions. 
 
This study has worked with a complimentary research group who has produced estimates of 
the predicted prevalence of STH infections in the Philippines by subnational levels (i.e., 
Luzon, Visayas, Mindanao).  The research group has utilized a metapopulation model that 
simulated the impact of STH to different control strategies (i.e., combination in terms of 
frequency and mode of delivery) over a 10-year period, taking into account the initial 
prevalence of infection, the corresponding cure efficacies of the albendazole to the different 
STH infections, and the transmission dynamics of infection. Through a mathematical 
simulation model, the group estimated the impact of the following treatment strategies, which 
have been evaluated in this study, to examine their cost-effectiveness acceptability in the 
country: 
 
1. Mass or community-wide and annual drugs (MA) treatment,  
2. Targeted and annual drugs (TA) treatment , 
3. Mass or community-wide and biannual drugs (MB) treatment, and 
4. Targeted and biannual drugs (TB) treatment. 
 
These 4 strategies were selected after consultations with the Philippine’s Department of 
Health as being relevant options to the delivery of the national programme. 
 
An economic decision model was developed to evaluate the expected cost-effectiveness 
acceptability of the four treatment strategies. The generated Incremental Cost-Effectiveness 
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Ratios (ICER) over a 10-year period for each strategy were compared with the country’s 
Willingness To Pay thresholds. The World Health Organization (WHO) recommended the 
use of GDP per capita of a country as threshold to determine the cost-effectiveness of a 
particular programme intervention.  A programme is considered higly cost-effective when its 
ICER is less than current GDP per capita; cost-effective when the ICER is between 1 to 3 
times current GDP per capita; and not cost-effective if it exceeds 3 times current GDP per 
capita.  This study has utilized two Willingness-To-Pay (WTP) thresholds – the country’s 
GDP per capita (estimated to be at $2,135) and the total expenditure on health per capita 
(estimated to be at $202), the latter being a stringent criterion. The uncertainty of model 
input parameters was examined in scenario analyses and probabilistic sensitivity analyses, 
wherein the random results have been simulated for 1,000 trials from which the mean value 
of each parameter has been determined.   
 
Results 
 
The devolved set-up of the country’s health system has a large impact in the delivery and 
implementation of the programme.  The Local Government Units, LGUs (i.e., provincial, city, 
municipality) have been operating under different budgets, socio-economic status and social 
services capacity, not to mention how local chief executives prioritize funding of competing 
social services, thus the delivery of intervention programmes have been constrained.  Such 
issues are evident in the limited involvement of some LGUs to the various phases or aspects 
of the programme implementation.  
 
Most of the non-financial or imputed costs came from the lower level of 
administration/government (i.e., city/municipality).  In terms of financial costs, ‘programme 
running’ category has the largest cost proportion amongst the five financial cost categories 
for the 3 island groups.  The 3 island groups, however, have different order or sequence of 
cost proportions for the remaining cost categories (i.e., community sensitization and 
screening, training, drug distribution and treatment, and production and distribution of IEC 
materials). Such result could be because both Visayas and Mindanao have different physical 
characteristics from Luzon in terms of road conditions, community and population densities, 
availability of ethnolinguistic groups in the area, as well as distance from the DOH central 
office.  Moreover, the variations in costs among the different levels of government that have 
been observed across the 3 island groups reflect the extent of responsibilities that each LGU 
health office unit has in the programme implementation. 
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Results of the predicted costs for the four intervention strategies showed that MB treatment 
strategy was the most ‘expensive’, while TA treatment strategy, the least ‘expensive.  Non-
financial or imputed costs remained to be substantial when we examined the total economic 
cost of delivering the intervention programmes. 
 
Lastly, the total cost per person treated was lowest in TA treatment with national level values 
of $0.97 compared to $1.83, $1.16, and $1.53 for MB, MA, and TB treatment strategies, 
respectively.  The order or pattern of the strategies remains the same even if only the 
financial costs have been considered.  This result holds true also at the subnational level. 
 
The estimated health outcome measures (i.e., DALYs averted and number of infections and 
reinfections averted) and health outcome measure per person treated showed similar 
patterns both at the national and at the subnational levels.  TA treatment strategy had the 
lowest DALYs averted, followed by TB and MA treatment strategies, respectively.  MB 
treatment had the highest health benefits.  The same sequence or pattern was also 
observed when the number of infections and reinfections averted was examined. 
 
Economic evaluation results show that TB treatment strategy is considered dominated for 
being both more costly and less effective than MA treatment.  This pattern is true when we 
look at DALYs averted and number of infections and reinfections averted both at the national 
and the subnational levels.  The intra-country variation of cost and effectiveness for each of 
the treatment options is also manifested from the CEA summary results, wherein Mindanao, 
being the farthest to the DOH Central office (which is situated in Luzon), has the most costly 
(highest) CE ratio, 50%-61% higher than that of Luzon for all the treatment interventions. 
Visayas recorded a slightly lower percentage increase of 52%-54% from that of Luzon 
across the intervention strategies. 
 
Considering the country’s WTP thresholds (i.e., GDP per capita of $2,135 and the total 
expenditure on health per capita of $202) or threshold ICERs, all the undominated options 
turned out to be below the country’s WTP thresholds allowing them to be considered as CE 
acceptable.  In such scenario, it would be practical and logical to select among the CE 
acceptable strategies the one that gives the highest health benefit. Probability Sensitivity 
Analyses that were carried out show that MB treatment has the highest probability on both 
thresholds (i.e., GDP per capital and total expenditure on health per capita) with 65.6% and 
58.9%, respectively.  This is followed by the MA treatment with just 21.9% and 27.4%, and 
  
Garcia, Fernando Jr., n8415790, School of Public Health and Social Work, QUT Page viii 
 
 
 
TA treatment 0.7% and 1.4%, all probabilities in the same order of threshold level.  This 
clearly suggests that MB treatment would be chosen for having the optimal benefit given the 
country’s threshold considerations. The pattern for choosing the MB treatment over the other 
strategies is the same for all the island groups as well as on both outcome measures. 
 
Conclusions 
 
This thesis adds to the current body of knowledge on economic evaluation of disease 
intervention strategies from the perspective of the healthcare provider.  It is believed to be 
one of the pioneer studies involving decision modeling technique in conducting full economic 
evaluation of multi-parasite control strategies for the Philippines.  Findings such as cost per 
person treated and cost per DALYs averted have shown to be generalizable to other 
settings.  The methods and data collection tool used in this research have been patterned 
with the standards and practices identified in published literature.  It is believed that a 
number of the processes used in this research can be applied to evaluate other parasitic 
diseases, such as schistosomiasis, looking at similar control programs. 
 
The results of this research are expected to guide the country’s health policy and decision-
makers to efficiently allocate scarce health resources and come up with a solid basis for a 
parasite control policy in the Philippines.  Moreover, this research opens up both opportunity 
and challenge for the country’s health sector, both at the national and local levels, to revisit 
and asses how programme planning and health intervention priorities are being done. The 
devolved set-up of health services in the country should further warrant the use of CEA in 
setting priorities. Adopting more test-proven systems to evaluate the cost effectiveness of 
programmes and strategies would give more health benefits for every money and resources 
spent by the government. 
 
The findings that MB treatment is the optimal choice have proven to be robust to decision 
uncertainty after subjecting them to some probability sensitivity analysis and consideration of 
financial versus economic costs.  Moreover, the findings turned out to be stable across a 
wide range of willingness to pay thresholds (i.e., the country’s GDP per capita and Total 
expenditure on health per capita).  This suggests, therefore, that there is a high level of 
confidence in the decision to choose MB treatment as the optimal strategy with the best 
value for money.  And since the findings are also stable across the country’s island groups, a 
blanket national strategy is the most appropriate for the Philippines. 
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CHAPTER I.   INTRODUCTION 
 
This chapter starts with a general overview of the disease that this research has examined 
(1.1). The rationale of the study (1.2) as well as the research objectives (1.3) are then 
presented, followed by the study’s major areas of contribution (1.4) and thesis outline (1.5). 
 
 
1.1. Overview 
 
Parasitic infection is  one of the major causes of human diseases and distress in most 
tropical countries in the world.  It is estimated that one out of four individuals harbors 
parasitic worms(1).  Among the most common parasitic infections worldwide are Soil-
Transmitted Helminthiasis (STHs) infections, transmitted by eggs that are present in human 
feces which contaminate the soil in areas where sanitation is poorly practiced.  The World 
Health Organization (WHO) has classified STH infections as Neglected Tropical Diseases 
(NTDs) for not being prioritized in terms of investment or research funding for greater control 
or treatment despite the health and economic impact of the disease to people living in less 
developed or developing countries.  Though there are already available preventive 
measures or acute medical treatments for them, such are still not universally accessible in 
many low-income developing countries where funding is needed to sustain treatment, 
making these diseases truly diseases of the poor(2). 
 
STHs, commonly known as intestinal worm infections, are caused by any of the following:  
roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura) and the anthropophilic 
hookworms (Ancylostoma duodenale and Necator americanus).  Aggravated by 
unhygienichealth practices, lack of sanitation facilities, poor living conditions, and meager 
access to health services, people living in the most deprived communities and countries are 
hit the hardest by the burden of these parasitic diseases(3-5).  The greatest at risk of morbidity 
due to these worm infections are children due to the debilitating effect of the disease to their 
physical and cognitive well being such as anemia, malnutrition, stunted growth, and learning 
development delays(6). Children belonging to the age groups 5 – 14 years carrying the 
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greatest risk of morbidity comprise almost half of the global disease burden of STH 
infections(7).  Moreover, it is even estimated that a third of the world’s population is infected 
with STHs(6), making it the most widespread and disabling chronic infections as well as the 
most common among the NTDs(8). 
 
Parasitic diseases are predominant in the Philippines, a tropical country in Southeast Asia at 
the Western Pacific Ocean.  In 2009, a very high prevalence of STH infections, wherein 
38.6% for A. lumbricoides, 38.5% for T. trichiura and 3.8% for N. americanus, was reported 
among pupils examined in selected endemic Local Government Units (LGUs) of the 
country(9).  Although control programs have been set up by the government to address and 
reduce the impact of these diseases, consistency and sustainability in the enforcement of 
control measures across the country together with the lack of resources, and the refusal by 
some individuals to participate in these programmes remain as challenges in their 
implementation. 
 
The WHO has recommended the mass distribution of the drugs benzimidazole (e.g., 
albendazole) for STH(10).  In addition, mass treatment is practiced since the drugs are 
effective with few side effects, in comparison to individual diagnosis which is expensive and 
time-consuming.  However, recent evidence from the Philippines shows that mass treatment 
programmes achieve low participation rates(11), which would suggest that pre-treatment 
screening and case-only treatment (i.e. targeted treatment) may be necessary to achieve 
high enough coverage among infected individuals to control parasites(12). 
 
Due to the scarcity of resources and the worsening plight of people confronting these 
diseases, it is necessary to approach resource allocation decisions and planning for parasitic 
control in a systematic way.  Aside from having alternative interventions competing for the 
same resources, the reality of opportunity cost (or the expected foregone value of choosing 
one alternative over the other) warrants the conduct of economic evaluation.  Economic 
evaluation in health care refers to the comparative examination of alternative options in 
terms of both their costs and consequences(13).  It is a systematic assessment of the 
effectiveness, cost effectiveness and impact of interventions on both patient health and the 
health care system(14).  It has been considered as an important tool not only because the 
results can be used as a component in the assessment and improvement of the 
performance of the health systems(15) but also as a guide to policy/decision-makers target 
areas where scarce resources are needed.  No less than the World Bank and the WHO 
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recognize the importance of conducting an economic evaluation (i.e., Cost Effectiveness 
Analysis) especially for developing countries to evaluate health interventions in their 
respective areas.   
 
 
1.2. Rationale of the study 
 
Although a number of economic evaluations of helminth control have been conducted in 
various parts of the world such as Cambodia(16), China(17), and Uganda(18), none has been 
done for the Philippines to our knowledge.  Evaluations of interventions in neighboring 
countries show that these constitute low treatment costs but they are not comprehensive in 
that cost-effectiveness was not estimated(19-21). Others did not consider the economic or 
opportunity costs of delivering the programme. Where full evaluations have been 
undertaken, it was found out that the mass treatment strategy was more cost-effective 
compared to no control(16) and targeted treatment(17) strategies.  However, such findings are 
sensitive to coverage achieved by mass treatment(22) which was found to be typically low in 
the Philippines(11).  For that reason, conducting an economic evaluation (i.e. CEA) comparing 
mass versus targeted treatment is essential to guide the country’s health sector 
policy/decision-makers come up with a solid basis for a parasite control policy in the 
Philippines.  In addition, a multi-parasite infection control is also preferred since it can 
present efficiency and cost-effectiveness benefits(23)especially in areas where different 
parasitic infections are co-endemic.   
 
It should also be noted that costs and effectiveness of intervention can differ even within a 
country, making it improbable to have a universally applicable single estimate of cost-
effectiveness(24).  This intra-country (i.e., subregional) variations may occur for several 
reasons such as differences in relative costs of inputs, technical efficiency, and factors 
associated with economies of scale(25) as well as differences with respect to the demography 
and epidemiology of disease, availability of health care resources and system of health care 
delivery(26).  With this intra-country variation of costs and cost-effectiveness, helminth control 
policies that vary subnationally may likely be more effective and efficient than a blanket 
national policy.  
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1.3. Research Objectives 
 
1.3.1. General Objective 
 
The general objective of this research is to conduct a cost-effectiveness analysis of 
multi-parasite control strategies for the Philippines and then identify the strategy option 
that gives the best value for money. Evidence synthesis (i.e., combining multiple 
sources of quantitative data) and model-based techniques will be utilized for the cost-
effectiveness analysis of the control strategies.   
 
 
1.3.2. Specific Objectives 
 
Specifically, this research has the following detailed objectives: 
 
1. To determine the financial and economic costs associated with each of the 
competing control strategies; 
 
2. To estimate the health outcomes of each of the competing control strategies 
looking at Disability Adjusted Life Years (DALYs) averted and number of infections 
and reinfections averted; 
 
3. To estimate the cost-effectiveness of each of the competing parasite control 
strategies in the Philippines, with uncertainty from parameters included; 
 
4. To establish the optimal parasite control strategy in terms of frequency (i.e., annual 
vs. biannual) and mode of delivery (i.e., mass vs. targeted) and identify whether 
this varies subnationally or among the three island groups: Luzon, Visayas, and 
Mindanao; and  
 
5. To establish whether a blanket national policy is more efficient relative to a multi-
regional/subnational tailored helminth control strategy in the Philippines. 
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1.4. Implications of the Research 
 
Examining the STH intervention strategies in terms of frequency and mode of delivery and 
eventually subjecting these strategies to a cost effectiveness analysis to determine whether 
a subnational or national programme policy is more appropriate to provide valuable 
information for decision and policy making at various levels of government in the Philippines, 
as well as other countries with similar settings of government.  Since there have been very 
limited full economic evaluation studies on parasitic diseases conducted in the country to 
date, this research would be of great benefit to the national and local health planners in 
coming up with efficient decisions in the future using systematic approach to evaluate 
disease control strategies.      
 
As the STH Control Programme is still being improved in the Philippines to come-up with an 
integrated and coordinated approach to sustain delivery of services in a devolved 
environment(27), the findings and results of this research can be used to further improve the 
design and implementation/delivery of the programme in order to get the best value for 
money.  Moreover, this research will further enrich the current discourses on the burden of 
diseases and on the economic evaluation of disease strategies, and thus, be able to 
influence future studies in these areas. 
 
 
1.5. Thesis Outline 
 
This section discusses the overall outline and organizational pattern of this thesis.  The 
thesis is comprised of eight chapters and each of the chapters has the following brief 
description. 
 
Chapter 1: Introduction (this chapter) provides a general background of the parasitic 
infections (i.e., STH infections) that are considered and the importance of giving them 
special attention amongst the public health issues today.  This chapter also presents the 
rationale of the study including the research objectives and implications of the research. 
 
Chapter 2: Literature review provides a more detailed picture of the extent and magnitude 
of STH infections, regarded as one of the causes of great sufferings especially of poor 
people in many parts of the world, including the Philippines. This chapter has briefly 
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identified some programme components that are being implemented in the Philippines, 
standards and guidelines to control the disease, and the respective roles and responsibilities 
of selected stakeholders.  Furthermore, some practices in estimating the health and burden 
of STH disease and the conduct of economic evaluation have also been presented. 
 
Chapter 3: This thesis has specially devoted a separate chapter on the systematic review 
of selected economic evaluation studies of multi-parasitic diseases control strategies 
basically to identify and examine the available literature that carried out full economic 
evaluation on two parasitic diseases (i.e., Schistosomiasis and STH)  that are common in the 
country.  Selected components of what constitutes good practice in economic evaluation 
which was carried out by the reviewed studies have been compared and their respective 
results/findings have been examined. 
 
Chapter 4: Methodology of the study presents this study’s theoretical framework outlining 
the general methods, processes, and approaches to be undertaken by this study.  It also 
presents the economic model used and the produced decision tree. 
 
Chapter 5: Costing Methods and Data identifies the data sources (i.e., locations across the 
country where cost data were collected), the content of the data collection, the various types 
and classifications of the data collected, analytical tools used, and assumptions made, 
among others. It also presents  the results of the financial and economic cost data collected 
at the various levels of administration (i.e., DOH regional offices/CHDs, Provicial, 
City/Municipal) in a round of mass treatment.  Together with some assumptions from 
relevant literature, the estimated/scaled-up financial and economic costs per round of mass 
treatment in both national and subnational levels are used to further estimate the financial 
and economic costs for the other treatment startegies. 
 
Chapter 6: Impact to health outcome provides detailed description on costs and health 
benefits estimated or derived for all the four intervention strategies both at the national and 
subnational levels. The chapter also looks at two effectiveness measures – the DALYs 
averted and number of infections and reinfections averted - discounted over a 10-year 
period.  The values presented for both DALYs averted and number of infections and 
reinfections averted  are the product of several component variables such as the 
predicted/forecasted prevalence, results data/findings from several studies, national data, 
and assumptions that were based on the published literature.  
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Chapter 7: Economic evaluation results presents the result summary of the cost 
effectiveness analysis that was carried out, primarily the effectiveness ratio (ICERs) of the 
four treatment strategies. This chapter also includes the cost efectiveness planes of both 
national and subnational levels outlining the cost effectiveness frontier, the 1,000 
bootstrapped ICER results for each treatment strategy, and the national threshold levels.  
Moreover, Cost Effectiveness Acceptability Curves of the strategies have also been 
presented.  Towards the end, results of the sensitivity analyses that were performed to 
address parameter uncertainties in each of the strategies have been provided. 
 
Chapter 8: Discussion  processes and synthesizes all the results into a good discourse.  
Some comparisons with results from other related published studies have been done to 
examine and establish possible consistencies  of  the findings. Some policy implications, 
contributions of the study to the body of knowledge, as well as limitations and future 
research directions have also been outlined in this chapter.  In the end, the chapter draws up 
some conclusive answers to research questions/objectives based on the findings and 
discussions of the study.    
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CHAPTER II.   LITERATURE REVIEW 
 
This chapter starts with a review of recent literature about STH infections at the global scale 
(2.1) looking at its distribution and prevalence (2.1.1), transmission (2.1.2), and 
recommended strategy of control (2.1.3).  After presenting the global picture of the disease, 
the review focuses at the country (i.e., Philippines) level (2.2) wherein a brief review on the 
epidemiology of the infections (2.2.1), background on the country’s devolved health sector 
(2.2.2), the Integrated Helminth Control Program (2.2.2), and the standards and guidelines 
for STH control under a devolved set-up of the country’s health sector (2.2.3) have been 
presented.  Furthermore, this chapter provides reviews on the estimates of health and 
burden of disease due to STH infections (2.3), the evaluation outcome measurement (2.4.1), 
the methods of economic evaluations (2.4.2), and the role of economic evaluation (i.e., Cost 
Effectiveness Analysis) to priority setting and decision-making in relation to health 
programmes (2.4.3).  Towards the end of the chapter, the discussion on the intracountry 
variation of cost in the health care delivery (2.5) and summary chapter (2.6) have been 
provided. 
 
2.1.  Global Picture of Soil Transmitted Helminthiasis (STHs) 
 
Soil-transmitted helminth infections are among the most common infections worldwide 
causing distress to people in many parts of the world. It is estimated that there are about 300 
million people worldwide with heavy infections who experience severe morbidity which 
resulted in an annual mortality of more than 150,000(28, 29).  The main species that infect 
people are roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura), and 
hookworms (Necator americanus and Ancylostoma duodenale).  Usually asymptomatic, 
these infections are transmitted by eggs present in human feces which in turn contaminate 
the soil particularly among poor areas of sanitation in the most poverty-stricken communities. 
 
2.1.1. Distribution and Prevalence of STH infections 
 
Pullan, et. al. (2014) identified two requirements in estimating the burden of parasitic 
diseases in relation to other diseases and injuries: first, is the presence of reliable 
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estimates of prevalence of the disease, and second, the use of analytic framework 
within which to estimate morbidity and mortality attributable to the disease (30). By 
examining these summary measures, one will be able to compare the relative 
importance of different diseases, track differences in trends across countries and 
trends over time, and provide a framework for evaluating the cost-effectiveness of 
interventions(31). 
 
There have been a number of efforts to estimate worldwide prevalence for STHs 
after the pioneering works of Norman Stoll in 1947(30, 32-36).  STH infections are still 
widespread in the Americas, China and East Asia, and Sub-Saharan Africa wherein 
2003 estimates revealed that globally, A. lumbricoides infects 1.221 billion people, T. 
trichiura 795 million, and hookworms 740 million(4).  However, the said estimates will 
have changed over time.  Prevalence may have declined in some parts of the world 
given the improvements in living conditions and intensified deworming efforts; on the 
other hand, increased number of people infected with the disease can be attributed 
to population growth.  Nonetheless, the lack of quality data on infection prevalence 
remains an issue when estimating numbers of infected (37).   
 
The Global Atlas of Helminth Infection (GAHI) was established to collate available 
data into a single resource, and to describe the geographical distribution and 
prevalence of infection (www.thiswormyworld.org) (38, 39).  Figure 1 shows the global 
distribution of prevalence by each STH infection(30).  Pullan et. al (2014) used the 
following data from the GAHI to derive, among others, the overall prevalence of STH 
infections in 2010: 7.8% (95% Credible Interval (CI), 7.2-8.5%) for hookworm 
globally, 14.5% (13.7-15.8%) for A. lumbricoides, and 8.3% (7.6-9.0%) for T. 
trichiura(30).   
 
It was found out that A. lumbricoides has the widest distribution of the three STH 
infections, with the highest rates of transmission seen in Cameroon (national mean 
infection prevalence 30.8%), Nigeria (25.4%) and the northwestern countries of 
Central sub-Saharan Africa (ranging from 32.2% in Congo to 38.8% in Equatorial 
Guinea).  Moreover, this infection is found geographically dispersed among Asian 
countries (including Bangladesh 38.4%, Malaysia 41.7%, Afghanistan 36.0%, and the 
Philippines 33.6%) and the southern countries of Central Latin America (Venezuela 
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28.4%, Colombia 26.0% and Ecuador 35.8%) (30).  A. lumbricoides is also common in 
the Central Asian and the Middle Eastern countries.  
 
Hookworm infections remain common throughout much of sub-Saharan Africa, in 
addition to Papua New Guinea (60.6%), Malaysia (21.0%), Nepal (30.7%) and 
Bangladesh (22.3%).  In contrast, hookworm infections are not found in most of 
Central Asia and North Africa (excluding Egypt, where prevalence was 6.0%). 
Similarly, prevalence of T. trichiura infections is low in these regions; however, 
theinfections reach their highest prevalence in Malaysia (49.9%) and the Philippines 
(45.5%) as well as much of Central Africa (ranging from 11.8% in Central African 
Republic to 38.8% in Equatorial Guinea) and Central America (5.1% in El Salvador to 
28.4% in Venezuela)(30). 
 
 
2.1.2. Transmission 
 
Parasitic worm eggs that are found in the feces of infected individuals are the main 
source of transmission of STH infections. The adult worms that live in the intestines 
of the infected individual could yield a thousand of eggs in a day. This public health 
issue becomes more of a concern in communities where sanitation practices are 
poorly managed.  People living in these areas have the higher tendency to have a 
prolonged contact with soils that are being contaminated by these eggs.  Among the 
possibilities where these eggs could be ingested by individuals include: eating 
contaminated vegetables that are not properly cooked, washed, or peeled; drinking 
from contaminated water sources; and placing unwashed hands inside the mouth 
after playing in the contaminated soil.  Moreover, one can get hookworm infections 
by just walking barefoot on contaminated soil where the eggs have been hatched and 
released into a form that can actively penetrate the skin(40). 
 
It should, however, be made clear that direct person-to-person transmission or 
infection from just released feces is not possible.  Such has been a worry of most 
individuals especially those who were not able to get proper information about these 
infections. It should be noted that it requires about 3 weeks before the eggs that 
passed in the feces to mature and infect the soil.  In addition, re-infection occurs only 
as a result of contact with the various infective stages in the environment and not 
because the worms multiply in the human host(40). 
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Figure 1:  The global distribution of STH infection prevalence by STH species, 2010  
(A) hookworm, (B) Ascaris lumbricoides, and (C) Trichuris trichiura; based on geostatistical 
models for sub-Saharan Africa and available emperical information for all other regions. 
Source: Pullan, RL., et. al., 2014(30) 
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2.1.3. Strategies for Control 
 
In a resolution crafted by the delegates of the World Health Assembly in 2001 
(see Appendix A), member states were highly encouraged to sustain and intensify 
their efforts in order to eliminate and control schistosomiasis and STH infections.  
Moreover, the Assembly also called the organizations of the United Nations system, 
bilateral agencies, and non-government organizations to strengthen their support to 
endemic countries for the prevention, control, and elimination of communicable 
diseases.   
 
STH infection control strategy is geared towards controlling morbidity through a 
series of medicinal treatment (deworming) of people who are at risk in the endemic 
areas.  The WHO has considered the following individuals who are at risk and 
vulnerable to the said infection: preschool and school-age children, women of 
childbearing age (including pregnant women in the second and third trimesters and 
breastfeeding women), and adults in certain high-risk occupations such as tea-
pickers, miners(40), and those of similar work environments.  There are three major 
strategies or interventions for STH control, namely, anthelmintic drug treatment, 
improved sanitation, and health education.(41) 
 
Anthelmintic drug treatment (also known as “deworming”) aims to reduce morbidity 
by decreasing the worm burden.  For all at-risk individuals living in endemic areas 
and who do not have prior individual diagnosis, the control strategy being 
recommended is periodic medicinal treatment.  WHO suggested that in areas where 
STH infection prevalence is more than 20%, a once a year treatment should be 
administered.  However, the treatment should step up to twice a year when the 
infection prevalence is over 50%(10, 42).  For preschool and school-age children, the 
control strategy can be integrated with child health days or school health 
programmes for efficient treatment administration.  Conducting deworming activities 
in schools have proven to be a good entry point and advantageous, as it allows easy 
provision in propagating health and hygiene education component of the public 
health programs, such as promotion of hand washing and improved sanitation.  With 
such strategy, over 368 million school children in 2013 have been treated with 
anthelmintic medicines in endemic countries, corresponding to 42% of all children at 
risk.  Albendazole (400 mg) and Mebendazole (500 mg) are the WHO’s medicines of 
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choice for being effective, affordable, and accessible to non-medical personnel (e.g. 
teachers).  Both drugs have been subjected through extensive safety testing and 
have been used with few and minor adverse effects.  These anthelmintic drugs that 
are intended for the treatment of all school-age children are donated through WHO 
and made available to the health ministries of all endemic countries(40). 
 
Given such added values, the importance of an integrated and comprehensive 
program to combat NTDs such as STH has been observed(43, 44).   However, 
coordinating and funding such a comprehensive approach are complex and 
expensive.  Since anthelmintic drugs are usually donated free of charge for the 
purpose of MDA programs, the focus of most control programmes and 
recommendations is mass drug administration (MDA).   
 
The three main drugs used for MDA or being recommended for use in public health 
interventions to control STH infections are the benzimidazole anthelmintics (BZAs), 
albendazole (single dose: 400mg, reduced to 200mg for children between 12 and 24 
months), or mebendazole (single dose: 500 mg), as well as levamisole or pyrantel 
pamoate.(10) These drugs can be used in different combinations but resistance is 
starting to develop to these.  MDA can be either population wide or it can focus on 
specific high risk groups (e.g. children, occupational groups, pregnant women etc.).   
There is, however, evidence that noncompliance and increasing drug resistance will 
undermine programs based on MDA alone. 
 
On the otherhand, improved sanitation and health education aim to control 
transmission and reinfection by reducing soil and water contamination through 
techniques that often cut across several sectors (e.g. health, education, 
infrastructure, veterinary services).  Evidences for these other types of intervention 
such as regular health education(45, 46), infrastructure and WASH (e.g., piped water 
supply, improved pit latrine)(47) have shown to be effective and sustainable.  
Moreover, evidence for a comprehensive approach that includes all other 
interventions such as health education and environmental management(48), performs 
better than deworming alone.  An integrated and comprehensive program that 
includes education and sanitation has the added advantage of offering the potential 
to eliminate rather than just control STH infections and may even be considerably 
cheaper than stand-alone approaches(49).   
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2.2. An Overview of the STHs in the Philippines 
  
A close examination of the demographic profile of the Philippines, a tropical country 
characterized by warm to hot temperatures and high humidity year round, would suggest 
that a great proportion of its populace would be at risk of STH infections due to the 
predominance of helminths. Among the people who are at very high risk of getting STH 
infections are those dwelling in poverty-stricken and overcrowded areas with poor water 
supply, inadequate facilities for human excreta disposal, poor eating habits, and unfavorable 
housing environment conditions. Moreover, the country’s health systems could also be a 
contributing factor as to how the country’s health agency and authorities respond to manage 
and control diseases.    
 
2.2.1. Epidemiology of Infections 
 
STHs persist to be one of the major public health concerns in the Philippines despite 
reforms initiated and efforts carried out to contain them.  In fact, studies have 
revealed a 67% cumulative prevalence (i.e., positivity for at least one type of STH 
infection) among elementary school children in selected sites of the country(50) and 
that 66% of preschool children nationwide are found to be harboring STH infection(51).  
Furthermore, in a survey among children in Metro Manila, Philippines, it was found 
out that the T.trichiura and A. lumbricoides remained to be the most prevalent 
helminths with infection rates of around 40%.  Although hookworm infection is also 
common, its prevalence tends to be lower than 10%(52).  The result of hookworm 
prevalence in the Philippines, which is an agricultural country in Southeast Asian 
region, however is remarkably lower compared with that of other STH endemic 
countries(4). 
 
STH infections have been identified as the primary disease of school-age population 
among developing countries worldwide(53).  Children, ages two to fourteen years old, 
have been identified to be of highest risk because of their poor personal hygiene, 
frequent outdoor exposures, and high risk behavior(5).  This trend has also been 
observed in the Philippines where most of the affected individuals are primary 
school-age children.  The high prevalence of  hand-to-mouth infection route for A. 
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lumbricoides and T. trichiura among school-age children can be explained by various 
grounds including lack of sanitation facilities (e.g., wash areas), poor sanitation 
practices and water quality, and low awareness of most children as well as their 
guardians of proper personal hygiene(52).  On the otherhand, hookworm infections are 
surprisingly not that significantly high as compared to the other infections mentioned, 
partly because cutaneous route could be impeded by factors such as susceptibility of 
the infective larvae to harsh and unfavorable environmental conditions(54, 55) where 
the country’s cyclic wet and dry weather seasons could have contributed to the 
unfavorable environment for hookworm larvae.  
 
“The morbidity caused by STHs is usually linked with heavy infections. At the global 
scale, around 300 million individuals with heavy infections have suffered severe 
morbidity resulting to at least 150,000 deaths annually(28, 29). Furthermore, helminth 
infections also impair physical and mental growth in childhood as well as impede 
educational advancement (41).  
 
On the other hand, STH infections hardly lead to mortality; rather, the burden of 
disease is related less to mortality than to the chronic and insidious effects on the 
hosts' health and nutritional status(41). Moderate and heavy hookworm infections 
result to intestinal blood loss that could lead to iron deficiency and protein 
malnutrition. Given poor iron status, vulnerable members of the society (i.e., children, 
women of reproductive age, and pregnant women) are oftentimes the ones most 
susceptible to developing hookworm anemia(56). During pregnancy, iron deficiency 
could result to adverse maternal-fetal consequences, including prematurity, low birth-
weight, and impaired lactation(10). 
 
 
2.2.2. The Health System of the Philippines 
 
The Philippine’s health system is a dual system, consisting of both the public sector 
(largely financed through a tax-based budgeting system) and the private sector 
(largely market-oriented where services are paid through user fees). Majority of the 
country’s expenditure on health, about 60%, is provided through the private sector 
that also employs 70% of all health professionals in the country(57) and consists of 
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for-profit and non-profit providers.  The public sector, on the otherhand, is composed 
of the Department of Health (DOH), other national government agencies, and LGUs. 
 
Before the enactment and implementation of the Local Government Code (LGC) of 
1991, the public health system of the country was financially, administratively, and 
technically managed by the DOH from the Barangay Health Stations (BHS) and the 
Rural Health Units (RHU)/city health centers to the provincial and district hospitals up 
to the referral core/tertiary facilities.(58) 
 
With the devolution of health service, LGUs have become in-charge of the provision 
of the direct health services at the primary, secondary, and tertiary levels of health 
care.  Figure 2 shows the organizational structure of health services after the 1991 
devolution.  The provincial government manages, supervises, maintains and finances 
the provincial and district hospitals. On the otherhand, the municipal/city government 
manages, supervises, maintains and finances the RHUs, health centers and BHSs.  
With this devolved set-up, the instituted Local Health Board (LHB) being chaired by 
the Local Chief Executive (LCE) in the respective LGUs acts as health advisory body 
to the local executive and the Sanggunian or local legislative council.(58) 
 
Under the devolved setting, the role of the DOH has shifted from being the sole 
provider of health services to provider of specific health services, regulatory, and 
technical assistance for health to LGUs.  Although the DOH has no longer 
administrative supervision to health services at the local levels (which are being 
represented by the dotted line in figure 2), it is still the lead agency in health having 
been mandated to provide national policy direction and develop plans, technical 
standards, and guidelines on health.  The Department is made up of the Central 
Office and regional offices known as Centers for Health Development (CHDs), and it 
maintains provincial health teams of DOH representatives to assist health offices at 
the local levels of government (i.e., provincial, municipal and city).  The CHDs 
provide the DOH with a presence in each of the 17 regions to provide regional 
oversight and manage DOH operations at the various levels of government. 
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Figure 2:  The organizational structure of health services, post devolution 
Source: Department of Health, 2002 (59). 
 
 
With the devolution of health services, several issues have been noted which 
resulted in the deterioration of health care delivery in the country.  The lack of 
adequate management capacity and inefficient system of communication between 
the various LGU levels have led to lower utilization of health services.(60)  Moreover, 
the lack of resources in most LGUs has resulted in considerable inequities in the 
provision of health care across the country.  The health care delivery system in the 
country become fragmented. To address the said limitations and issues of the 
devolved health system, health sector reform programmes have been introduced.  
These reforms include expanding public and preventive health programmes, 
improving access to basic and essential health services in underserved areas, and 
establishing Inter Local Health Zones (ILHZs) to facilitate coordination of health 
activities between the LGUs and DOH retained services. (57, 60)  However, despite 
these health programme reforms, fragmentation in the overall management of the 
health system still exists due to the involvement of the different levels of government 
in the different levels of health care.  A considerable autonomy and discretion to 
interpret central (i.e., DOH) policy directions are retained by the local and provincial 
authorities.  Likewise, local political influence often dictates the provision of the health 
services which results in significant variations of the quality of health services 
delivery throughout the country. 
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2.2.3. The Integrated Helminth Control Program (IHCP) under the 
country’s devolved health sector set-up 
 
In 1999, the country implemented a 3-year Soil Transmitted Helminthiasis Control  
Programme (STHCP) with the aim of reducing the intensity of infection from 
high/medium to low and reducing the prevalence of infection to <30%, administering 
mass deworming for school-age children(61).  However, the success of the 
programme was just minimal since prevalence rates remained high despite the 
nationwide coverage of STHCP deworming campaign.   
 
Several studies have revealed that infections still range high from 36.0% to 51.2% for 
A. Lumbricoides, 27.6% to 51% for T. trichiura, and 7.0% to 23.4% for hookworms (52, 
62, 63).  The issue of low treatment coverage across regions can be traced back to 
several factors such as the refusal of village people to participate in the programme, 
lack of resources to sustain program activities, and even non-prioritization of some 
LGU heads to fund such health programmes and activities.   Aside from poor 
coverage of targeted population, other factors that account for the slow and low 
containment of the infection include (i) failure to comply with the recommended 
standards or technology; (ii) weak promotion and advocacy; (iii) lack of enabling 
environment that supports STH prevention and control; and (iv) increased cost of 
intervention and ineffective implementation(27).  Thus, in the programme impact 
evaluation that was conducted, its was suggested that a reassessment of the existing 
helminth control strategies be made focusing on semi-annual mass treatment 
programmes, associated with improved educational campaigns, and enhanced 
environmental sanitation and surveillance(9).  
 
Faced with the issues of the containment of STH infections, aggravated by 
unfavorable conditions such as significant proportion of households without access to 
sanitary facilities, limited resources of both national and local governments, and 
adverse effects of the disease to human development, the STHCP was 
strengthened.  Within the Department, there exist a number of programs which are 
viable mechanism to operate an integrated approach to effectively and efficiently 
address STH infections.  The DOH-National Center for Disease Prevention and 
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Contol (NCDPC) explored the opportunity to integrate its STHCP efforts with its other 
deworming programs (i.e., the Garantisadong Pambata, Filariasis and 
Schistosomiasis Programs) and to closely link the STHCP initiatives with similar 
programs undertaken by the other national agencies, particularly the Department of 
Education (DepEd) and the Department of Social Welfare and Development 
(DSWD).  This Integrated Helminth Control Program (IHCP), a coordinated approach 
with other stakeholders working in this endeavor, aims to boost multi-sectoral 
participation (public-private sectors), rationalized financing and sharing of resources, 
and ensure sustained delivery of services in a devolved environment. 
 
The IHCP has identified the following program components: 
a) Chemotherapy  
As the major intervention for helminth infection control, two approaches are 
applied: (a) mass targeted deworming – applied to preschool children and 
school children; and (b) selective deworming – recommended for adolescent 
females, pregnant women, and the special population groups of food 
handlers, soldiers, farmers, and indigenous people. 
 
b) Water, Sanitation and Hygiene (WASH) 
 
c) Behavioral approaches 
 Identification of behaviors that promote health or ill-health 
 Development and implementation of advocacy and communication 
 Involvement of families and communities for behavioral change 
 Advocacy and social mobilization(27). 
 
In a concerted effort to guide program managers, coordinators, health workers and 
other stakeholders as to the strategy in the prevention and control of STH, the DOH 
came out with the IHCP Manual.  This Manual/Guide has three parts:  
 
Part I contains the guidelines and protocols in administering the deworming drug, 
particularly with regard to dosage and frequency for each target group including the 
proper management of side effects/adverse reactions.  
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Part II provides the implementing guidelines regarding the procurement and 
allocation of deworming drugs including the steps in calculating the required quantity 
of drugs for a given catchment area, and the recording and reporting of coverage and 
accomplishments.  
 
Part III presents  the roles and responsibilities of the different entities/stakeholders 
involved in the deworming program.  But for the purpose of this study, particular 
attention was given to selected stakeholders such as the DOH, CHD, Provincial 
Health Office, and City/Municipal Health Offices or RHUs: 
 
A. The National Center for Disease Prevention and Control (DOH-NCDPC) through 
the Infectious Disease Office 
 Updates policies and guidelines on the implementation of mass treatment 
program; 
 Orients regional/provinciaL IHCP coordinators on program, policies and 
guidelines; 
 Provides proficiency training to medical technologists/microscopists on 
laboratory diagnosis of helminths and other parasites; 
 Assists in the procurement of deworming drugs for mass treatment through 
UNICEF/WHO or PTIC; 
 Advocates among LGUs to allocate funds to augment supply of deworming 
drugs for mass treatment; 
 Develops prototype IEC materials on STH; and 
 Monitors and evaluates the mass treatment program. 
 
B. The Centers for Health Development (CHDs) 
 Provides budgetary allocation for the procurement of deworming drugs for 
mass treatment; 
 Conducts orientation of provincial/municipal health workers on mass 
treatment implementation guidelines; 
 Coordinates with the LGUs/RHUs on mass treatment implementation; 
 Advocates among LGUs the allocation of funds to augment supply of 
deworming drugs for mass treatment; 
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 Reproduces prototype IEC materials for distribution to LGUs; and 
 Monitors implementation of mass treatment programmes and submit 
accomplishment report to Central Office. 
 
C. The Provincial Health Office 
 Coordinates with the LGUs and RHUs/health centers on mass treatment 
implementation; 
 Advocates among LGUs to allocate funds to augment supply of deworming 
drugs for mass treatment; and 
 Records and submits accomplishment reports to the CHDs 
 
D. City/Municipal Health Offices/RHUs 
 Complete the masterlists of targeted population for mass deworming; 
 Implement the mass deworming program; and 
 Record and submit the accomplishment reports to the PHO(64). 
 
Identifying the various stakeholders and their respective roles and responsibilities is 
noteworthy and useful.  It highlights some important factors or features of the 
country’s helminthiases control programme such as the different levels of 
government involved, the various levels of responsibilities for different but interrelated 
activities, the different resources that are available at the disposal of each level of 
government, and the fact that different government units operate under different 
budgets.  Given the devolved setting in the delivery of health care services, 
governments at the local level (i.e., provincial, city, municipal) are allowed and 
encouraged to explore avenues to be more efficient  and economical in attending to 
the needs of their populace.  To this effect, relevant resources provided at a discount, 
donated or volunteered are welcome as cost-saving opportunities in the delivery of 
control programmes.  Given such situation, extending data sources to include levels 
of government beyond the regional and provincial levels would be beneficial since 
volunteers and similar resources are significant and often evident in service delivery 
points such as cities and municipalities. 
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The rationale of  STH Control Program is to integrate all related efforts and 
strengthen coordination of the various stakeholders in implementing the programs 
nationwide to ensure better complementation of resources, obtain higher coverage, 
and generate better health outcomes.  In order to operationalize this integrated 
approach, programs from the DOH have been expanded to other national and local 
agencies and organizations that are engaged in the same endeavor.  It has been 
recognized that the country’s STH interventions would only become effective and 
successful if supportive and enabling environment is present, that is, good 
governance at all levels of operations.  In addition, the following components in the 
delivery of the country’s STH program should also be considered: (i) the presence of 
political will and support both at the national and local chief executives, (ii) quality and 
access of deworming services, (iii) financing reforms where LGUs have to allocate in 
their budget their respective deworming activities for sustainability of the services and 
where the DOH have to establish an equitable or rationalized allocation of deworming 
assistance, and (iv) monitoring of the LGUs compliance to STH policies. 
 
Given the country’s low-income setting, affordability of the program interventions may 
have been one of the considerations in its decision to invest.  However, in order to 
realize the rationale of the integrated STH control program, prioritization was given to 
the cost effectiveness of the program, i.e., cost per coverage or cost per health 
outcome.” 
 
 
2.3.  Burden of disease and health metrics of STH infections 
 
The burden of the disease due to STH infections was determined by carrying out mortality 
estimates.  It was estimated that 27,000 people die annually from both STHs and 
Schistosomiasis (case fatality rate of 0.0014 percent)(10) but this is considered to be an 
underestimate by many investigators wherein at some point, the difference of the estimates 
for helminth-associated mortality even reached 10-fold(41).  A recent study conducted by 
Pullan, et. al. (2014)estimated that in 2010, 438.9 million people (95% Credible Interval (CI), 
406.3 - 480.2 million) were infected with hookworm globally, 819.0 million (95% CI, 771.7 – 
891.6 million) with A. lumbricoides and 464.6 million (95% CI, 429.6 – 508.0 million) with T. 
trichiura.  Moreover, it was estimated that there were 2,824 deaths due to STH in 2010, with 
most occurring in populations from Asia.(30)  Deaths due to STH are all attributed to heavy A. 
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lumbricoides infection, causing intestinal obstruction and biliary or pancreatic disease in 
children under 10 years of age(65). 
 
However, merely considering the mortality figures is not enough to show the impact to health 
outcome of these infections primarily because it is unusual for STH to kill their human 
hosts(41).  Measurements by case fatality fail to sufficiently capture the non-fatal health 
outcomes (i.e. lifelong physical and functional disabilities to individuals or society) of the 
disease and impact on non-working populations(37).  Direct estimates of morbidity, on the 
otherhand, face issues such as unreliable national health statistics since signs and 
symptoms of infection are generally non-specific which oftentimes go unreported, few clinical 
signs are specific to helminth infections, and the ubiquity of co-infection and co-morbidity(66).  
Besides, it was observed that population-based studies do not deliver a clear assessment of 
the effect of chronic infections on performance status or overall quality-of-life(67). 
 
 
2.3.1. Health metrics: The use of DALYs 
 
Summary measures of public health are designed to integrate information on length 
of life and quality of health into a single numerical measure to provide unique 
perspectives on levels of health and key contributing causes to loss of health. The 
most common measures used are the Disability Adjsuted Life Years (DALYs) and 
Quality-Adjusted Life Years (QALYs) which in a general level, are conceptually very 
similar to one another since both are weighted to account for disease severity in 
order to summarize mortality and morbidity.  
 
QALYs is an index that uses quality-adjustment weights called “utilities”.  These are 
acquired by asking specific groups of people questions that allow the analyst to 
derive their implied preferences for different outcomes. Possible health states 
associated with an intervention in terms of a consistent set of health dimensions must 
be described by the questions(68). STHs do not have utility weights and certainly not 
ones from the Philippines making QALYs difficult to use in the study. Deriving utility 
weights is further complicated by the fact that many infections are seen in children 
and experimenting on children to procure utility weight data is more complex. 
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Meanwhile, DALYs which are considered as a modification of QALYs, measure the 
gap between a population’s existing health condition and what should be an ideal 
health state(69). Simplified, the burden for a particular health state as expressed in 
DALYs is computed as follows: 
 
DALYs = Σ YLLs + Σ YLDs, 
with YLLs from a single death equal to (standard life expectation - age at 
death) * (age weight) * (future discount); 
 
and YLDs from a certain disabling condition equal to (disability weight) * 
(incidence) * (duration of disabling event) * (age weight) * (future 
discount). 
 
Therefore, the main difference between the two is that DALYs measure the amount 
of potential health lost from disease or illness while QALYs measure the amount of 
health gained from treatment. Moreover, the two measures can be used in both 
burden of disease and CEA studies, despite the common misconception that DALYs 
necessarily relate more to burden of disease as an illness approach and QALYs to 
cost-effectiveness as a treatment approach since no distinction is made between 
disabled and able-bodied people. Perhaps, the most important difference is that 
DALYs internalize age weighting while QALYs do not. Age weighting involves 
assigning more weight to the health of those in the working age than in the start or 
the end of life groups. In a developing country context, active members of the society 
who are in their productive age years usually contribute significantly to the economy 
and should therefore be accorded more weight. 
 
In the Philippines, DALY is used by the health sector as recommended by the WHO 
and the World Bank who fund most implemented health programmes. Programmes 
such as the calculation of smoking-attributable burden of lung cancer(70), the return 
on investment of needle syringe programs in HIV infections(71), and the feasibility and 
cost-effectiveness study of DOTS-Plus for Multi-Drug Resistant Tuberculosis (MDR-
TB)(72)use DALYs to consider mortality with age at death, incidence of various types 
of adverse health conditions with age at onset, prevalence of morbidities with 
severity, duration and sequelae, and remission rates.  The increasing popularity of 
DALYs and burden of disease estimates clarified that for STHs that mainly cause 
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morbidity rather than mortality, the average disability incurred by a diseased 
individual is crucial for correctly compiling data to global burden estimates. DALY 
allows comparison of efficiency to other disease programmes and are suggested to 
be used in generalized CEA(73) as an approach to evaluate a wide range of 
alternative strategies for chronic diseases and disabling health conditions to identify 
the optimal health care programme given only limited resources(13). 
 
Accounted for the use of DALY in the study is its ability to infuse information about 
non-fatal health outcomes such as STHs into debates of health inequalities, the only 
measure to do so. Moreover, DALYs uncouple social and epidemiological 
assessment of health inequalities from advocacy. It can also measure the magnitude 
of premature death and non-fatal health outcomes attributable to proximal biological 
causes, including diseases and injuries or attributable to more distal causes such as 
poor living standards as in the case of STHs, tobacco use or socio-economic 
determinants. It is a reasonable measure that can be used for purposes of 
comparisons either between different communities or between different points of 
time(74). In a study on the burden of micronutrient deficiencies by socio-economic 
strata in Filipino children(75), the intangible costs were calculated using the DALYs 
lost due to current illness, premature death and future permanent disabilities without 
applying age weights. Another study covering the toxicity of chemicals from waste 
sites in India, Indonesia and the Philippines compared the DALYs of the different 
health conditions estimated by the WHO and served to determine the cost-
effectiveness of clean up interventions in toxic sites to remove environmental 
exposure to hazardous chemicals(76). 
 
This particular study used the estimated disability weights that were recently 
examined(67) to estimate the DALYs averted by each control strategy based on 
changes in the incidence of infection predicted by the mathematical models.  The 
other measure of effectiveness used in this study was the number of infections and 
reinfections averted. However, it is important to subject the cost/DALY averted 
estimates to some form of sensitivity and to provide disaggregation in the calculation 
in order for others to assess the robustness of DALY estimates as well as to transfer 
results between settings with degree of reliability(77).  
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Although widely used in evaluations in developing countries, there is still much 
debate on the burden of disease methodology and the use of DALY measure. The 
topics contested include the determination of age-specific weights, future discounting 
and disability weights; the desirability and implications of extrapolation of population 
health estimates where basic descriptive epidemiological data are limited, uncertain 
or even missing; and the argument that global burden of disease analyses do not 
help in setting health priorities. Advocates suggest that the inclusion of disability in 
the DALY suggests that people with disability are less vaued than those in full health.  
 
Moreover, health economists are concerned that burden of disease analysis might 
result in priority setting solely on the basis of the magnitude of disease burden, 
arguing that burden of disease studies are irrelevant for priority setting and that all 
one needs to know is the marginal cost-effectiveness of potential interventions.  The 
WHO framework for health system performance assessment directly emphasized 
reducing health, financial, and other inequalities as an objective of health systems(78). 
 
The WHO definition of ‘health’ is grounded in a multidimensional notion of health 
functioning, which include body functions such as fertility, respiration, vision, or pain, 
as well as more complex functions such as mobility, affect, or cognition. Although the 
concepts of disability vary widely across societies, the WHO International 
Classifiction of Functioning, Disability and Health defines ‘disability’ as a general term 
for impairments, activity limitations, and participation restrictions that are health-
related. By this definition, anyone who is disabled has a reduction in functional health 
and thus, does not have ‘full health’ in terms of the functional health concept that the 
DALY quantifies. The term disability was used to emphasize a vision of health that 
goes beyond the absence of disease to include decreases in functioning resulting 
from disease. It is suggested that the term ‘health-adjsuted life years’ would be a 
better term to encapsulate the value of DALY without the ethical dilemma. 
 
2.3.2. Global burden of disease estimate 
 
Worldwide burden of disease due to STH infections has been estimated to be at 5.2 
million DALYs(79), wherein almost half of it is borne by children 5 to 14 years of age(7).  
In the Philippines, the burden of these intestinal nematode infections in 2010 has 
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been estimated to be at 359 thousand DALYs and almost one-third of it came from 
children in that range of age(66).  Recent estimates by Pullan, et. al. (2014) showed 
that the 2,824 deaths in 2010 that are attributable to A. lumbricoides have occurred 
mostly in populations in Asia and have resulted to 1.31 million (0.71 – 2.35 million) 
increase in the global DALYs attributable to A. lumbricoides.  Since there were no 
deaths attributed to hookworm and T. trichiura, their respective years lived with 
disability (YLDs) represent the total DALYs that these infections have contributed.  
Hence, the total DALYs contributed due to STH in 2010 is estimated to be at 5.18 
million, from which 3.23 million is caused by hookworm, 1.31 million by A. 
lumbricoides and 0.64 million by T. trichiura.  And from the 4.98 million estimated 
YLDs attributable to STH, 65% were attributable to hookworm, 22% to A. 
lumbricoides and the remaining 13% to T. trichiura.  Moreover, the literature also 
shows that the vast majority of STH infections (67%) and YLDs (68%) have occurred 
in Asia.(30) 
 
After providing some background reviews of STH infections, the prevalence, and 
estimated health and burden of the disease both in the global scale and in the 
Philippines, the succeeding sections provide brief reviews on some practices in the 
conduct of economic evaluation of health programmes and the importance of cost 
effectiveness analysis in priority-setting and decision-making.  After looking into the 
situation of STHs in the Philippines, the relevance of intra-country variations of costs 
and effectiveness estimates has also been briefly reviewed given the country’s 
devolved delivery of health programmes.  
 
 
2.4. Overview of Economic Evaluation of Health Care Programmes 
 
Health economics is an important aspect of health care research that focuses on the efficient 
use of scarce resources. Society aims to provide the best care for the population but this is 
limited by resource constraints; thus, health care resources must be used as efficiently as 
possible. Recently, there is a growing reliance by decision makers on clinical effectiveness 
and economic efficiency when making health care decisions due to rising health care 
costs.Economic evaluations are studies carried out to compare the costs and consequences 
of two or more courses of actions or health care interventions(13) where the consequences 
can vary from clinical effects to health-related quality of life. Several advantages of 
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performing economic evaluations include: clearly identifying all relevant alternatives through 
systematic analysis, significantly improving analysis by involving several viewpoints, and a 
decline in the magnitude of uncertainty. Without measurement and comparison of outputs 
and inputs, there is little basis for the judgment of value for money. The real cost of a 
programme is not the money spent but rather the value of the benefits achievable. It is the 
‘opportunity cost’ that economic evaluation seeks to estimate and to compare with 
programme benefits(13). 
 
Economic evaluations are best suited for services or programmes that relate to outcomes 
that are associated with long-term changes with strong economic value and are easily 
quantified. Carrying out an economic evaluation requires a considerable investment of time 
and management attention especially when new data is being collected. However,these 
economic evaluations pose the risk of wasting resources under some parameters such as 
the absence of a good estimate of the difference you make (in non-monetary terms) on 
which to base an economic evaluation, the irrelevance of the monetary value of the 
difference you seek to make, the incredibility of the results for the intended audience,and 
when the difference you seek to make is not meaningful in a monetary form(80). These 
evaluations are also not easily performed locally, particularly in low to middle income 
countries such as the Philippines where there are limited resources for carrying it out. As a 
result, policy makers may end up gathering data elsewhere. Unfortunately, the findings of 
cost-effectiveness analysis do not transfer well due to the differences between the health 
care systems since an economic evaluation is most useful in the settings in which the study 
was conducted. 
 
Currently, despite the dramatic improvement in the health status of the Philippines, 
considerable inequities in health care access and outcomes between socio-economic groups 
remain. The high cost of health care access and utilization has been considered as the 
primary reason for such inequities(57).  For this purpose, Philhealth, the Philippines’ national 
health insurance agency, has introduced Health Technology Assessment (HTA) to study and 
evaluate health interventions being implemented in order to come up with an evidence-
based result to guide policy, utilization and reimbursement.  
Overall, there are two primary bases in conducting economic evaluations despite the cons 
that have been presented in the literature: (1)  the apparent reality of the scarcity of 
resources; thus, choices must be made as to where to put these resources amongst 
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competing interventions or options; and (2) the effectiveness and efficiency of health 
programmes currently considered by decision-makers when making choices(13, 81).  The 
recognition of the value of conducting economic evaluation studies is evident in its significant 
growth and widespread application in various fields of health care delivery on both 
preventive(82-84) and curative interventions(85-87).   
2.4.1. Forms of economic evaluation 
 
Economic evaluations have been defined as the comparative analysis of alternative 
courses of action in terms of both their costs and consequences. There are several 
types of economic evaluations depending on the characteristics of the consequences 
namely: (i) Cost Minimization Analysis (CMA); (ii) Cost Benefit Analysis (CBA); (iii) 
Cost Effectiveness Analysis (CEA); and Cost Utility Analysis (CUA).  Across these 
types of economic evaluations, one can notice that identification and measurements 
(in monetary units) of costs are similar; however, the measurements and valuations 
of the nature of consequences by the concerned interventions differ considerably(13, 
88).    
 
CMA will not be a useful approach for this research mainly because it can possibly 
be applied only in situations where there is already a previous knowledge that the 
effectiveness of the alternatives is equal(13). Here, the consequences of compared 
interventions are required to be equivalent, and only relative costs are compared. For 
CBA, the approach has a limited application when it comes to health care (and thus, 
will not be used for this research) since it requires that  programme consequences be 
measured and valued in monetary terms.  Such monetary valuation of health 
outcomes poses ethical questions on placing value to human life; whether or not the 
value being placed is valid as a result of being healthy or reduced morbidity and 
mortality (human capital approach); and on people’s willingness to pay which 
depends on several factors that vary to a great extent(81).  
 
On the otherhand, CEA, wherein health benefits are measured in terms of cost per 
unit of effect or effects per unit of cost(13), has been the groundwork in the allocation 
of health care resources for most programmes.  Expressed in terms of effects per 
unit of cost, CEA has been a useful approach especially when working within a 
restraint budget(89).  
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CUA has been considered as a special case of CEA(90) wherein instead of looking at 
consequences in terms of physical units, it combines quantity (i.e., reduced mortality) 
and quality (i.e., reduced morbidity) of life into a single metric(13, 88, 90).  Where quality 
of life is the primordial outcome of programme interventions(91) and when different 
interventions with varied target outcomes or produce multiple health benefits 
necessitate a common unit of measurements(73), an evaluation technique considering 
both quantity and quality of life is important.  
 
2.4.2. Frameworks for economic evaluation 
 
An economic analysis structure can only be judged if it can inform two key decisions 
and be consistent with the objectives of a health care system according to its 
resource constraints. The first key decision is whether to adopt a health technology 
given existing evidence and secondly, an assessment of whether more evidence is 
required to support this decision in the future. A framework of economic analysis is 
needed which can estimate costs and effects, based on all the available evidence, 
relating to the full range of possible alternative interventions and clinical strategies, 
over an appropriate time horizon and for specific patient groups. It must also enable 
the accumulated evidence to be synthesized in a clear way in order to fully represent 
the decision uncertainty(92).  
 
These requirements of economic evaluation for decision making are the starting point 
for considering an appropriate framework for analysis. Definitely, it is true that in their 
methods guidelines, many decision makers are not prescriptive about preferred 
methods. However, unless these requirements are recognized and implemented, the 
value of formal economic evaluation for resource allocations decisions will be 
compromised(36, 37). There are two primary methods available in conducting economic 
evaluation, namely: 
 
Randomized Controlled Trials (RCTs) 
 
RCT is an approach that utilizes patient level data or that involves primary data 
collection.  It has a central role in the evaluation of health care interventions and also 
serves as a vehicle for advantageous economic analysis in terms of relative 
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effectiveness of the intervention should it be free of selection bias. However, RCT 
based evaluations fall short in terms of the requirements mentioned in the previous 
section. RCTs face issues such as failure to compare all relevant options since it is 
implied that RCTs usually only compare a sub-set of relevant options for a given 
patient population. Allowing a single trial to define the scope of an economic 
evaluation will invariably produce a partial analysis. If one or more relevant options 
have not been included in an analysis, there is a risk of inappropriate adoption and 
research decisions. Quantifying the costs of decision uncertainty in terms of forgone 
health and resource costs is part of the value of information analysis. These methods 
depend on all sources of parameter uncertainty being included in an analysis, 
including full life expectancy. Value of information methods based on a truncated 
time horizon which is common in trial-based economic evaluations could produce 
misleading results as evaluations relating to interventions in many areas of health 
care will exhibit a gap between the costs and benefits which can be estimated in the 
trial, and those which are needed for decision making(92).  
 
Moreover, the most damaging criticism of RCTs is the fact that single trial is unlikely 
to include all evidence relevant to a given evaluation. They will invariably fail to reflect 
all the available evidence relating to a particular decision problem. In some trials,  not 
all the data (eg. resource utilization, health-related wuality of life) necessary for CEA 
are collected. RCTs also have the tendency to lack the relevance to the specific 
jurisdiction in which the decisions are made usually in the setting of pharmaceutical 
and medical device manufacturers. Compounding factors include the inadequate 
quantification of decision uncertainty, limitedcomparators, and restricted 
generalizability to different settings or countries(92). Considering these issues and 
working within the context of a highly fragmented Philippine healthcare delivery 
system,  it will not be feasible to conduct an RTC-based evaluation.  Instead the use 
of modeling approach will be very much relevant for this research. 
 
Decision Analytical Modeling 
 
Circumstances such as when it is impossible to conduct a trial, there is insufficient 
evidence from clinical trials, when it is necessary to project costs or outcomes 
beyond the follow-up period of a clinical trial, or when it is important to consider other 
relevant comparators or important outcomes, using models for complex situations 
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together with full evidence synthesis has been regarded as a viable option to present 
it in a plain and comprehensive way(93).  Mathematical modelling offers health policy 
makers the ability to predict the impact of emerging diseases and the effects of 
possible response and control measures. These models are used to bridge the gap 
between clinical trials that measure individual-level efficacy over a short period of 
time for highly selected people and population-level use. This is particularly critical for 
infectious diseases, where mass interventions such as vaccination and screening 
can result in effects at a population level not seen on an individual level, including 
herd immunity, changes in the epidemiology of infection and changes to pathogen 
ecology as a consequence of selective pressure(94). 
 
Decision models provide a structure within which evidence from a range of sources 
can be directed at a specific decision problem for a defined population and context. 
Using the decision analytical modeling for economic evaluation enables analysts to: 
(a) compare all relevant options; (b)  reflect all appropriate evidence not just 
effectiveness evidence but also relating to resource use, unit costs, etc.; (c) link 
intermediate endpoints to final outcome; (d) extrapolate over the appropriate time 
horizon of the evaluation; and (e) make results applicable to the decision-making 
context(13).  
 
The entire decision modeling method can be summarized in four stages: (i) a 
systematic review of the relevant data, (ii) estimation of all inputs into the model 
(including effectiveness, transition probabilities, and costs), (iii) sensitivity analysis for 
data and model specification, and (iv) evaluation of the pre-developed model.  
 
Decision makers have requirements that are vital in identifying the appropriate 
perspective of the analysis, time horizon, relevant outcome measures, and scope or 
boundaries of the model. Thus, it is important to define all relevant options available 
for evaluation such as the recipient population, and the geographical location and 
setting in which the options are being delivered when using a decision analytical 
model.  
 
A decision tree is simple and transparent, and using it as a model is an excellent way 
of clarifying the options of interest. It provides deterministic outcomes such as 
expected cost and health benefits of a decision. Comprised of three nodes, the first 
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point in the tree is a decision node (square) which represents the decision question. 
The pathways that follow each option represent a series of logically ordered 
alternative events, denoted by branches stemming from chance nodes (circles). The 
end points of each pathway are represented by outcome nodes (triangles) to which 
values or pay-offs, such as costs, life years, or DALYs, are assigned. Once the 
probabilities and pay-offs have been entered, the decision tree is ‘averaged out’ and 
‘folded back’, allowing the expected values of each option to be calculated. Another 
form is the Markov model that allows a more direct and flexible sequencing of 
outcomes through time unlike decision trees that represent sequences of events as a 
large number of potentially complex pathways. An important limitation is the 
assumption that the transition probabilities depend only on the current health state, 
independent of historical experience. Other alternative models include the patient 
level simulation (microsimulation), discrete event simulations, and dynamic 
models(95). 
 
In recent years, health economic evaluations that were built upon by the integration 
of economic models and more advanced statistical decision, particularly under 
Bayesian approach, were increasingly required to address the uncertainties on 
parameters and observable variables (96-99).  Uncertainties typically exist in economic 
evaluations employing modeling techniques(93) primarily because parameters are 
seldom based on hard facts not to mention the dubiety on their magnitude. It is 
important to deal with uncertainty and heterogeneity since models are built on 
assumptions. Key concepts in understanding uncertainty and heterogeneity include 
variability, parameter uncertainty, decision uncertainty, and heterogeneity(100). 
Variability shows the randomness arising from the modeling process since models 
typically use random numbers when determining whether an event with a given 
probability of occuring happens or not in any given cycle or model run, so that an 
identical patient will experience different outcomes each time they proceed through 
the model. This variability, sometimes referred to as Monte Carlo uncertainty, is not 
informative and needs to be eliminated by running the model reppeatedly until a 
stable estimate of the central tendency has been obtained. Parameter uncertainty 
reflects the uncertainty and imprecision surrounding the value of the model variables 
such as transition probabilities, costs, and health utlities(95).  
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Finally, heterogeneity should be clearly differentiated from variability because it 
reflects differences in outcomes or in cost effectiveness that can in principle be 
explained by variations between subgroups of patients, either in terms of baseline 
characteristics such as age risk level, or disease severity or in terms of both baseline 
characteristics and relative treatment effects. As in the analysis of clinical trials, 
subgroups should be predefined and carefully justified in terms of their clinical and 
economic relevance. A model can then be re-run for different subgroups of patients. 
Alternatively, heterogeneity can be addressed by making model variales functions of 
other variables. As with subgroup analysis in clinical trials, care must be taken to 
avoid generating apparently large differences in cost-effectivenss that are not based 
on genuine evidence of heterogeneity(95). 
 
Standard sensitivity analysis, in which each variable is varied separately and 
independently, does not give a complete picture of the effects of joint uncertainty and 
correlation between variables. One of the methods that are increasingly used and 
has been considered as state-of-the-art in addressing these uncertainties is the 
probabilistic sensitivity analysis (PSA)(101), in which all variables are varied 
simultaneously using probability distributions informed by estimates of the sample 
mean and sampling error from the best available evidence, is therefore the preferred 
way of assessing parameter uncertainty. PSA is usually executed by running the 
model several thousand times, each time varying the parameter values across the 
specified distributions and recording outputs(95). 
 
Moreover, the National Institute for Clinical Excellence (NICE) in UK suggested that 
in order to come up with unbiased result estimates as well as to characterize decision 
uncertainties, PSA should be applied in doing health economic evaluations(102-
104).PSA is a useful sensitivity analysis technique that provides some level of 
confidence to economic evaluation outcomes.  The procedure entails treating the 
uncertainties of input parameters as random quantities associated with specific 
probability distribution based on prior information of the decision maker. This method 
is in accordance with the Bayesian analysis carrying its trademark that parameters 
have a probability distribution.  To support the process, a Monte Carlo simulation is 
carried out by randomly drawing one value for each parameter based on the 
probability distribution and then estimating the outcome in relation to the set of 
parameters drawn.  The model is run repeatedly or bootstrapped for X trials, yielding 
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X outcome values (or bootstraps) that represent the probability distribution made(101, 
105).  
 
These methods provide a framework within which an appropriate structure for the 
underlying disease and the impact of all relevant options under evaluation can be 
developed, all existing evidence can be brought to bear and, through PSA, joint 
implications of parameter uncertainty on the uncertainty in the decision can be 
quantified. 
 
 
 
 
2.4.3. The role of CEA for priority-setting and decision-making in 
relation to multi-parasite control strategies 
 
Cost-effectiveness analysis has become a widely used technique in evaluating health 
interventions to guide health policy(18)  in both developed(106) and developing 
countries(53, 107).  It has been considered to be a key guiding tool in crafting health 
policy where resources are limited, especially in developing countries(108).  Although a 
number of economic evaluations had already been conducted such as those that 
looked at parasitic intervention programmes in Cambodia(16), China(17), and 
Uganda(18), a similar economic evaluation has not yet been done for the Philippines. 
Several Asian studies found out that deworming programmes for school children in 
Lao PDR(20), Vietnam(19) and Cambodia(21) constitute low treatment costs, however, 
these studies were not comprehensive evaluations since cost-effectiveness was not 
estimated.  
 
On the otherhand, mass treatment has been found out to be more cost-effective 
compared to no control of Schistosoma mekongi in Cambodia. Such finding that 
mass treatment is cost-effective also applies when compared to targeted treatment 
based on the study that looked into the strategies for S. japonicum control in 
China(17).  However, such approach has been proven to be unsuccessful in Africa(109), 
Sahelian County(110), and Mali(111). It was also found out that the target audience (i.e., 
infants and preschool children) were not really treated (only less that 50% of the high 
risk groups did receive the drug) and that the uninfected population was 
unnecessarily provided with treatment(112-114). Such approach has been questioned 
primarily because it sets out to treat everyonerather than focus on case finding and 
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targetedchemotherapy(115), and it has shown to be sensitive to coverage achieved(22), 
which has been found to be typically low in the Philippines(11). Thus, a comparison of 
the cost-effectiveness of mass-treatment against targeted-treatment is necessary to 
come up with a more sensitive parasite control policy for the Philippines.  
 
 
2.5. Intracountry variation of cost in the healthcare delivery 
 
Cost-effectiveness analysis has become a widely used technique in evaluating health 
interventions to guide health policy(18)  in both developed(106) and developing countries(53, 107).  
Cost data can provide valuable information for national decision makers. However, the 
representativeness of reported costs is frequently questionable because they are often 
based on national estimates of total expenditure or estimates from only a few facilities. Thus, 
it is important to look at possible variations of costs and effectiveness estimates of the 
interventions since they can differ even within a country, making it improbable to have a 
universally applicable single estimate of cost-effectiveness(24). Understanding how and why 
costs vary can help assess the degree to which cost and cost-effectiveness estimates can 
be reliably extrapolated across different settings and enable health policy makers and 
programme managers improve national budgeting and planning, identify cost inefficiencies 
and identify priorities by acting as an input to cost-effectiveness analyses.  
 
It is more likely that costs and cost-effectiveness vary even within a single country as what 
has been found out in the delivery of various health interventions in Peru(116), Cuba and 
Thailand(117), Uganda(118), Malawi(119) and Egypt(120).This intra-country variations occurred 
because of several factors such as the differences in relative costs of inputs, technical 
efficiency, and economies of scale(25).   
 
The study in Uganda (2008) suggests that it is possible that further expansion of the 
programme into more remote areas may entail diseconomies of scale due to greater 
transport costs and stretched administrative structures and human resources. The study also 
highlighted the substantial variation between districts in the cost per individual treated with 
praziquantel and albendazole and in cost-effectiveness. Since the same costing methods 
were used in each district, methodological inconsistencies were excluded and instead 
focused on the differences in the underlying production and cost frontiers and in the 
technical efficiency in delivering the intervention. They found that the percentage of total 
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costs attributed to community sensitization differed across districts and was statistically 
associated with the delivery cost per child treated. Differences in these costs were 
predominantly due to the higher number of participants. 
 
In addition, an analysis by Sicuri et.al (2012) on malaria determined that differences in direct 
costs were associated with variations between health system user fees across geographic 
areas. They proposed that heterogeneity of household expenditure should be taken into 
account when the equity of treatment is debated(121). Such variations also reflect the 
differences with respect to the demography and epidemiology of disease, availability of 
health care resources and system of health care delivery(26) of the various sub-national 
levels.  The spatial component of costs and effectiveness, therefore, is expected to differ not 
just among countries but also within a single country. It is important to carefully consider 
which costs can be reliably extrapolated across different programmes with the use of 
empirical studies together with the development of modeling techniques. These studies can 
identify potential cost savings and technical efficiencies, thereby producing informed policy 
decisions and promote long-term sustainability of national programmes(118). 
 
Considering the gaps in the conduct of economic evaluation of control strategies (i.e., mass- 
versus targeted treatment, and annual- versus biannual administration), not to mention its 
significance in the decision-making aspect for the Philippines, a developing country with 
competing priorities but with limited resources, it is just timely and essential to conduct this 
research that will lead to more effective (and value for the money) preventive interventions 
for important human parasitic diseases. 
 
 
2.6. Summary 
 
STH infections, which are primarily transmitted by eggs that can be found in human feces, 
are considered as one of the most common infections worldwide especially in most tropical 
countries like the Philippines.  It was observed that countries where these infections are 
endemic are also being faced with compounding factors such as poverty, inadequacy of 
sanitary facilities and knowledge on desired health behaviors, indiscriminate defecation and 
poor eating habits of the populace.  Moreover, the responsiveness of a country’s health 
systems could also serve as contributing factor as to how the country’s health agency and 
authorities manage and control these diseases.    
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The devolution of health services in the Philippines has resulted in the deterioration and 
inequities of health care delivery in the country.  Several reasons have been noted such as 
the lack of adequate management capacity, the inefficient system of communication both 
vertical (i.e., at various levels of government) and horizontal (i.e., within the same levels of 
government), and the lack of resources in most LGUs.  Despite reforms to address these 
issues, a fragmented health system continues to exist in the country because of the 
involvement of the different levels of government with considerable autonomy and discretion 
in the interpretation of central (i.e., DOH) policy directions.  Local politics play great control 
and influence in the provision of the health services in the respective areas of jurisdictions, 
resulting in significant variations of the quality of health services delivery throughout the 
country. 
 
Global efforts are being undertaken to address these worm infections. WHO recommends 
periodic medicinal treatment (deworming) without previous individual diagnosis to all at-risk 
people living in endemic areas. Treatment is accordingly given once a year when the 
prevalence of soil-transmitted helminth infections in the area is over 20%, and twice a year 
when the prevalence of soil-transmitted helminth infections in the area is over 50%.  People 
who are considered at risk include the school-age children, pregnant women, and adults 
whose occupations include direct exposure to endemic environments. 
 
The global prevalence and burden of the disease have been estimated to further examine 
and understand these STH infections.  An approach to measure the overall disease burden 
of STH is the DALYs, which combines both the years of life lost due to premature mortality 
(YLL) and years of life living with disability (YLD).  On the other hand, economic evaluations 
are being carried out to compare and anemia the costs and consequences of two or more 
course of actions or health care interventions. There have been cost-effectiveness analyses 
of parasitic intervention progammes in countries such as Cambodia, China, and Uganda.  
However, there is no similar economic evaluation conducted yet for the Philippines.  
Moreover, given the country’s devolved health set-up, it is interesting to look at possible 
variations of costs and effectiveness estimates of the STH interventions.  It has been 
observed in other countries that costs and cost -effectiveness estimates of various health 
interventions have varied even within the country.  
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After reviewing several studies in the literature about the extent of STH infections, the global 
and country-level strategies and efforts being undertaken, and the importance of measuring 
the burden of disease and evaluating some interventions in relation to these infections, a 
more in-depth review of how economic evaluation should be carried out is deemed 
necessary.  The next chapter walks us through some economic evaluation studies of multi-
parasite control strategies that have been conducted by examining what constitute a good 
practice in performing such.  Furthermore, through this process, we can understand better 
the economics of controlling these parasitic diseases. 
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CHAPTER III.   A SYSTEMATIC REVIEW OF  ECONOMIC EVALUATION 
STUDIES OF MULTI-PARASITIC DISEASES CONTROL 
STRATEGIES 
 
 
This chapter starts with a brief overview and introduction in conducting the systematic review 
of economic evaluation studies using some good practice guidelines as presented in the 
literature as well as the CHEERS statement (3.1).  The aims and objectives of the study are 
also presented (3.2) followed by the methodology (i.e., search strategy and selection criteria) 
used to identify economic evaluation studies to be included in the systematic review (3.3), 
followed by the presentation of the results of the review examining and comparing some key 
economic evaluation components (3.4.1), costs and outcomes that have been considered 
(3.4.2), the respective economic evaluation results or findings of these studies (3.4.3), and 
the assessment results of the report of quality (3.4.4).  Discussions of the results (3.5) and 
summary conclusions (3.6) of the reviewed economic evaluation studies have been carried 
out to end the chapter.  
 
 
3.1. Overview 
 
Soil-transmitted helminth infections are among the most common infections worldwide 
causing distress to people in many parts of the world particularly in poor rural communities. 
High intensity or long-standing infections lead to a variety of sequelae such as the negative 
impact on pregnancy and birth outcome, cognitive and physical development, and work 
capacity. Globally, there are several programs dealing with prevention and control of 
parasitic diseases. Approaches to resource allocation and planning for parasitic control must 
be done in a systematic way and an important tool developed is the conduction of economic 
evaluations that systematically assess the effectiveness, cost effectiveness and impact of 
interventions on both patient health and the health care system(14).   
 
The recognition of the need to evaluate disease intervention strategies is evident in the 
growing number of economic evaluation studies being conducted and published. Evidence-
based policy making cannot solely rely on a single study thus, there is a need for policy 
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makers and the researchers that support them to utilize all partially relevant studies that are 
already available. In order to rule out that there is not already in existence a recent, highly 
relevant and rigorously conducted analysis of essentially the same problem, it is necessary 
to conduct a systematic review of previous economic evaluations. The huge amount of 
research produced each year often arrive with conflicting findings. These between-study 
differences may be due to study differences, flaws or chance (sampling variation). In such 
situations, it is not always clear what the overall picture is, or which results are most reliable 
and should be used as the basis for practice and policy decisions.  Systematic reviews aim 
to address these problems by identifying, critically evaluating, and integrating the findings of 
all relevant, high-quality individual studies addressing one or more research questions.  
Although a number of economic evaluation studies on parasite control strategies have been 
published and made available, not all of them can be considered as valuable and useful in 
assisting programme managers and policy makers choose which among the competing 
intervention strategies has the best value for the money. 
 
In this study, we are planning a model for estimating the cost and effectiveness of four 
strategies that could possibly help in the control of STHs and schistosomiasis in  the 
Philippines.  For priority setting in the field of multi-parasitic disease control strategies, there 
is a high demand for economic evaluation studies according to a method of high-quality.  
Economic evaluation studies will gain value when they are of high quality and use 
comparable methods across the field that are in line with the methodology used for other 
public health issues. Therefore, it is critical to compile the existing economic evidence to 
reveal which methodological approaches are currently used within the field of helminthic 
control and prevention. Moreover, it is necessary to assess some key economic evaluation 
factors that have been considered by these studies and also to critique their value in 
understanding the economics of controlling parasitic diseases.  This review focuses on two 
of the major parasitic infections (i.e., Schistosomiasis and Soil Transmitted Helminthiasis, 
STH) in many low-income developing countries like the Philippines. 
 
In performing economic evaluations, good practice guidelines have been laid down(13, 88, 122, 
123).  Although there are disagreements among health economists over what constitutes good 
practice, broad areas of agreement are as follows(124): 
a. Evaluate reliability.  Readers should be provided with sufficient details on how 
costs and effects were evaluated and measured; 
b. Marginal rather than average costs should be used; 
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c. Options or alternatives used for comparison should be clearly stated; 
d. The viewpoint or perspective of the analysis should be clearly stated;  
e. Some form of discounting to either costs or effect or both; and  
f. The sensitivity of the results should be explored. 
 
This set of broad agreements of what constitutes a good practice will be used to present and 
characterize the information that has been captured in the selected economic evaluation 
studies given the predefined inclusion criteria. 
 
Aside from the above guidelines, assessing the quality of economic evaluations follow the 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist 
supported by the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) organization and jointly endorsed by BMJ and nine other publications. All of the 
checklist have a number of key criteria in common that need to be reported in order for 
studies to adequately examine costs within an economic analysis. The CHEERS checklist 
includes 10 basic areas: (1) title and abstract (2 items); (2) introduction (1 item); (3) methods 
(14 items); (4) results (4-items); (5) discussion (1 item); and (6) other, which is related to 
funding and conflict of interest (2 items)(125). Not all questions can be applied to all studies as 
the checklist covers questions related to cost-effectiveness modeling and preference-based 
outcomes, which are not appropriate to all methods. However, it does specify clear criteria 
what the studies that purport to be economic analyses should include. Such checklists can 
give an indication of how well the published literature are adhering to the established 
guidelines and criteria for the reporting of economic analyses. A limitation to any such 
checklist is that it simply gives an indication to any such checklist is that it simply gives an 
indiction of how many items have been included or excluded within an article but not the 
relative importance. However, it can be inferred that those articles who answer and include 
more criteria from the checklists are likely to be of higher quality. 
 
This study due to certain limitations is coded solely by the researcher. Although it was 
technically shown in a study(126) that the use of two or more independent screeners/coders 
results in substantial reductions in errors in systematic review and suggests that as an 
‘evidence-based’ practice, one should always use multiple coders unless it can provide a 
burden of proof that attempts were made to minimize bias and error at each step in the 
review process. The burden of proof is on reviewers to show that the use of a single coder 
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does not diminish accuracy.  A single coder has been utilized in this research since no other 
individuals (investogators/Research Assistants) were employed and deeply involved in the 
collection of the data.  Moreover, the researcher has no reason for bias or no personal stake 
or interest in whatever findings the research would turn out 
 
 
3.2. Aims and Objectives 
 
The purpose of this section is to conduct a systematic review of the existing peer-reviewed 
literature on the control strategies used in parasitic diseases (i.e., STH and schistosomiasis). 
This also done to critically assess the quality of economic evaluations of control 
interventionsusing the CHEERS checklist thatoffer an opportunity to examine how well the 
published literature reported the recommended key criteria that had been identified for 
reporting economic analyses. In the end, we intend to critique these studies in terms of their 
significance in decision making and to equip future researchers with a deeper understanding 
of the economics of controlling these parasitic diseases. 
 
 
3.3. Methods 
 
A systematic review was conducted to identify studies that evaluated health programmes 
and intervention on muti-parasitic diseases. The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines were followed in this report.  
 
3.3.1. Search Strategy 
 
Searches were conducted in EM BASE, Science Direct, Medline, CINAHL with Full 
Text (Cumulative Index to Nursing & Allied Health), Econ Lit, and ACADEMIC 
SEARCH ELITE, by using search keywords or phrases such as schistosomiasis (or 
Schistosoma), Soil-Transmitted Helminthiasis (or helminth) cost analysis, cost 
effective analysis, cost benefit analysis, or cost utility analysis to identify published 
articles thatmet the set predefined inclusion and exclusion criteria (Table 1). Full 
articles were obtained and further evalutaion regarding their suitabilty was assessed. 
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Table 1:  Details of search strategy 
 
Search 
Criteria Keywords/synonyms Keywords/synonyms 
Electronic 
Databases 
Population Developing countries 
Schistosomiasis 
Schistosoma 
Soil-Transmitted 
Helminthiasis 
Helminth 
 
EM BASE 
Science Direct 
Medline 
CINAHL 
Econ Lit 
Academic 
Search Elite 
Intervention Mass treatment Targeted therapy 
Clinical Trial Based 
Evaluation 
Decision Analytic 
Model 
Comparison  Cost analysis 
Cost effective analysis 
Cost benefit analysis 
Cost utility analysis 
Outcomes 
DALY 
QALY 
YLD 
 
 
3.3.2. Selection Criteria 
 
Using the predefined inclusion and exclusion criteria (Table 2), a review of published 
on-line articles between January 1990 and December 2012 was conducted.  We 
included all published on-line full text articles or manuscripts in which STH and 
schistosomiasis control strategies underwent full economic evaluation.  Database 
searches were also restricted to studies written in English language that have been 
published between January 1990 and December 2012.  We also considered both 
clinical trial-based evaluation and decision-analytic model in our inclusion criteria. 
Unlike in trial-based evaluations wherein costs and effectiveness parameters are 
obtained from the same data collection exercise, parameter values for modeling 
studies have been derived from various sources which are then combined in a 
decision-analytic model. Both evaluation approaches come with their own 
advantages and disadvantages(127). However, given the ability to include long-term 
costs and outcomes, side by side evaluation of all relevant competing control 
interventions, and it being more generalizable, model-based evaluations are 
becoming more preferred approach to healthcare economic evaluations compared to 
trial-based evaluation(92).  Nevertheless, we should take into consideration the 
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quality, design, and unbiasedness of the models for them to be more useful in 
policymaking(127). 
 
Table 2:  Inclusion and exclusion criteria 
 
Inclusion Criteria 
 Full text of the article or manuscript is available through the identified 
databases; 
 The study presents a full economic evaluation; 
 The approach of evaluation is based on a decision-analytic model or clinical 
trial-based evaluations rather than case studies; and 
 Written in English. 
Exclusion Criteria 
 Not an economic evaluation study or does not consider both the resource input 
(cost) and gains/outcome of the intervention; 
 Dealt with case study evaluations only; 
 Article did not include an original analysis (e.g., editorials, reviews); 
 Merely confined with hypothetical data (e.g., methods articles); 
 Provided partial or unclear details on methods (e.g., letters); and 
 Evaluation did not involve/deal with chemotherapy as control strategy. 
 
 
3.4. Results 
 
From the initial database search, there were 139 studies that have been identified.  Ninety-
four studies were excluded because they were neither economic evaluation studies nor full 
economic evaluations.  Of the remaining 45 potential economic evaluation studies, 14 were 
excluded because they were case studies or did not include an original analysis; 10 because 
they dealt with merely hypothetical data or partial/unclear details on methods; and 8 because 
they did not involve chemotherapy as control strategy, singly or in combination with other 
strategies.  The final literature sample consisted of 13 economic evaluation studies that 
satisfied the inclusion criteria.  Figure 3 shows the flow chart of the manuscript selection 
process. 
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Figure 3:  PRISMA flow diagram of the manuscript selection process 
 
 
3.4.1. Comparison of selected components of the economic evaluation 
studies 
 
The set of broad agreements of what constitutes a good practice in performing 
economic evaluations mentioned earlier was used to characterize the information 
contained in the 13 economic evaluation studies that have been qualified given the 
predefined inclusion criteria.  Table 3 presents the comparison of selected 
components or factors that have been captured in the selected economic evaluation 
studies.  This study looked at the following components to compare what have been 
considered by these economic evaluation studies: a) year when the strategy 
intervention was implemented or carried out; b) setting of the study; c) disease or 
diseases looked at; d) alternatives being compared;  e) evaluation approach used; f) 
whether marginal analysis was employed or not; g) to whose perpective has the 
study been carried out; h) type of economic evaluation analysis; i) whether 
discounting was employed or explicit in the study; and j) presence of sensitivity 
analysis. 
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Table 3:  Economic evaluation studies of STH and schistosomiasis control strategies 
Study 
no. 
Year 
When 
intervention was 
implemented 
Setting Disease looked at Alternatives being compared
a Evaluation approach 
Marginal 
analysis 
employed? 
Perspective Analysis 
Accrued 
over 
time? 
Sensitivity 
analysis? 
1 2003-2005 Uganda 
STH and 
Schistosom
iasis 
a) “do nothing” 
b) nationwide school-based treatment of 
helminth 
 
clinical trial-
based 
evaluation 
 
Yes 
Government 
(national 
provider) 
CEA 
Yes, cost 
discount
ed at 3% 
Scenario 
scenario 
sensitivity 
analysis 
2 
1990 
(published 
empirical data 
from studies) 
Egypt Schistosomiasis 
a) school-based (85% coverage) 
b) school-aged targeted  (25% coverage) * 
c) school-aged targeted  (50% coverage) * 
d) school-aged targeted  (85% coverage) * 
* includes option a 
 
decision-
analytic 
model  
Yes 
Government 
(national 
provider) 
CEA 
Yes, a 
discount 
rate of 
5% to the 
number 
of cases 
prevente
d  
probabilistic 
sensitivity 
analysis; 
one way; 
scenario 
3 1995-2003 Cambodia Schistosomiasis  
a) “do nothing” 
b) Schistosomiasis control program based 
on a Mass Drug Administration (MDA) 
 
clinical trial-
based 
evaluation 
 
Yes 
 Governm
ent 
(national 
provider) 
and  
 the 
society 
 CEA  
 
and  
 
 CBA 
Not 
stated 
probabilistic 
sensitivity 
analysis; 
multi-way; 
scenario 
4 2004-2005 Burkina Faso 
STH and 
Schistosom
iasis 
a) “do nothing” 
b) combined school- and community-
based campaign for school-age 
population  
 
clinical trial-
based 
evaluation 
 
Not stated 
Government 
(national 
provider) 
CEA Not stated Not stated 
5 1998-2000 China Schistosomiasis 
a) traditional mass chemotherapy  
b) ‘passive chemotherapy’ plus health 
education 
 
clinical trial-
based 
evaluation 
 
Yes 
Government 
(national 
provider) 
CEA Not stated Not stated 
6 1996-1997 
United 
Republic of 
Tanzania 
STH and 
Schistoso
miasis 
a) “do nothing” 
b) school-based anthelmintic treatments 
(mass treatment with albendazole and praziquantelon anemia in school-age children) 
clinical trial-
based 
evaluation 
 
Yes 
Government 
(district 
provider) 
CEA Not stated Not stated 
7 1989-1990 Nigeria STH 
a) Selective chemotherapy 
b) Targeted chemotherapy 
c) Mass chemotherapy 
 
clinical trial-
based 
evaluation 
Not stated 
Government 
(district 
provider) 
CEA Not stated Not stated 
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Table 3:  Economic evaluation studies of STH and schistosomiasis control strategies 
Study 
no. 
Year 
When 
intervention was 
implemented 
Setting Disease looked at Alternatives being compared
a Evaluation approach 
Marginal 
analysis 
employed? 
Perspective Analysis 
Accrued 
over 
time? 
Sensitivity 
analysis? 
8 2001-2002 Nigeria Schistosomiasis 
a) Chemotheraphy using praziquantel 
b) Chemotheraphy using oral artesunate 
(given two doses, each of 6 mg/kg, given 2 
weeks apart) 
 
clinical trial-
based 
evaluation 
Not stated 
Government 
(national 
provider) 
CEA Not stated Not stated 
9 Not stated Kenya Schistosomiasis 
a) Status quo (SQS);  
b) Household piped water supply 
(HPWSS);  
c) House-to-house health education visits 
(HHEVS);  
d) Household vented improved pit latrine 
(VIPLS); 
e) Focal mollusciciding (FMS); 
f) Mass population chemotherapy with 
praziquantel (MPCPS); 
g) Mass population chemotherapy with 
oxamniquine (MPCOS);  
h) Selective population chemotherapy with 
praziquantel (SPCPS); and 
i) Selective population chemotherapy with 
oxamniquine (SPCOS). 
decision-
analytic 
model 
Yes Social perspective CUA 
Yes, 
benefits 
and 
costs 
were 
discount
ed at 
10%. 
probabilistic 
sensitivity 
analysis 
10 2004 Niger 
STH and 
Schistoso
miasis 
Mass Drug Administration (MDA) 
programme 
 
a) School Based Mass Drug 
Administration  
b) Community Distributed Mass Drug 
Administration 
clinical trial-
based 
evaluation 
Yes 
Government 
(national 
provider) 
CEA 
Yes, cost 
discount
ed at 3% 
Scenario 
sensitivity 
analysis 
11 Not stated Bangladesh STH 
a) Albendazole chemotherapy to all 
household members at the 
commencement of the 18-mo. study 
period 
b) Same as option “a” and regular 
education throughout the study period. 
c) Albendazole chemotherapy to all 
household members at the 
commencement of the study and 
clinical trial-
based 
evaluation 
Yes 
Government 
(district 
provider) 
CEA Not stated Not stated 
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Table 3:  Economic evaluation studies of STH and schistosomiasis control strategies 
Study 
no. 
Year 
When 
intervention was 
implemented 
Setting Disease looked at Alternatives being compared
a Evaluation approach 
Marginal 
analysis 
employed? 
Perspective Analysis 
Accrued 
over 
time? 
Sensitivity 
analysis? 
subsequent chemotherapy to all 
children at intervals of 6 months. 
d) Same as option “c” with the addition of 
regular education throughout the study 
period. 
 
12 1998 - 2000 China 
Schistoso
miasis 
a) ‘clue’ chemotherapy (treatment to those 
with contact with infected water and/or 
symptoms of infection) 
b) ‘mass’ chemotherapy 
(treatment to all the villagers except those 
not able to take praziquantel) 
c) ‘screen’ chemotherapy 
(treatment prescribed to the stool egg 
positive cases after Kato-Katz examination) 
 
clinical trial-
based 
evaluation 
 
Yes 
Government 
(national 
provider) 
CEA 
Yes, cost 
discount
ed at 
10% 
Yes 
13 1992-2000 China Schistosomiasis 
a)  “do nothing” 
b) Community chemotherapy plus health 
education and snail control by means of 
environmental management and 
mollusciciding 
clinical trial-
based 
evaluation 
 
Yes 
Government 
(national 
provider) 
CBA & 
CEA 
Yes, 
discount
ed rate 
not 
specified. 
Not stated  
Sources: Study 1(18); Study 2(128); Study 3(16); Study 4(129); Study 5(45); Study 6(130); Study 7(131); Study 8(132); Study 9(47); Study 10(133); Study 11(46); Study 12(17); Study 13(48) 
a“do nothing” refers to a situation wherein no efforts are being carried out in relation to the control of helminth infection prior to the implementation of control programme/intervention, aside from 
passive detection of cases in health centres and presumptive treatment. 
 
 
In terms of settings, 62% (study #1,2,4,6-10) enganged in economic evaluation of 
parasitic diseases from African countries, while the rest, 38% (3,5,11-13),  came from 
Asia.  Of the thirteen studies that fitted the criteria mentioned above, 7 studies 
(2,3,5,8,9,12,13) looked at strategies for schistosomiasis and 2 studies (7,11) for 
STH singly, the rest (1,4,6,10) considered both diseases together.  In terms of 
evaluation approach, 11 studies (1,3-8,10-13) appliedclinical trial-based evaluation 
and 2 (2,9) made use ofdecision-analytic model.  All of the studies (1-8,10-13) that 
looked at government perspective applied CEA as economic evaluation (2 of them 
considered CBA in conjuncture with CEA), while study (9) that considered the social 
perspective made use of the CUA to evaluate the respective strategies.  Majority of 
the studies, 77% (1-3,5,6,9-13), employed marginal analysis in their evaluation while 
23% (4,7,8) did not state or conduct such process.  Despite the significance of 
discounting costs and outcome measures as well as engaging the results to some 
kind of sensitivity analysis, only 46% of these studies carried out such processes.  
Studies (1,2,9,10,12,13) that carried out discounting made use of either 3%, 5%, or 
10% to costs and/or outcome measures.  On the other hand, studies (1-3,9,10,12) 
that engaged the results to some kind of sensitivity analysis made use of scenario 
and probabilistic sensitivity analysis. The rest of the studies did not explicitly state 
whether discounting or sensitivity analysis had been employed in their evaluation 
process.    
 
Five studies (3,5,7,9,12) compared alternative strategies in terms of mode of delivery 
(e.g., mass vs. targeted/screened); one study (6) in terms of delivery (e.g., single- vs. 
multi-parasite), two studies (8,11) in terms of frequency (e.g., semi-annual, annual, 
etc.), and the remaining five studies (1,2,4,10,13) in terms of setting (e.g., school- vs. 
community-based).   
 
The comparison of studies in terms of mode of delivery was in a wide array: from 
comparing mass drug administration vs. “do nothing”(16); to mass chemotherapy vs. 
selected strategies of the disease control methods (e.g., health education, snail 
control, and sanitation and water improvement)(45, 47); and to mass chemotherapy vs. 
targeted/screened or selected chemotherapy(17, 131).  In terms of delivery, the effect of 
mass treatment with both albendazole and praziquantel on anemia in school-age 
children was evaluated(130).  In terms of frequency, one study evaluated the use of 
oral artesunate as against the use of praziquantel(132) and the other one looked at the 
use of Albendazole chemotherapy on different intervals through out the study 
period(46).  The other five remaining studies that considered the settings in evaluating 
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the alternatives looked at “do nothing” vs. school-based treatment(18), vs. combined 
school- and community-based(129) vs. community chemotherapy with other control 
methods(48); and school-based drug administration vs. school-age targeted (at 
different coverage rates)(128) vs. community distributed mass drug administration(133). 
 
 
3.4.2. Evaluation of costs and outcomes 
 
Table 4 shows the categories and data sources for costs and outcomes of selected 
economic evaluation studies. 
 
ESTIMATED COSTS. Cost inputs that have been considered in the selected 
economic evaluation studies are comparable in general terms; though, in some 
instances, they have been categorized differently.  For example, cost inputs such as 
salaries, allowances, trainings and drugs are categorized either under project or 
programme costs (1,2,11), household- and government-borne costs (9,10), or 
intervention costs (12); or as part of a broader programme activity (3,4 13).Other 
studies did not consider categorizing these costs inputs but rather cited them directy 
in their cost analysis (5-8).  Aside from study 8 which considers only the cost of 
drugs, all the remaining studies have factored in the other components of cost.   
 
Looking at the data sources for the costing exercise, except for studies 2 and 9, all of 
the studies used either of or in combination the following methods: field monitoring 
records, documents and reports from government agencies (either district or national 
level), and interviews with key individuals.  Studies 2 and 9 which made use of 
decision-analytic model as evaluation approach, have sourced cost inputs through 
estimation and simulation. 
 
Majority (62%) of the studies (2,4-8,11,13) considered only the financial aspect of 
cost.  The remaining 38% of the studies (1,3,9,10,12) not only looked at the cash 
expenditure paid for the implementation of the intervention but also considered the 
opportunity or economic cost of using health workers/staff and school teachers, the 
annuitized capital costs, among others, to represent the true cost of theintervention.  
 
 
 
Table 4:  Categories and data sources for costs and outcomes of STH and schistosomiasis control strategies 
Study 
no. 
Cost Outcome Measures 
Categories Data sources Financial/ Economic Data sources Indicators/Measures 
1 
Programme running costs; 
community awareness; training; 
imported drugs; drug registration 
and distribution; and IEC material 
 
Sub-national figures through 
semi-structured interviews 
with district officials and from 
accounting records. 
Both 
Local outcomes through 
longitudinal surveys of 
programme impact 
Cost per child treated 
 
Cost per anemia case averted 
2 
Programme costs, as well as costs 
not only in providing additional 
anthelmintic treatments but also 
extra delivery costs 
 
Literature and simulation Financial Model-based projections 
Unit cost per person needed in 
the group of not enrolled 
individuals 
3 
Initial investment; Coordination and 
overhead; Distribution cost; and 
Survey cost 
Interviews, National Center 
for Malaria Control (CNM) 
documents/annual reports, 
International Drug Price 
Indicator Guide,  
 
Both 
Programme implementation 
scenario outcomes; 
documents/reports 
Cost per treated person; 
Cost per severe infection avoided; 
Cost per death avoided; 
ICER; 
Cost Benefit Value. 
4 
Coordination (planning; 
supervision; equipment 
allocation and others); Capital 
equipment; Social mobilization; 
Training; Drug distribution; Drugs 
Monitoring forms and reports 
from dispensary level up to 
district, regional, and national 
levels 
Financial Programme monitoring forms and reports 
Costs per child treated 
 
5 
All medicines, including drugs for 
treatment of side effects, 
materials, and salaries for health 
personnel 
Monitoring forms and 
reports Financial 
Laboratory results of 
parasitological 
diagnoses. 
Cost per infected person who 
received treatment  
6 
Cost, Insurance and Freight, CIF; 
training, drug distribution, survey 
questionnaire; 
and drug clearance, movement, 
and repackaging. 
Literature, monitoring forms 
and reports Financial 
parasitological examination 
and anemia evaluation 
reduction in the prevalence of 
anemia ; 
cost per anemia case prevented; 
cost per child treated. 
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Table 4:  Categories and data sources for costs and outcomes of STH and schistosomiasis control strategies 
Study 
no. 
Cost Outcome Measures 
Categories Data sources Financial/ Economic Data sources Indicators/Measures 
8 Cost of drugs National figures Financial 
Literature; standard 
parasitological procedure 
results 
 
Praziquantel Artesunate cost ratio 
9 
Costs to the government of 
organizing and operating 
community-based and health facility-
based schistosomiasis control 
interventions;  
 
Costs borne by households under 
community-based interventions; and  
 
Costs borne by patients, their 
households and community 
members under health facility-based 
intervention options  
 
Delphi panel experts, 
Estimation/simulation Both 
Delphi panel experts, Model-
based projections Incremental cost per QALY 
10 
International support costs; 
Programme expenditure and costs; 
Government contribution such as 
cash & recurrent in kind costs (e.g. 
staff salaries and vehicle usage); 
drug costs; and economic costs 
national programme to 
control schistosomiasis and 
soil-transmitted helminths 
(PNLBG) accounts, receipts 
and record, retrospective 
survey, questionnaire and 
salary grid 
 
Both Result of the longitudinal health impact study 
cost per treatment based on 
delivery mode. 
11 
Project related costs (i.e., salaries 
and allowances of manpower, 
training, production of health 
education materials, drugs, and 
transport) 
monitoring forms and 
reports Financial 
Results of the parasitological 
evaluation 
Cost of unitary Weighted 
percentage reduction in 
prevalence (WPRP) 
 
Cost of unitary Weighted 
percentage reduction in intensities 
(WPRI)  
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Table 4:  Categories and data sources for costs and outcomes of STH and schistosomiasis control strategies 
Study 
no. 
Cost Outcome Measures 
Categories Data sources Financial/ Economic Data sources Indicators/Measures 
12 
Intervention costs (personnel salary, 
per diem, and training, 
consumables, vehicle, capital)  
Monitoring/record forms and 
reports, expert guesses were 
made based on values 
reported in the literature 
(where the data were 
missing) 
Both 
Interview, ultrasound 
examination, parasitological 
examination,  
Cost per infected case prevented 
Cost per 1% reduction of egg per 
gram of feces (EPG) 
Cost per case of liver abnormality 
prevented 
Cost per case of 
spleen abnormality prevented  
 
13 
Case detection and chemotherapy, 
Snail survey and mollusciciding, 
Health education, Livestock control, 
Project management, and Training. 
 
Records and databases of 
the study counties (i.e., local 
antischistosomiasis 
control stations), interview 
with local hospitals and clinic 
specialists, existing 
veterinary records 
Financial 
Field surveys, relevant 
departments of the 
local governments 
Effectiveness indicators: 
 
Reduction in the prevalence rates; 
Total benefit of the project. 
 
Overall cost of project per person; 
Cost for case detection per person; 
Average cost for case detection to 
reduce 1% human infection rate 
per 100 people; 
Overall cost of project to reduce 
1% human infection rate per 100 
people; 
Cost for mollusciciding to reduce 
1000m2 of snail infested areas; 
Cost to reduce1% bovine infection 
rate per 100 cattle. 
 
Cost-benefit: 
 
Total per capita benefit ; 
Net benefit-cost ratio; 
Net benefit (net value). 
Sources: Study 1(18); Study 2(128); Study 3(16); Study 4(129); Study 5(45); Study 6(130); Study 7(131); Study 8(132); Study 9(47); Study 10(133); Study 11(46); Study 
12(17); Study 13(48) 
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OUTCOMES MEASURES.  Cost pe outcome Eleven studies (1,3-8,10-13) looked at 
measures of outcomes  using available programme data (either as a result of 
parasitological evaluation or survey/monitoring reports) while the remaining two 
studies (2,9) used the generated output of the model-based projection and delphi 
panel experts.  Majority of the studies, 92% (1-7,9-13), examined outcome measures 
looking at cost-outcome ratios. Ratios include cost per child/person treated, cost per 
treatment delivery, costs of unitary WPRP and WPRI, cost per case prevented, cost 
per anemia case averted, cost per case of liver abnormality prevented, cost per case 
of spleen abnormality prevented, cost per 1,000EPG, and incremental cost per 
QALY.  On the otherhand, study 8 looked at the ratio of two regimens – the 
praziquantel-artesunate cost ratio. Other outcome measures included reduction in 
the prevalence rates and total, as well as net benefit of the project due to successful 
control activities.  
 
3.4.3. Results of the economic evaluation studies 
 
Results from the selected economic evaluation studies have been tabulated and 
outlined in Table 5. Studies that took the government’s perspective looking at cost-
outcome ratios (1-7,10-13) have examined a wide array of outcome measures.  
 
Cost per child/person treated 
 
As to the cost per child/person treated, studies 1 and 4 have comparable outcome 
results for STH and schistosomiasis wherein financial cost is at US$0.39 and 
US$0.32, respectively. Study 1 looked at nationwide school-based treatment option 
while study 2 considered the combined school- and community-based treatment 
option. The cost figure, however, increases to US$0.54 after considering the 
economic cost (1). Study (6) that looked at cost per child treated for both diseases for 
school-based treatment option came up with a higher financial cost of US$1.02 
(US$0.79 and US$0.23 for school-based Schistosomiasis and STH treatment, 
respectively) over a 15-month period. On the otherhand, study 3 came up with cost 
per person treated for MDA-based Schistosomiasis control program of 
US$1.02/annum, a bit higher than that of study 6 partly because of the inclusion of 
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economic costs in estimating the total cost of intervention.  It should be noted, 
somehow, that figures for the baseline intervention ‘do nothing’ options were not 
explicitly specified in these studies. On the contrary, study 7 estimated the financial 
cost per person treated for three STH control strategies as follows: US$46.96 for 
selective chemotherapy, US$2.76 for targeted chemotherapy, and US$1.39 for mass 
chemotherapy (local currency converted already to US$ using 1990 conversion rate).  
Given the cost-outcome results, it is evident that mass chemotherapy (7) is generally 
the strategy of choice for STH having the least cost per person treated.
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Table 5:  Results of economic evaluations of STH and schistosomiasis control strategies 
Study 
no. Intervention Estimated cost Estimated gain/benefits 
Cost per outcome 
Outcome Ratio 
1 
• Baseline: “do nothing” 
 
• Nationwide school-based 
treatment of helminth 
 
• Not stated 
 
• US$161,312 – total financial cost 
    US$218,303 – total economic cost 
 Prevalence (%) of anemia: 35.2% 
(512 cases) 
 52.5% reduction in the proportion 
of anemia cases 
   -- 
 Cost per child treated: 
- Financial cost 
- Economic cost 
 
Cost per case of anemia 
averted 
   -- 
 
 
 
- US$0.39 
- US$0.54 
 
 US$3.19 
2 
 
 
• School-based (85% 
coverage) 
 
• School-aged targeted  
(25% coverage)  
 
• School-aged targeted  
(50% coverage)  
 
• School-aged targeted  
(85% coverage)  
 
 
Cost per child treated (Assumption) 
• US$ 0.60 
 
 
• US$ 0.2 - US$ 1.00 
 
 
• US$ 0.2 - US$ 1.00 
 
 
• US$ 0.2 - US$ 1.00 
   S. mansoni        S. haematobium 
Infection   Early diseaseInfection Early disease 
 
 70764       17417        20279         
143 
 
 
 86222       19966        32318          
223 
 
 
 97353        21498       39682          
268 
 
 
107117       22680       44889          
289 
   S. mansoni            S. haematobium 
InfectionEarly diseaseInfectionEarly disease 
 
  [0.6]          [0.6]           [0.6]       [0.6] 
 
 
  1.64          1.10           1.50       1.42 
 
 
  1.41          0.88           1.21       1.11 
 
 
  1.14          0.67           1.02       0.92 
 
unit cost needed per person in the group of not enrolled 
individuals (groups 3 and 4) for the strategy to be cost 
effective as the school-based approach (strategy 1). 
3 
 “Do nothing” 
 
 
 
 Schistosomiasis control 
program based on a 
Mass Drug Administration 
(MDA) 
 
 estimated to beUS$ 20,000 per 
year (TC: US$180,000 for 9 years 
of implementation 
 
 the total cost of the 
implementation phase (1995–
2003) is estimated to be 
US$737,982. 
 
 
 schistosomiasis prevalence: 
estimated 77% (61,600 individuals 
infected) 
 
 schistosomiasis prevalence: 
estimated 0.5% 
 
The effectiveness of the 9 years 
programme in reducing the number of 
infected individuals was calculated to 
be 99.35%. 
 
 
 The benefits were estimated to be 
US$180,000 (saved costs) 
 -- 
 
 
 
 Cost per treated person 
for the 9 years  
 
 
 
 Cost for each severe 
infection avoided 
 
 Cost for each death 
avoided in 9 years 
 -- 
 
 
 
 US$9.29 per person 
(or US$1.02 per year) 
 
 
 
 
 US$61.50 
 
 
 
Chapter 3. A Systematic Review of Economic Evaluation Studies of  
Multi-Parasitic Diseases Control Strategies 
 
 
Garcia, Fernando Jr., n8415790, School of Public Health and Social Work, QUT Page 60 
 
 
Table 5:  Results of economic evaluations of STH and schistosomiasis control strategies 
Study 
no. Intervention Estimated cost Estimated gain/benefits 
Cost per outcome 
Outcome Ratio 
  
 ICER (representing the 
cost to increase the 
effectiveness of one 
unit)  
 
 Cost-Benefit Value 
(CBV) 
 US$6,531 
 
 
 
 US$7.02 per capita 
 
 
 0.24 
4 
 “Do nothing” 
 
 Combined school- and 
community-based 
campaign for school-age 
population  
• Not stated 
 
• Total cost was US$ 1,067,284. 
 
Delivery costs: US$ 325,936;  
Drug cost was US$ 741,348.  
• -- 
 
• In total, 3,322,564 children treated 
or 90.8% of the estimated school-
age population.  
school coverage rate: 95.6% 
community coverage rate: 87.7%. 
-- 
 
 Costs per child treated 
 
-- 
 
 US$ 0.32 
5 
 Traditional mass 
chemotherapy  
 
 
 
 ‘Passive chemotherapy’ 
plus health education 
 RMB yuan 3,556.7(for the entire 
study period) 
 
 
 
 RMB yuan 1,713.8 (51.8 lower than 
traditional mass chemotherapy) 
 
 100% (treatment coverage rate) 
 
 
 
 
 96.2%-97.1% (treatment coverage 
rate) 
 Cost per infected person 
who received treatment 
 
 
 
 Cost per infected person 
who received treatment 
RMB yuan 44.6 
(1998/1999) 
RMB yuan 77.1 
(1999/2000) 
 
RMB yuan 18.2 (year 
1) RMB yuan 24.4 
(year 2) 
6 
 “Do nothing” 
 
 
 School-based 
anthelmintic treatments 
 Not stated 
 
 
 US$ 40,159.44. 
Effect of mass treatment with albendazole 
and praziquantel on anemia in school-age 
children 
                              Baseline:         15 months 
Prevalence Pre-treatmentPost treatmentHb 
<110 g/l       54.1%         40.0% 
Hb <90 g//l         9.7%            6.1% 
Hb <70 g/l          1.5%            0.8% 
 
 
A total of 39,372 children were treated 
with both praziquantel and albendazole. 
 -- 
 
 
 Cost per child treated 
 
 
 
 
 
Cost per anemiacase 
prevented over 15 months  
 -- 
 
 
 US$1.02(US$0.79 
and US$0.23 for 
praziquantel and 
albendazole, 
respectively) 
 
 
US$7.43 
7 
 
 
 Selective chemotherapy 
 
 
  Nigerian Naira (NGN)  12,490.80 
Reduction in egg intensity was used 
as an intermediate measure of output: 
 2,496 eggs per gram  
      (36 people treated) 
Cost per 1,000 egg         Cost per person  
reduction per gram           treated       . 
 NGN 5,004.00             NGN347.00 
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Table 5:  Results of economic evaluations of STH and schistosomiasis control strategies 
Study 
no. Intervention Estimated cost Estimated gain/benefits 
Cost per outcome 
Outcome Ratio 
 
 Targeted chemotherapy 
 
 Mass chemotherapy 
 
 
 Nigerian Naira (NGN)    3,956.10  
 
 
 Nigerian Naira (NGN)    4,700.90 
 
 6,478 eggs per gram  
(194 people treated) 
 
 10,417 eggs per gram  
(455 people treated) 
 
 NGN    611.00             NGN  20.40 
 
 
 NGN    451.00             NGN  10.30 
8 
 Chemotheraphy using 
praziquantel 
 
 Chemotheraphy using 
oral artesunate 
 
For subjects weighing 20–60 k: 
 cost of artesunate:  U.S.$1.11–3.33  
cost of praziquantel: U.S.$1.93–
5.93.  
 
Praziquantel treatment would 
generally be about 1.78-fold more 
expensive than artesunate. 
 .-- 
 
 
 Of the 87 subjects who were 
treated with two doses of 
artesunate, 61 (70.1%) appeared 
cured by the treatment. 
 Praziquantel Artesunate 
cost ratio  1.73:1 to 1.81:1 
9 
 
 
• Status quo (SQS);  
• Household piped water 
supply (HPWSS);  
• House-to-house health 
education visits (HHEVS);  
• Household vented 
improved pit latrine 
(VIPLS); 
• Focal mollusciciding 
(FMS); 
• Mass population 
chemotherapy with 
praziquantel (MPCPS); 
• Mass population 
chemotherapy with 
oxamniquine (MPCOS);  
• Selective population 
chemotherapy with 
praziquantel (SPCPS); 
and 
• Selective population 
Total cost (in Ksh) 
Foreign expertsLocal experts 
• Ksh 347,548,217        Ksh 
569,055,519 
• Ksh 361,521,325        Ksh 
424,271,493 
 
 
• Ksh 291,750,508        Ksh 
452,153,928 
 
 
• Ksh 810,363,736        Ksh 
946,857,458 
 
 
• Ksh 244,151,321        Ksh 
290,643,818 
 
• Ksh 212,735,211        Ksh 
236,390,603 
 
 
 
Total Expected QALYs 
Foreign expertsLocal experts 
•    335,132                   2,504,365 
•    377,990                 11,998,780 
 
 
•    387,689                 11,887,600 
 
 
•    387,575                 12,138,675 
 
 
•    402,779                 12,037,874 
 
•    425,365                 14,013,933 
 
 
 
•    425,365                 13,489,119 
 
 
 
•    420,134                 14,013,933 
 
Incremental cost per QALY 
Foreign expertsLocal experts 
•           ---                          --- 
•          326                       -15 
 
 
•      -1,062                       -12 
 
 
•       8,825                        39 
 
 
•      -1,529                       -29 
 
•      -1,494                       -29 
 
 
 
•      -1,063                       -26 
 
 
 
•      -2,301                       -35 
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Table 5:  Results of economic evaluations of STH and schistosomiasis control strategies 
Study 
no. Intervention Estimated cost Estimated gain/benefits 
Cost per outcome 
Outcome Ratio 
chemotherapy with 
oxamniquine (SPCOS). 
• Ksh 251,626,046        Ksh 
274,496,299 
 
 
 
• Ksh 151,998,743        Ksh 
162,723,615 
 
 
 
• Ksh 174,154,033        Ksh 
198,435,423 
 
 
•    420,134                 13,489,119 
 
 
 
•      -2,040                       -33 
 
10 
• Mass Drug Administration 
(MDA) programme 
 
 
 
Two systemsused to treat 
children and targeted adults 
• School Based Mass Drug 
Administration  
 
 
 
 
 
 
 
 
 
 
 
 
 
• Community Distributed 
Mass Drug Administration 
 
 
 
• US$ 456,718 (Total discounted 
economic cost of the MDA 
programme) 
 
 
 
 
 
 
• -- 
 
 
 
 
 
 
 
 
 
 
 
 
 
• -- 
• People treated in two years 
totalled 818,562 (781,883, 
discounted at 3%). 
 
 
 
 
 
• 70 treatments average per teacher 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 407 treatments average per 
Community Drug Distributor 
(CDD) 
• Total economic cost per 
treatment 
 
Financial or programme 
cost per treatment 
 
• Economic delivery cost 
per treatment 
 
Financial or programme 
cost per treatment 
 
Cost/person school 
based delivery 
(Sub district programme 
delivery cost)  
 
• Economic delivery cost 
per treatment 
 
Financial or programme 
cost per treatment 
 
Cost/person CDD 
delivery 
(Sub district programme 
delivery cost) 
• US$ 0.58 
 
 
 
US$ 0.48 
 
 
 
• US$ 0.76 
 
 
 
US$ 0.47 
 
 
 
US$ 0.11 
 
 
 
 
 
• US$ 0.46 
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Table 5:  Results of economic evaluations of STH and schistosomiasis control strategies 
Study 
no. Intervention Estimated cost Estimated gain/benefits 
Cost per outcome 
Outcome Ratio 
 
 
 
US$ 0.41 
 
US$0.05 
11 
 
 
a) Albendazole 
chemotherapy to all 
household members at 
the commencement of 
the 18-mo. study period 
b) Same as option “a” and 
regular education 
throughout the study 
period. 
c) Albendazole 
chemotherapy to all 
household members at 
the commencement of 
the study and 
subsequent 
chemotherapy to all 
children at intervals of 6 
months. 
d) Same as option “c” with 
the addition of regular 
education throughout 
the study period. 
 
Project Cost (in takas) 
•               155,431 
 
 
 
 
 
 
•            1,016,765 
 
 
 
 
•               175,431 
 
 
 
 
 
 
 
 
 
•            1,036,765 
 
 
 
WPRPWPRI 
•         39%                 64% 
 
 
 
 
 
 
•         28%                 60% 
 
 
 
 
•         38%                 69% 
 
 
 
 
 
 
 
 
 
•         95%                 67% 
 
 
      Cost of unitary          Cost of unitary 
WPRP (in takas)WPRI (in takas) 
•         3,985                              2,429 
 
 
 
 
 
 
•        36,313                            16,946 
 
 
 
 
•         4,617                              2,542 
 
 
 
 
 
 
 
 
 
•        10,913                            15,474 
 
 
12 
 
 
a) ‘Clue’ chemotherapy 
 
b) ‘Mass’ chemotherapy 
 
c) ‘Screen’ chemotherapy 
 
Cost after the two years of 
intervention: 
 
 
 RMB yuan 12,053.3 
 
 RMB yuan 13,379.0 
 
Number of  cases prevented (after the two years 
of intervention) 
Schistosome  Abdominal               Liver            Spleen 
Infection pain     DiarrheaAbnormalityAbnormality 
• 86         95       36        41         20 
 
• 83       134       32      134         61 
 
• 59         --        --         --            20 
 
Cost per infected case 
prevented 
 
Cost per 1% reduction of 
EPG 
 
Cost per case of liver 
abnormality prevented 
Interventions: 
  A      B     C  . 
• 140.2   161.2   190.0 
 
 
• 169.3   176.3   145.0 
 
•    ---       99.8      --- 
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Table 5:  Results of economic evaluations of STH and schistosomiasis control strategies 
Study 
no. Intervention Estimated cost Estimated gain/benefits 
Cost per outcome 
Outcome Ratio 
 RMB yuan 11,210.6   
Cost per case of 
spleen abnormality prevented 
 
 
• 602.7   219.3   448.4 
13 
a) “Do nothing” 
 
b) Community 
chemotherapy plus 
health education and 
snail control by means 
of environmental 
management and 
mollusciciding 
 
 --- 
 
 RMB yuan 97,169,632 
- Cases detection:    RMB Yuan 
12,830,878 
- Chemotherapy:      RMB Yuan 
16,502,478 
- Snail survey:          RMB Yuan   
5,213,797 
- Mollusciciding:       RMB Yuan 
48,372,383 
- Health education:  RMB Yuan   
2,415,022 
- Livestock control:  RMB Yuan  
4,632,367 
- Management:        RMB Yuan   
5,415,551 
- Training:                RMB Yuan   
1,787,157 
 -- 
 
Effectiveness: 
The prevalence rates decreased 
significantly over time in the six 
counties: 
From:  0.7–9.0% in 1992  
To:      0.1–2.7% in 2000 
 
 
Benefit:  
 
Total benefit of the project in the six 
counties during the 9-year evaluation 
period was RMB Yuan 699.512 
million.  
 
Direct benefit of schistosomiasis 
control was RMB Yuan 650.676 
million. 
 
Benefit from mollusciciding 
engineering project was RMB Yuan 
48.835 million. 
 -- 
Cost-effectiveness: 
 
Overall cost of project per 
person 
 
Cost for case detection per 
person 
 
Average cost for case 
detection to reduce 1% 
human infection rate per 100 
people 
 
Overall cost of project to 
reduce 1% human infection 
rate per 100 people 
 
Cost for mollusciciding to 
reduce 1000m2 of snail 
infested areas 
 
Cost to reduce1% bovine 
infection rate per 100 cattle 
 
Cost-benefit: 
 
Total per capita benefit  
 
Net benefit-cost ratio 
 
Net benefit (net value) 
RMB Yuan 41.86 
 
 
RMB Yuan 12.48 
 
 
RMB Yuan 2,176.72 
 
 
 
 
RMB Yuan 7,732.42 
 
 
 
 
RMB Yuan  3,573.18 
 
 
 
RMB Yuan 162,891.10 
 
 
 
RMB Yuan 1,804  
 
6.20RMB Yuan 602.34 
million 
Sources: Study 1(18); Study 2(128); Study 3(16); Study 4(129); Study 5(45); Study 6(130); Study 7(131); Study 8(132); Study 9(47); Study 10(133); Study 11(46); Study 
12(17); Study 13(48)
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Study 10 has estimated the cost per treatment for school- and community-based 
delivered MDA strategies in 2005/06 for both Schistosomiasis and STH.  Dealing 
only with financial or programme cost, school-based MDA costs US$0.47, and for 
community-based, US$0.41. Figures increase when we consider the economic cost 
reaching US$0.76 and US$0.46, respectively.  The cost per person based on 
delivery mode registers a 50% cheaper using the community approach (US$0.15) as 
compared to school-based (US$0.11).  Moreover, average treatment per Community 
Drug Distributor is at 407, a far better-off outcome compared to just 70 average 
treatment per school teacher.  The other cost-outcome ratios which consider both 
diseases include the cost per anemia case averted for school-based treatment, 
US$3.19 per annum (1) and US$7.43 over 15 months (6).  
 
 
Cost Outcome Ratios 
 
Meanwhile, cost-outcome ratios for MDA-based Schistosomiasis control programme 
(3) include the cost per severe infection avoided, US$61.50; cost per death avoided 
in 9 years, US$6,531; and an ICER registers US$7.02/capita.  Study 12 has 
considered other cost-outcome ratios identifying the most cost effective strategy 
option after 2 years of intervention as follows:  cost per infected case prevented, 
US$16.94 for clue chemotherapy; cost per 1% reduction of EPG, US$17.52 for 
screen chemotherapy; and cost per case of liver and spleen abnormality prevented, 
US$12.06 and US$26.50, respectively, both for mass chemotherapy.  Study 5 looks 
at the financial cost per infected person who received Schistosomiasis treatment 
comparing traditional mass chemotheraphy and passive chemotheraphy with health 
education.  Study 5 shows the importance of integrating health education to existing 
strategy wherein the cost per infected person who received treatment (i.e. US$2.20 
in the first year and US$2.95 in the following)  is 3 times lower compared to 
traditional mass chemotherapy with US$5.63 and US$9.31, for consecutive years 
(local currency converted already to US$ using 1999 conversion rate). On the 
otherhand, the importance of combining health education and environmental 
management with chemotherapy treatment is also observed in study 13 wherein 
prevalence rates decrease significantly by 0.6%-6.3% and register a total benefit of 
US$80.875 Million for the 9-year evaluation period.  This particular schistosomiasis 
strategy (i.e., community chemotherapy plus health education and environmental 
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management) has also been evaluated in terms of its overall project cost per person, 
US$5.03; case detection cost per person, US$1.50; average case detection and 
overall project costs to reduce 1% human infection rate per 100 people, US$261.81 
and US$930.03, respectively; mollusciciding cost to reduce 1000m2 of snail infested 
areas, US$429.77; and cost to reduce 1% bovine infection rate per 100 cattle, 
US$19,591.92 (local currency converted already to US$ using 1996 conversion rate).  
Study 2 that looks at the unit cost per person needed in the group of school-aged 
targeted population (with varying coverage rate) to be as cost-effective as the school-
based approach comes up with decreasing unit cost per person as the number of 
coverage and children treated increases. 
 
 
Cost Benefit Analysis 
 
Cost Benefit Analysis for Schistosomiasis from the government perspective has also 
been carried-out in conjuncture with CEA.  Study 3 comes up with Cost Benefit Value 
of US$0.24, while study 13 registers a net benefit-cost ratio of US$0.75 with net 
value of US$72.447 Million in the 9-year evaluation period.   
 
Study (9) that takes the social perspective in evaluating a number of Schistosomiasis 
control strategies looks at incremental cost per QALY.  Its finding, using delphi and 
model-based estimation approach is that the selectivepopulation praziquantel 
chemotherapy (SPCPS) is the optimal strategy amongst the identified intervention 
strategies.  SPCPS strategy gets an incremental cost per QALY of -US$38.12 and –
US$0.58, based on probabilistic effectiveness estimates from foreign and local 
experts, respectively (local currency converted already to US$ using 1998 conversion 
rate). 
 
Study 8 looks at the cost ratio of schistosomiasis chemotherapy using praziquantel 
with that of oral artesunate.  Its finding is that praziquantel treatment is more 
expensive than using oral artesunate having a cost ratio of 1.73:1 – 1.81:1.  
Moreover, artesunate’s efficacy with cure rate of 70.1% is even slightly higher when 
compared to the 67% using praziquantel in the same area as demonstrated in a 
previous study(134).  
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The other outcome measures that have been examined for STH control strategies 
include the cost per 1000 egg reduction per gram, EPG (7) and the costs of unitary 
weighted percentage reduction in prevalence, WPRP, and weighted percentage 
reduction in intensities, WPRI (11).  The study 7 finding shows that mass 
chemotherapy is the most cost effective, the cost per 1000EPG is US$61.03 as 
compared to selective and targeted chemotherapy with values of US$677.20 and 
US$82.69, respectively (local currency converted already to US$ using 1990 
conversion rate).  Meanwhile, the study 11 finding shows that the most cost-effective 
strategy among the 4 regimens is the use of albendazole mass chemotherapy at an 
interval of 18 months, the costs of unitary WPRP and WPRI being US$97.79 and 
US$59.61, respectively (local currency converted already to US$ using 1995 
conversion rate).   
 
 
3.4.4. Results of the assessment of report quality 
 
Figure 4 shows for each item the proportion of studies reported completely adequate, 
partially or not at all. The most frequent partially or not reported items were the 
‘measurement and valuation of preferences-based outcomes’ (i.e., description of the 
population and methods used to elicit preferences for outcomes; item 12) and 
‘analytic methods’ (i.e., description of all structural or other assumptions underpinning 
the decision–analytic model; item 17).  The reporting of time horizons and choice of 
health outcomes could be improved (items 8 and 10). In addition, ‘currency, price 
date and conversion’ (i.e., reporting of the dates of the estimated resource quantities 
and unit costs and description of the methods for adjusting estimated unit costs to the 
year of reported costs; item 14) were not always included while comparators were 
sometimes considered without (proper) justification. Justification for conflicts of 
interest or the presence of such (item 24) is not provided in majority of the articles. 
The description of approaches used to estimate resources and costs was also not 
complete in several articles. Also, some articles did not provide incremental costs 
and outcomes (item 19) and characterized uncertainty and heterogeneity (items 20 
and 21). Generally, the articles discussed the key findings, limitations, 
generalizability, and how the findings fit with current knowledge (item 22). The source 
of funding and the role of the funder in the identification, design, conduct, and 
reporting of the analysis was only fully reported in more than half of the articles. 
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Substantial differences in the quality of reporting were observed between articles with 
an average score of 18.73 out of 24 (range 13.5–21.5).  
 
 
 
Figure 4:  Quality of reporting of cost-effectiveness analysis of multi-parasite disease control 
strategies per items of the CHEERS checklist.  
CHEERS Consolidated Health Economic Evaluation Reporting Standards, NA not 
applicable, No not reported, Part partially reported, Yes reported 
  
 
The average scores are higher for articles published in 2008–2011 (score of 20.17) 
and articles published in 2000-2002 (score of 21). African studies reported an 
average score of 19.25 while studies done in Asia had an average score of 18.4. 
Articles with both a financial and economic models have a higher reporting score 
(average score of 20.4) than articles that only used a financial model (average score 
of 18). 
 
 
3.5. Discussion 
 
Economic evaluation of disease intervention strategies can be an effective tool to key 
stakeholders and policy makers in helping them decide how limited resources can be used 
most efficiently.  A growing number of economic evaluation studies have already been 
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published and made available looking at two of the major parasitic infections – STH and 
schistosomiasis.  Both diseases have been classified by the WHO as Neglected Tropical 
Diseases (NTDs) for not being prioritized in terms of treatment and research funding despite 
their health and economic impact especially in many low-income developing countries.  
Despite the growing number of economic evaluation studies on STH and schistosomiasis, 
not all of them are valuable and useful to guide the various stakeholders come up with a 
solid decision in prudent resource allocation.   Thus, it is important to examine and assess 
these studies into what most health economists consider as good practice in conducting 
economic evaluation(124).  
 
Given the inclusion and exclusion criteria set by this review, we systematically reviewed and 
assessed the quality of thirteen final samples of economic analysis published within the 
period January 1990 to December 2012 looking at STH and schistosomiasis control 
strategies have been examined and evaluated.   The current systematic review shows a 
wide variety of methodological approaches across studies, including differences in type of 
economic evaluation, perspective, time horizon, study design, cost categories, effect 
outcomes, and adjustments for timing and certainty used. Using the parameters that have 
been mentioned earlier, the findings and the results of this review are as follows: 
 
All of the studies have complied with parameter items a (sufficient details on how costs and 
effects were evaluated and measured), c (options or alternatives used clearly stated), and d 
(viewpoint of the analysis clearly identified) which have been considered as good practice in 
conducting economic evaluation.  However, costs and effects under ‘do nothing’ baseline 
option for studies 1,3,4,6, and 13 were not explicitly mentioned.  It would be more valuable 
and useful for various stakeholders to compare the alternatives that have been presented 
had these values been properly identified.  Furthermore, care should be properly observed in 
extrapolating the results of cost effectiveness studies from one setting to another primarily 
because CEA is very context specific and is influenced by external factors such as disease 
prevalence and quality of service delivery.  Validation of published resources using local 
data and programme costs and effects should be carried out and considered(127). 
 
It should also be noted that most of the studies have assessed intervention strategies from 
the government’s or providers’ perspective.  However, a viewpoint that goes beyond that of 
the provider may also be needed.  This is primarily because of the fact that the economic 
burden of STH and schistosomiasis, like any other chronic diseases, is greatest among the 
poorest household of the population.  The importance of taking into consideration the 
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household perspective is also supported in a case study from Bangladesh wherein the 
poorest households lose more time from work due to chronic diseases compared to better-
off households(135).  Being unproductive and unable to work when a family member becomes 
ill results to loss of income, sale of family’s property, and/or need to borrow money to finance 
medication.  Thus, cost effectiveness analysis from the household perspective can be 
considered as crucial and as important as the other perspectives in making decisions.  It can 
support further or alter the choice of intervention strategy. 
 
Majority (77%) of the studies employed parameter item b (marginal analysis) in their 
evaluation process.  Three studies did not employ or did not explicitly indicate in their 
process that such analysis had been carried out.  In economic evaluation analysis, 
increment or decrement in programme costs and effects is more important to anemia than 
merely comparing their averages.  Comparing programme costs and effects using absolute 
or averages endangers one to select an alternative strategy that is not considered as the 
most prudent or cost effective option when evaluated using some baseline values. 
For each of parameter items e (discounting) and f (sensitivity analysis), less than half of the 
selected economic evaluation studies employ such practices.  A standard practice in 
economic evaluations is to incorporate time preferences of current and future costs and 
health benefits.  Discounting is the process ofconverting future costs to their present value, 
to reflect the fact that, ingeneral, individuals and society have a positive rate of time 
preference forconsumption now over consumption in the future(73).  Rates used from these 
selected studies to discount cost and effect or both are varied from 3% (1,10) to 5% (2), to 
as high as 10% (9,12).  For comparability across studies, WHO-CHOICE used a discount 
rate of 3% for the base case(73).  
 
On the otherhand, various types of sensitivity analysis (i.e., scenario, multi-way, scenario, 
probabilistic sensitivity analysis) have been employed not only to test how the result of the 
study changes if key assumptions are varied but also to explore how results behave given a 
hypothetical situation, the ‘what if..’ questions.  Moreover, sensitivity analysis is used to deal 
with uncertainties in economic evaluations due to methodological disagreement among 
analysis, the study’s data requirements, the need to extrapolate outcomes over time, or the 
desire for generalizability of the result to another setting(136).   
 
In general, the economic evaluation studies that have been examined in this review have 
passed the set of criteria of good practice in conducting economic evaluation.  Although 
there were some identified concerns such as unemployment of marginal analysis, 
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discounting, and sensitivity analysis, this should not greatly affect the concerned studies to 
be considered as STH and schistosomiasis economic evaluation studies.  Just like any other 
assessment or reviews, this article has its limitations such as possible broad search strategy 
used for these diseases, criteria that were employed were insufficient or that other 
parameters have been overlooked, and what were examined are those that were only 
reported.  Because of word limits for published studies, authors are oftentimes compelled to 
provide an abridged description of their study’s methods. Nevertheless, assessing economic 
evaluation studies to some set of criteria or practices is a helpful and valuable exercise for 
policy makers and other stakeholders.  It provides appreciation and better understanding of 
the processes to be considered in order to come up with more solid basis in choosing the 
intervention strategy with the best value for the money. 
 
In a developing and low-income country like the Philippines, economic evaluations are 
focused in promoting equity that integrates health and social policy, underpinned by a 
growing understanding of the importance of social determinants of health, and integrating 
evaluations across human and animal health and food systems are developing areas of 
interest. However, economic evaluations in developing countries present several challenges. 
One potential problem is the increased interest from global funders who are concerned with 
assessing value for money across a range of countries is driving demand for model-based, 
multi-country evaluation, which may encompass dozens of countries. Moreover, novel 
methods are required to integrate heterogeneity in epidemiology, demography, unit costs, 
and supply and demand constraints across diverse settings in an expedient and informative 
way. There is also the issue of data scarcity that is expected to remain for some time ahead. 
In addition, considerable investment in large-scale costing studies and further analysis of 
cost functions will be required to inform assessments of the costs of scaling up interventions 
and the generalizability of unit costs across settings. These large-scale cost surveys remain 
expensive; thus, further work is required to improve the efficiency and accuracy of cost-
estimation methods. Further methodological development and investment are also required 
to support economic evaluations to inform national-level decision-making in developing 
countries. In addition to efforts to develop routine health management information systems, 
including both cost and health outcomes data, further research is required into the 
generation and use of evidence for economic evaluation, in particular guidance on data 
collection together with trials in real-world implementation. The application and further 
development of methods to assess the transferability of economic evaluation findings from 
other countries and adapt them to the local context could make a substantial contribution to 
increase the use of economic evaluation results(137). 
Chapter 3. A Systematic Review of Economic Evaluation Studies of  
Multi-Parasitic Diseases Control Strategies 
 
 
Garcia, Fernando Jr., n8415790, School of Public Health and Social Work, QUT Page 72 
 
 
 
Generally most studies only looked at the cost per person targeted or treated and not the 
cost per health outcome. Given this, all strategies appear to be of low cost since treatment of 
the community is cheaper to deliver than targeted as well as school-based interventions. A 
few studies have reported cost per reduction in egg count, per case anemia averted or death 
averted, these may offer value for money depending on the willingness to pay. 
Chemotherapy with health education is therefore deemed more cost-effective than 
chemotherapy alone. 
 
 
3.6. Summary conclusions 
 
After the thorough review of related literature using the CHEERS statement and the 
guidleines we have set, we come to see that the wide variation of outcome measures and 
intervention settings that have been examined from the selected economic evaluation 
studies makes it difficult to come up with a single conclusion across all of the thirteen 
studies.  However, looking at some comparable studies, there is a consistent evidence that 
from the government’s perspective, community-based MDA or chemotherapy is more cost-
effective than selective and targeted (7), than school-based MDA (10), than ‘clue’ and 
‘screen’ chemotherapy (12) and than ‘do nothing’ option (3, 4).  Notwithstanding such 
finding, outcome measures for ‘do nothing’ option which was used as baseline reference in 
said studies, need to be specified to get a clearer picture and come up with a better 
comparison of all the strategies.  The choice between or among the alternative options 
should be more straightforward than what was just implied in the discussion. Likewise, 
preventive measures (i.e., health education, IEC, and environmental management) in 
conjuncture with chemotherapy treatment (5, 11, 13) have also improved the outcome 
measures.  In practice, however, strategies with health education component inducing 
behavior change turn out to be poorly implemented(138).   
 
Most of the studies in this review did not assess the respective interventions from the 
societal and household perspectives.  To fully understand the cost effectiveness of disease 
intervention, these other perspectives or views should be considered rather than just the 
perspective of the government or providers.  Household perspective looks at optimal 
strategies for the patient and their families; while societal perspective evaluates the 
intervention at the population level.  Taking these perspectives into consideration, 
programme managers and decision makers would be able to arrive at a more reasonable 
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and justified choice and policy decision.  Moreover, the importance of including the economic 
costs in the costing exercise should also be noted to acknowledge all the resources involved 
in each of the strategies. 
 
After the systematic review of economic evaluation studies of multi-parasite control 
strategies as presented in this chapter, we become more aware of the good practices of 
conducting economic evaluation.  Moreover, we become better informed of the processes 
and procedures in evaluating health programme interventions.  This understanding of the 
economic evaluation of disease interventions will serve as practical guide in structuring the 
methodology of this study. 
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CHAPTER IV.   METHODOLOGY OF THE STUDY 
 
This chapter starts with the presentation of the conceptual framework (4.1) outlining the 
overall methods and processes of this study (4.2). The second half of the chapter describes 
the methodology in estimating the impact or health benefits (4.3). A summary conclusion 
(4.4) of this study’s methodololgy is presented at the end of the chapter.  
 
 
4.1. Conceptual Framework 
 
The conceptual framework was used to provide the overall program of research and indicate 
how this specific body of work sits within the border of the program of research.  The broader 
context for this research study is a project entitled From Maps to Efficient Parasite Control 
funded by NHRMC grant number GNT1006254. This grant involved academics from 
research institutions in Australia (Queensland University of Technology, Australian National 
University, University of Queensland, QIMR Berghofer) and the Philippines (University of the 
Philippines – Manila) alongside key personnel from the national parasitic disease control 
program within the Department of Health (DOH) Philippines. 
  
The project involved three stages: (1) developing spatial maps of STH disease prevalence 
for the whole country based on results of an earlier prevalence survey conducted by the 
College of Public Health, University of the Philippines – Manila; (2) using the results of the 
spatial mapping, develop a mathematical model to predict how prevalence of STH would 
change over a 10-year period under different MDA based control strategies; and (3) using 
the predictions from the mathematical model, estimate the health impact, cost and cost 
effectiveness of the control strategies. 
 
The first two stages were led by academics based at Australian National University and the 
University of Queensland. This research constitutes stage 3 and was led by Queensland 
University of Technology by the candidate, and his supervisory team with support from 
colleagues at the University of the Philippines-Manila and the Department of Health (DOH) 
Philippines. 
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The value of a conceptual framework in any research can never be underestimated for it 
embodies the specific direction or outline the possible courses of action that will have to be 
explored. Figure 5 presents the conceptual framework of this study.  The framework, which 
follows the standard schema of the Input-Process-Output model, presents an overview of the 
preferred approach or the methods and processes of this investigation.  The highlighted 
portion in the diagram represents the components that this research has carried out.   
 
This study worked with a complimentary research team/group who has produced estimates 
of the predicted prevalence of STH infections in the Philippines by subnational levels (i.e., 
Luzon, Visayas, Mindanao).  The research group has utilized a metapopulation model that 
simulated the impact of STH to different control strategies (i.e., combination in terms of 
frequency and mode of delivery) over a 10-year period taking into account the initial 
prevalence of infection, the corresponding cure efficacies of the albendazole to the different 
STH infections, and the transmission dynamics of infection. The technical details of the 
mathematical model used for this work are given in Appendix B.  Through a mathematical 
simulation model, the group estimated the impact of the following treatment strategies which 
have been evaluated in this study to examine their cost-effectiveness acceptability in the 
country: 
1. Mass or community-wide and annual (once in a year) drugs (MA) treatment,  
2. Targeted and annual drugs (TA) treatment , 
3. Mass or community-wide and biannual (twice in a year) drugs (MB) treatment, and 
4. Targeted and biannual drugs (TB) treatment. 
 
These 4 strategies were selected after consultations with the Philippine Department of 
Health as being relevant options to the delivery of the national programme.  Results outcome 
looking at optimal strategy of this national program, where no full economic evaluation has 
been carried out before, could be considered as a novel contribution of this Ph.D. research 
taking into account the outline or blueprint as presented in the framework. 
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Figure 5:  Conceptual Framework 
 
 
Examining the outlined conceptual framework, it is evident that the overall methods and plan 
of this research are subdivided into three stages as follows: 
 
Stage 1: Collection and estimation of financial and economic cost data associated 
with each competing control strategy; 
Stage 2: Determination of the health outcomes associated with each competing 
control strategy; and 
Stage 3: Undertaking CEA of the control strategies. 
 
The research group’s output for this work, together with national records and assumptions 
from published literature, was used to estimate the impact of the various control programmes 
in terms of DALYs averted and number of infections and reinfections averted.  Cost 
estimates for the identified treatment strategies were based on analysis of data collected 
from interviews and office records provided by the DOH and programme managers at the 
local government level, national records, and existing research evidence.  The relative 
changes in costs and health outcomes achieved under each strategy were then compared 
using an economic decision model to identify the optimal strategy and the level of 
uncertainty associated with this decision. 
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4.2. Overall approach to the evaluation 
 
Laying out the general foundation of the study that has been considered in evaluating the 
various control strategies is important to set the context, scope and processes of the study.  
In particular, brief identification and discussion  have been made on the choice of decision 
context, study perspective, modeling technique, unit for effectiveness measurement, 
reference year and time horizon, and discounting.  
 
 
4.2.1. Choice of decision context 
 
Recognizing the importance of systematic and evidence-based identification of the 
most likely cost-effective strategy or the one that gives the best value for money from 
among the competing helminthiasis control intervention strategies, an economic 
evaluation that will assist the country’s primary health care providers from both the 
national and local government units will be very helpful and worth doing.  This project 
can contribute to the economical aspect of policy making in the systematic 
approaches and strategies for the prevention and control of soil-transmitted helminth 
(STH) infections and diarrheal diseases in support of the Integrated Helminth Control 
Program and the Food and Waterborne Diseases Prevention and Control Program of 
the DOH. Therefore, this evaluation was done within the context of public health care 
provider which is the Department of Health (DOH) Philippines together with its 
intersectoral alliances, the Department of Environment and Natural Resources 
(DENR) and the Department of Public Works and Highways (DPWH), and the local 
government units (LGUs) with a goal of enabling health service providers and other 
stakeholders to make provisions for early diagnosis, treatment, prevention, and 
control of these diseases consistent with existing diseases consistent with existing 
disease control programs (139). 
 
 
4.2.2. Choice of study perspective 
 
This study adopted the perspective of the healthcare provider.  Bringing non-health 
sectors in the equation may be important in some diseases or risk factors that deal 
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with interventions outside the health sector(140).  However, considering the scope of 
the work (i.e., to evaluate the alternative interventions available at the disposal of the 
health sector), as well as the limited time and resource constraints, it will not be 
feasible to include intervention costs and impacts that are outside the health sector.  
For these reasons, other control program components like Water, Sanitation and 
Hygiene (WASH), specifically provision of safe, adequate and sustainable water 
supply, and installation of low cost technology and culturally-acceptable sanitation 
facilities,  will not be looked at and evaluated as these involved multiple sectors of the 
society outside health.  Trying to quantify costs and outcomes outside the health 
sector is beyond the scope of this study.  On the other hand, patient costs of 
accessing treatment are negligible and will not be considered, as also seen in the 
study of nationwide school-based helminth control in Uganda(18). 
 
With regard to health sector costs, one of the innovative processes in this thesis is 
the factoring of all the opportunity costs rather than just focusing on the financial cost 
of delivering the STH intervention.  As have seen in the previous studies where they 
only looked at financial costs and failed to capture the burden on households and 
patients, this thesis considered both sides of the equation – the economic costs and 
the morbidity/mortality which are captured by the DALYs. 
 
‘Do nothing’ comparator is not a relevant policy option.  This is because the country 
have been running a national programme for long period of time and it turns out that 
there is a need to level-up the STH intervention program in order to address the low 
coverage issue in the implementation of the status quo intervention.” 
 
 
4.2.3. Choice of modeling technique 
 
Decision models have been considered to be particularly suitable for health economic 
evaluations. Taking into account efficiency criterion in evaluating health intervention 
strategies entail dealing with various types of information from various sources such 
as clinical, economic, epidemiological, and sociological.  Economic decision models 
make it possible to estimate the expected costs and health outcomes of the health 
intervention being studied by integrating all these data, including addressing 
situations where information is imperfect or where evidence is incomplete or 
fragmented across different studies(141).  Moreover, modelling studies enable 
Chapter 4. Methodology of the Study 
 
 
 
Garcia, Fernando Jr., n8415790, School of Public Health and Social Work, QUT Page 80 
 
 
comparison of all relevant competing interventions, inclusion of long-term cost and 
death outcomes, and generalization of findings compared to those achieved in a 
controlled experiment(92). Given such edge in the conduct of economic evaluation, 
modelling technique is best suited over clinical studies especially when the goal is to 
make decisions. 
 
The use of decision trees and alternative modelling techniques such as the Markov 
models need not be mutually exclusive. Several studies have already been made 
using a single decision-analytic framework where both approaches have been used.  
The choice of decision tree as a modelling technique has been made as a significant 
initial stage to characterise short-term events due to STH control strategies. Through 
this, information on the proportions of the infections or patient cohort entering 
particular Markov health states could be determined. 
 
This cost-effectiveness analysis has used the decision tree technique, a simple 
decision analytical model developed to evaluate the expected cost-effectiveness 
acceptability of the four treatment strategies. A decision tree is simple and 
transparent, and using it as a model is an excellent way of clarifying the options of 
interest. It provides deterministic outcomes such as expected cost and health 
benefits of a decision. Comprised of three nodes, the first point in the tree is a 
decision node (square) which represents the decision question. The pathways that 
follow each option represent a series of logically ordered alternative events, denoted 
by branches stemming from chance nodes (circles). The end points of each pathway 
are represented by outcome nodes (triangles) to which values or pay-offs, such as 
costs, life years, or DALYs, are assigned. Once the probabilities and pay-offs have 
been entered, the decision tree is ‘averaged out’ and ‘folded back’, allowing the 
expected values of each option to be calculated. Another form is the Markov model 
that allows a more direct and flexible sequencing of outcomes through time unlike 
decision trees that represent sequences of events as a large number of potentially 
complex pathways. An important limitation is the assumption that the transition 
probabilities depend only on the current health state, independent of historical 
experience. Other alternative models include the patient level simulation 
(microsimulation), discrete event simulations, and dynamic models (96).   
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4.2.4. Reference year and time horizon 
 
The reference year used in this study was 2012, the year in which the cost data 
captured at each stage and level of intervention were incurred.  The time horizon 
used in this study was 10 years to follow the 10-year predicted prevalence generated 
from the mathematical simulation model.  As this study has worked with a 
complimentary team’s estimates using mathematical modeling to predict the 
prevalence of the STH infections in the Philippines, the use of 10-year time horizon in 
this study conforms to the parameter output of the said team.   
 
 
4.2.5. Discounting 
 
One of the standard practices in the conduct of economic evaluation is discounting.  
Such practice is necessary in order to incorporate time preferences for current and 
future costs and benefits. In this study, discounting was applied to both costs and 
effectiveness measures. The choice of discount rate was 3% per annum although the 
usual range suggested for developing countries is 8-15 percent. However, if the 
evaluated project has a long gestation period, intergenerational costs and benefits 
become important, and using a high estimate will unfairly discount the future values; 
thus, a lower discount rate is used by most countries for inteventions such as this 
project(142). 
 
The general approach that has been presented serves as guide and consideration in the 
collection, estimation, and derivation of the respective costs and effectiveness of each of the 
control strategies.  
 
 
4.3. Economic model 
 
In an economic evaluation setting, a decision analytic model utilizes mathematical 
relationships to outline a set of possible consequences coming from a set of alternative 
courses of action being evaluated.  Economic decision models have been found to be useful 
in evaluating the cost-effectiveness of infection control strategies in healthcare setting(143-146). 
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Utilizing decision analytic model allows a reasonable and scientific approach to measure the 
efficiency of the different intervention strategies by using the best available evidence of 
different sources to produce corresponding estimates of the economic costs and 
consequences of these interventions. To increase the validity and utility of the economic 
model, methodological aspects have to be considered and the set of limitations inherent to 
the use of the model be contemplated(147).  
 
In the implementation of decision analytic modeling in healthcare evaluation, the model 
assumptions and parameter estimates have to be continually assessed against data. 
Moreover, conditional relationships between inputs and outputs have to be provided through 
sensitivity analyses(148).  
 
In this study’s economic decision model, considerations have been given to the cost data 
that have been collected, the predicted/forecasted prevalence values (generated after 
passing through some mathematical simulation)  as well as the alternative strategies and 
health states.  The significance of using mathematical models to substantiate the economic 
models in evaluating infectious disease interventions is evident as it captures indirect 
impacts of the intervention that occurs due to reduction in the net rate of transmission of 
infectious diseases, a principle of herd immunity(149, 150).  However, such process lacks 
application or  little has been done for evaluations of helminth control programmes.  
 
Using spreadsheet that follows a decision tree (Figure 6) technique, a simple decision 
analytical model was developed to evaluate the expected cost-effectiveness acceptability of 
the four treatment strategies.   
 
The decision tree that inspired this study’s decision analytical model aims to identify the 
optimal cost-effective parasite control strategies from among the four competing 
interventions (i.e., MB, MA, TB, and TA treatment).  Individuals living in a given locality, 
possibly, could either be infected with any of the STH infections (i.e., ascaris, trichuria, and 
hookworm) or no infection at all.  This study further looked at those hookworm-infected 
individuals because of the great risk of morbidity (i.e., YLDs) being attributed to people who 
suffer anemia due to hookworm infection(151).  At the end of each infection arm is the 
probability of staying alive or ending up dead.  It should be noted, however, that it is unusual 
for STH to kill their human hosts(41) and that death cases, if any, could occur only with 
Ascaris infection. 
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The decision tree requires quality data on resources costs, impacts or health benefits, and 
chance events, to present the natural history of the competing options.  After attaching the 
respective values of all the structures, evaluation is then made by going back to the decision 
node (i.e., from endpoints to decision node).  However, it was noted that the available cost 
data collected from the Philippines did not specifically identify the STH infection that they 
had served.  The data have been recorded, in general, under the whole deworming 
programme and not disaggregated according to the type of infection.  In such case, 
estimated and derived cost data for STH have been considered to be the total cost under 
each of the intervention treatment/strategy.  A spreadsheet was developed eventually 
incorporating the techniques of a decision tree.   
 
An extended 10-year time period, with assumption that the costs will remain constant over 
this period, has been incorporated in the model in order to capture the long term cost-
effectiveness of the strategies.  In addition, this study has used 3% per annum discount rate 
to incorporate time preferences of current over future, one of the standard practices in 
economic evaluation.  This study has also adopted the perspective of the healthcare 
provider. 
 
Through the economic decision analytic model, the estimated costs and the derived health 
benefits (i.e., DALYs averted and # of infection averted) of the intervention strategies were 
used to generate the incremental cost-effectiveness ratio (ICER) for each strategy. DALYs 
which are considered as a modification of QALYs, measure the gap between a population’s 
existing health condition and what should be an ideal health state(69). Simplified, the burden 
for a particular health state as expressed in DALYs is computed as follows: 
DALYs = Σ YLLs + Σ YLDs, 
with YLLs from a single death equal to (standard life expectation - age at death) * 
(age weight) * (future discount); 
 
and YLDs from a certain disabling condition equal to (disability weight) * (incidence) * 
(duration of disabling event) * (age weight) * (future discount). 
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Figure 6:  Decision tree structure 
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For cost–effectiveness analyses to contribute to sound resource allocation, it was proposed 
that the estimates of both costs and effectiveness must be situated firmly within the relevant 
context, which includes the disease burden and budget of the setting in question. Simple 
cost–effectiveness thresholds – whether based on per-capita incomes or benchmark 
interventions – fail to evaluate and rank interventions within countries and disregard 
budgetary constraints. By short-circuiting a more thorough assessment of policy-relevant 
alternatives, they contribute little to good decision-making and can actually mislead. While 
the currently available data will not support comprehensive off-the-shelf league tables for 
most settings, the results of cost–effectiveness analyses should be compared with as many 
relevant interventions as reasonable in a given situation. Decision-makers would then be in a 
far better position to interpret the results of cost–effectiveness analyses(152). 
 
A consensus process should be convened, perhaps by WHO, to develop a new framework 
for articulating cost–effectiveness in global health policy – specifically focusing on low- and 
middle-income countries. Rather than referencing a uniform standard, this new consensus 
should come up with evaluation processes that put ICERs in the context of other health 
policy and program options, as well as funding sources, admissible to the  local setting.  
While not resolving all of the issues affecting cost–effectiveness analysis as a guide for 
resource allocation, a new framework could offer an improvement on the use of simple 
thresholds based on per-capita incomes(152). 
 
Uncertainties in economic evaluations arise due to methodological disagreement among 
analysis, the study’s data requirements, the need to extrapolate outcomes over time, or the 
desire for generalizability of the result to another setting(136).  To deal with the uncertainties in 
this study, the use of other threshold other than the WHO recommended threshold level, as 
well as probabilistic sensivity analysis (PSA), were carried out in which structural elements of 
the economic decision model were explored(13). 
 
In order to establish the likelihood that a particular strategy or intervention as being cost-
effective at a particular threshold level, a PSA is performed. Such analysis also demonstrate 
the robustness of the ICER with regard to input. Thus, a higher probability of an intervention 
or technology being cost-effective correlates with more positive decision-making(153). 
Although the PSA does not have the ability to reduce uncertainty regarding the analytical 
method being used(136), critical attention should still be  given to the PSA in addition to the 
ICER estimate(153).  
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PSA is a useful sensitivity analysis technique that provides some level of confidence to 
economic evaluation outcomes.  The procedure entails treating the uncertainties of input 
parameters as random quantities associated with specific probability distribution based on 
prior information of the decision maker. This method is in accordance with the Bayesian 
analysis carrying its trademark that parameters have a probability distribution.  
 
The results of the PSA model have been graphically presented using the cost-effectiveness 
plane and cost-effectiveness acceptability curve (CEAC). The CE plane is divided into four 
quadrants (refer to figure 7) where respective values are plotted to.   
 
      
Figure 7:  The four quadrants in a cost effectiveness plane 
 
Quadrants are numbered I-IV and each quadrant implies a different cost effectiveness 
outcome.  Incremental cost and incremental effectiveness combinations that are both 
positive are plotted in quadrant I, while combinations that are both negative are plotted in 
quadrant III.  On the other hand, quadrants II and IV contain treatment interventions that are 
considered dominated (i.e., decreased effectiveness and cost more) and dominant (i.e., 
decreased cost and increased effectiveness), respectively.  
 
In dealing with this kind of assessment, it is expected that we right away reject treatment 
interventions that fall inside the dominated quadrant basically for not being cost effective 
(i.e., cost more with no positive effect or benefit).  However, the choice for the non-
dominated treatment strategies situated in the other remaining quadrants is more complex 
that requires examination of the ICERs and consideration of willingness to pay threshold 
levels, among others.  These concepts are graphically captured using a cost-effectiveness 
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plane wherein ambiguities on cost effectiveness are resolved and relevance to decision 
making are illustrated(154).  
 
The CEAC illustrates the probability that the intervention or strategy is cost-effective 
compared with the other alternative interventions, given the data and for a given value of the 
maximum acceptable ratio.  In interpreting the information provided by the CEAC, it should 
be noted that it simply presents the probability that an intervention is cost-effective compared 
with the alternative for a range of values of the maximum acceptable ratio. In addition, 
interpreting CEACs is bound by the uncertainties of the estimates of cost-effectiveness. In 
general, the information derived from a CEAC should not be used to make statements about 
the implementation of the intervention(155).  
 
CEAC is an intuitive graphical technique of presenting and summarizing the uncertainty 
about the cost-effectiveness of a particular intervention strategy(156).  The use of CEAC as 
part of economic evaluations is becoming more widespread (157-167)and popular because of 
its simplicity to construct, summarize and interpret PSA results (96, 156, 168). CEAC in a 
treatment strategy has been defined as  
, 
and incorporates the willingness to pay threshold (or ceiling ratio) parameter ‘k’ for health 
benefits. 
 
So that when the expected net benefit, kΔe– Δc, of a particular treatment strategy is greater 
compared to that of the other strategy options, the optimal decision would be for that 
particular treatment strategy. At the same time, Net Monetary Benefit (NMB) is calculated by 
subtracting the cost associated with each strategy from the corresponding health benefits 
that have been converted into common currency metric.  A critical factor in converting the 
health benefits into currency matric is the level of the willingness to pay threshold.    
NMB = (E * WTP) – C 
where, E = effectiveness; WTP = willingness-to-pay threshold; C = cost  
Some advantages noted in the use of NMB framework include: (i) clear comparison of 
multiple strategies, (ii) consideration of multiple willingness-to-pay thresholds, and (iii) less 
instability compared to incremental cost- effectiveness ratios when there are small 
differences in effectiveness (169).  
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Therefore, the rational of PSA through the use of CEAC is to examine the expected net 
benefit of a treatment strategy and to summarize the probability that the said strategy is cost 
effective, taking into account the varying levels of willingness to pay threshold or ceiling ratio.  
Such process of presenting the results of economic evaluation is helpful and practical 
especially for decision makers who usually want to see first possible intervention outcomes 
before they make commitments for certain level of ‘k’(96).  Notwithstanding its widespread 
popularity in the conduct of economic evaluations, some critical limitations have been noted. 
CEACs can only address issues on the likelihood that resolving parameters uncertainty will 
change the optimal decision making(170) and that evaluation by means of CEACs is not 
comprehensive considering the usual complexities of the overall decision process(96).  
 
A scenario sensitivity analysis was also carried out to examine whether the decision alters if 
different WTP thresholds were used.  This study has utilized two WTP threshold – the GDP 
per capita and the total expenditure on health per capita, the latter being a stringent criterion. 
 
 
4.4. Summary Conclusions 
 
This chapter serves as the backbone structure of this study and identifying beforehand the 
conceptual framework of this study has been beneficial to recognize and understand in a 
glimpse the scope of work that will be explored.  A description of the economic model has 
also been provided.  Unavailability of quality and disaggregated data, such as cost per type 
of infection, necessitates implementing the decision tree techniques through spreadsheet. 
The developed economic model includes a 10-year time horizon, 3% discounting rate, and 
relevant sensitivity analysis, a standard methodology in conducting economic evaluation in 
health. 
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CHAPTER V.  COSTING DATA METHODS AND RESULTS 
 
 
This chapter presents the costing method (5.1) employed in the study, including the cost 
data sources (5.1.1) and the cost data collection tool (5.1.2) are presented. It is followed by 
the methodologies in estimating and scaling up the cost of one round of mass treatment 
(5.1.3) and in deriving the cost estimates for the remaining strategies (5.1.4). This chapter 
the proceeds with the programme implementation structure set up (5.2) followed by the 
results of the cost estimation that was carried out in relation to Mass Annual (MA) treatment 
(5.3) then the predicted cost for the other STH strategies (5.4) and the cost per person 
treated (5.5).  Summary conclusions (5.6) have been carried out to end the chapter.  
 
 
5.1. Costing Method 
 
This section deals with the processes and methods that were undertaken to estimate and 
derive the cost of each intervention strategy.  Discussions have been focused on the 
sources of cost data, the data collection tool, the process of cost scale-up, and the cost 
estimation and derivation using assumptions based on published literature of related 
diseases. 
 
Cost estimation is one of the initial considerations in the conduct of economic evaluation.  
This chapter presents the results of the cost estimation that was carried out in relation to 
Mass Annual (MA) treatment and the prediction of the respective costs for the other 
alternative strategies (i.e., MB treatment, TA treatment, and TB treatment) based on the 
estimated costs and some assumptions from other literature. 
 
 
5.1.1. Cost Data Sources 
 
A multi-level source data collection was carried out to capture the available resource 
inputs and to determine how and how much of these are being utilized given the 
country’s devolved setting.  Such approach of data collection is deemed appropriate 
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to acknowledge the differences in disease transmission as well as differences in 
socio-economic, health service capacity, and level of support at the local level. 
 
Given the multi-level structure of managing the program, cost data were collected 
from three (3) levels of government (i.e., Regional, Provincial, City/Municipality) 
through interviews with key individuals who are directly involved in the management 
and/or delivery of helminth control programme in each corresponding level.  Except 
for a light snack after the conduct of each key informant interview and an assurance 
that a copy of the final output (e.g., findings and recommendations) of this study 
would be provided to their unit, no other inducement of any kind was used to obtain 
the respondents’ cooperation and participation.   
 
To be more efficient in the collection process, it was decided that one of the two 
provinces where cost data would be collected from would be that province where the 
CHD office is situated.  The same technique applied in selecting cities/municipalities, 
such that one of the two cities/municipalities where cost data would be collected from 
would be that city/municipality where the health office of the selected province was 
situated. This process worked well for several considerations such as logistics during 
the time of the study, travel time and distance needed to transfer from one LGU to 
another, and safety and security of the researchers especially in remote areas. 
 
The map in Figure 8 shows the hookworm prevalence in selected provinces of the 
country’s main island groups (i.e., Luzon, Visayas, and Mindanao).  It illustrates that 
the prevalence of infection varies among provinces (or cities and municipalities) 
within the same region (or province).  Moreover, it also implies that the prevalence of 
infection can vary even among localities that are classified under the same category 
level.  This suggests that LGUs have been addressing the issue at different levels of 
capacity and logistics and that the intra-country or geographical variation of cost is 
present or manifested.     
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Figure 8:  Regional map of the Philippines showing hookworm prevalence to 
selected provinces in Luzon, Visayas, and Mindanao.  
Source:  Map was an output of the complimentary group that worked on 
prevalence prediction of the disease. 
 
 
To capture regional/geographical variation in costs, local data were obtained from 
purposively selected LGUs (i.e., provinces, cities, and municipalities) that were 
visited during the period June 2013 – October 2013. Figure 9 presents the diagram 
of the three levels of government were collected cost data came from. 
 
Figure 9:  Three levels of government where collected cost data came from 
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Costs from the national level have been captured through the Centers for Health 
Development (CHD), Department of Health’s regional offices, which offices are 
strategically located across the country.  For each of the 17 regions or CHDs, two 
provinces have been purposively sampled or selected  to be subjected for cost data 
collection.  Then in each selected province, two cities/municipalities have been 
purposively sampled or selected for cost data collection.   
 
As a result, cost data collection was conducted across the country in 16 regional 
offices (i.e., CHDs), 27 provinces, and 60 cities and municipalities.  A summary of the 
disaggregated levels of government per main island group where cost data were 
collected and the respective target population for the programme in each island 
group is presented in Table 6.  
 
Table 6:  Cost Data Sources according to Levels of Government and Respective Target 
Population in each Main Island Group 
Island Group 
13.5% 
Target 
Populationa 
Regional/CHD Provinces Cities / Municipalities 
Luzon 7,069,005 8/8 13/39 30/770 
Visayas 2,430,532 3/3 4/16 13/409 
Mindanao 2,965,703 5/6 10/27 17/456 
TOTAL 12,465,240 16/17 27/82 60/1,635 
 
a 13.5% of the locality’s total population was set as the target population per round of deworming 
programme. 
 
 
Refer to Appendix C for the list of DOH Regional offices and LGUs where cost data 
have been collected. Figure 10 shows the locations of cities and municipalities where 
cost data have been collected. 
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Figure 10:  Location map of municipalities and cities where 
cost data have been collected 
Source:  Map was an output of this study using 
ArcGIS mapping software 
 
 
5.1.2. Cost Data Collection Tool 
 
The ingredients approach has also been carried out to determine the costs of the 
resource inputs from the control intervention being implemented.  Some usefulness 
of this approach include the allowability to validate the assumptions used, 
determinability whether the estimates can be applied to one’s setting, and replicability 
of the analysis to one’s setting by changing some of the parameters(15, 122, 171).   
Primary data collection which was organized at the CHDs, PHOs, City or Municipal 
Health Offices involved interviewing key individuals who were largely engaged in the 
management and/or delivery of helminth control programme. Secondary data were 
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sourced from local studies and published government reports such as Annual 
Operations or Investment Plans (AOP/AIP) and Work and Financial Plan (WFP).   
 
A data collection tool was developed by the researcher for the purpose of capturing 
the various costs incurred in the year 2012 at each stage of programme management 
and in each level of intervention.   The researcher developed the tool based on a 
range of exisiting tools.(18-20, 122)The tool was structured and organized accordingly, 
taking into account the potential resources and activities required by the programme, 
into five categories or cost centers (Box 1).  
 
Box 1:  Cost Centers and Description of Programmatic Activities Involved 
 
1. Programme Running Costs: Primary resource inputs used in making the 
programme intervention available.  It includes proportion of time that staff 
devoted to the programme,  building space and vehicles as well as their relative 
operations and maintenance. 
 
2. Community Sensitization and Screening: Activities prior to treatment to raise 
awareness about the disease. It includes the opportunity cost for using health 
workers. 
 
3. Training: Capacity building and other related activities to provide service 
delivery frontliners/participants general information about the disease and the 
programme.  It includes costs incurred with respect to the smooth delivery of the 
training. 
 
4. Drug Distribution and Treatment:  Costs of medicines and administration of 
related chemotherapy for treating STH infection. It covers per diems of 
personnel who performedrelated activities and other resource inputs intended 
for this purpose. 
 
5. Production and Distribution of  IEC materials: Communication 
paraphernalias associated with programme-related campaigns such as  media 
events and print materials containing health education messages that 
encourage people to follow prescribed regimens. 
 
 
Classifying the costs according to their components or categories is important to 
avoid overlap and confusion which can result in double-counting or failing to include 
cost items altogether(122). The use of this approach has proven to be effective and 
successful in previous evaluations of helminth control programmes(16, 18-20, 48).  
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Moreover, the use of structured data collection tool is better than just collecting the 
financial accounting records from the target audience both at the national/regional 
and local levels primarily because critical information such as opportunity costs, 
volunteer time, and resources that are shared, donated and provided free of charge 
are costly to be missed out. Contents and structure of the data collection tool were 
further discussed with concerned National Programme Coordinators of the DOH’s 
National Center for Disease Prevention and Control (NCDPC).  After pilot testing the 
tool to check its worthiness, a tailor-fit cost and data collection tool (Appendix D)  was 
developed and used to elicit appropriate information from different levels of the health 
service. 
 
Recognizing the importance of this study to health policy and decision makers in the 
management and delivery of helminth control programme in the country, the DOH 
supported access by the researcher to interview key individuals at the local 
government level.  A memorandum addressed to the CHD Regional Directors and 
Regional/ Provincial/ Municipal STH Coordinators was issued by the DOH Office of 
the Secretary to extend support and assistance to the study (Appendix E).  Together 
with this memorandum, request letters containing the details and schedule of the key 
informant interviews were sent out through email/facsimile addressed to each of the 
respective office/unit heads (i.e., Regional Director for the CHD level, and 
Governor/Mayor for the local government unit level) prior to the actual field work,.  
Further follow-up calls were carried out to confirm that requests/notifications had 
been received and tabled by the corresponding individuals. 
 
Before each key informant interview, respondents were requested to read, ask 
questions/clarifications, and sign the accompanying informed consent form 
(Appendix F).  During the course of the interview, the respondents were requested to 
estimate the number of units, proportion of time, or quantity of resource inputs used 
(Box 2).  All respondents were extensively asked to estimate the amount of time they, 
including the other health personnel involved in the programme, spent in each 
treatment round of the deworming programme.  The estimated total time spent was 
converted to an equivalent number of 8-hour working days which was then multiplied 
by the personnel’s computed salary per day depending on their salary grade level.  
Likewise, costs for building space (i.e., stockroom) used to store deworming drugs 
and other related paraphernalia were estimated: first, the total area alloted and the 
duration when it was used for the said purposes were calculated, and  then valued 
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accordingly based on the regional rate of a commercial space for rent.  Consumables 
used in relation to the programme intervention were valued using the local market 
price and based on the programme’s financial records that were shared by the 
respondents.  
 
Box 2:  Classification of Costs by Inputs 
 
Capital Costs 
• Buildings, space: Administrative offices, storage facilities 
• Vehicles: Trucks, four-wheel-drive vehicles, motorcycles 
• Equipment: Refrigerators, sterilizers, manufacturing machinery, scales, other 
equipment with unit cost of more than P5,000 
• Training, nonrecurrent: Training activities for health personnel that occur 
only once or rarely. 
• Social mobilization, nonrecurrent: Social mobilization activities, e.g. 
Promotion, public campaigns, that occur only once or rarely 
 
Recurrent Costs 
• Personnel:  Supervisors, health workers, administrators, technicians, 
consultants, casual labour. 
• Supplies: Drugs, small equipment, other related materials (unit cost of less 
than P5,000). 
• Vehicles, operation & maintenance: Petrol, diesel, lubricants, tires, spare 
parts, registration, insurance 
• Building, operation & maintenance: Electricity, water, telephone/telefax, 
cleaning/janitorial services, repairs 
• Training, recurrent: i.e. short in-service courses 
• Social mobilization: Operating costs 
• Others: Other operating costs which do not fall under the above-defined 
categories 
 
 
 
Since there were a lot of volunteers who received no compensation from their 
participation in relation to the programme (in some more affluent LGUs, honoraria 
were being provided), their ‘donated’ time spent in each treatment round were 
estimated during the interview. The non-financial or imputed costs of their donated 
time were valued by converting their estimated total time spent to an 8-hour working 
day and multiplying this to the mean value of the country’s regional daily minimum 
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wage rates set for non-agricultural sectors in the country(172) (Refer to Appendix G for 
the Summary of Current Regional Daily Minimum Wage Rates)   This study 
recognizes that placing a precise value on the volunteers’ donated time is difficult 
and awkward, yet resources like these are important cost component that should be 
factored in when conducting economic evaluations.  This study’s approach to 
estimate economic costs followed the standard process used in the cost 
effectiveness literature where most studies assumed that market prices, except 
volunteer labor, reflect the opportunity cost of all the inputs used.  From an 
economics point of view, such assumption holds true only when markets are 
competitive and that there is one single equilibrium price.  Although this study 
acknowledges employing such assumption, it is also taking note of the fact that there 
are different rules to estimate shadow prices when inputs are added or substituted to 
the current pool. 
 
Both the financial and non-financial or imputed costs (i.e., the opportunity cost of 
utilizing personnel and other resources) of a round of mass treatment strategy have 
been collected and examined.  All corresponding resource inputs under the non-
financial costs have been estimated based on the records of the national and local 
control programme, market price, regional wage orders, and others.  Furthermore, all 
costs have been converted from the Philippine local currency, Peso (PhP), to United 
States dollars (US$), using the average 2012 conversion rate of US$ 1.00 to PhP 
44.2288(173). 
 
To ensure the quality and reliability of the cost data that have been captured from the 
interviews,  mechanisms have been carried out such as cross-checking with 
respective financial reports and plans, asking interviewees to estimate resources 
used other than just the money spent, and validating collected data against different 
disease control programmes where STH programme activities are integrated. 
 
 
5.1.3. Cost Data scale-up 
 
Cost data collected from the various administrative levels were scaled up in order to 
capture the estimated total (economic) cost which represents a round of mass 
treatment at the national and the corresponding island group of the country.  
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Of the 17 CHDs, 16 were visited (CHD 9: Zamboanga Peninsula was the only region 
that was not visited due to armed conflict that erupted in the area during the 
scheduled field work).  All of the 8 and 3 CHDs from Luzon and Visayas, 
respectively, were visited; the remaining 5 CHDs came from Mindanao.  Costs from 
the regional level were proportionately distributed to the province and city health 
offices.  For instance, medicines (i.e., albendazole) were apportioned based on the 
target (13.5%) population of the locality that was prepared and submitted by the 
programme coordinators at the provincial and city levels.  The CHDs’ role in the 
deworming programme includes providing technical assistance for training and 
capacity building, budgetary allocation for the procurement of deworming drugs for 
mass treatment, monitoring and coordinating the implementation of mass treatment 
programmes in their jurisdiction areas, and providing prototype IEC materials for 
distribution to LGUs(27, 64).   
 
Non-financial costs for the donated deworming drugs (i.e., albendazole) have also 
been computed at this level of programme administration since these drugs that were 
allocated and distributed to the respective LGUs were centrally sourced from DOH 
through the regional CHDs.  Several copies of the invoice or delivery receipt  that 
were collected from the sampled offices showed that the deworming drugs were 
valued at PhP1.00 (approx US$0.024(173)) per tablet.  
 
Of the 39 (Luzon), 16 (Visayas), and 27 (Mindanao) provinces from each of the 
island group, 13, 4, and 10 provinces were sampled or visited, respectively.  Costs 
from the provinces were proportionately distributed to the municipal health offices.  
Coordination during mass treatment, and advocation to allocate funds for deworming 
drugs were the primary role of the Provincial Health Offices (PHOs)(27, 64).   
 
Of the 770 (Luzon), 409 (Visayas), and 456 (Mindanao) cities and municipalities 
across the country, 30, 13, and 17 cities and municipalities were sampled, 
respectively.  City/Municipal Health Offices/Rural Health Units have the primary role 
of completing the masterlists of targeted population for mass deworming; 
implementing the mass deworming program; and recording and submitting the 
accomplishment reports to their respective PHOs (27, 64).    
 
Across all levels of administration, the average (arithmetic mean) costs incurred by 
the sampled health offices under each subnational or island group (i.e., Luzon, 
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Visayas, Mindanao) were scaled-up (i.e., multiplied accordingly) by the total number 
of CHDs/PHOs/CMHOs in each respective island group to estimate the aggregated 
cost of a round mass treatment intervention in each respective level of government.  
 
To illustrate the process of cost scaling-up in each island group , the following 
methods were carried out:   
 
a. Get the average cost incurred for each three levels of government (i.e., 
regional, provincial, city/municipal).  The total collected cost for each level of 
government under each island group  was divided by the corresponding 
number of health offices that had been visited and subjected to cost collection.  
For Luzon, data collection was done in 8 CHDs/regions, 13 PHOs/provincial, 
and 30 C/MHOs.  For Visayas, it was done in 3 CHDs/regions, 4 
PHOs/provincial, and 13 C/MHOs.  For Mindanao, it was done in 5 
CHDs/regions, 10 PHOs/provincial, and 17 C/MHOs.   
 
b. Scale-up the  cost for each levelof government. The derived average cost per 
health office in each level of government was then multiplied accordingly by the 
total number of regional, provincial, or city/municipal health offices comprising 
each island group. Luzon has 8 CHDs, 39 PHOs, and 770 C/MHOs; Visayas 
has 3 CHDs, 16 PHOs, and 409 C/MHOs; and Mindanao has 6 CHDs, 27 
PHOs, and 456 C/MHOs .   
 
c. Estimate the total scaled-up cost for each island group.  This is done by simply  
summing-up the respective scaled-up costs of the various levels of government 
under each island group.   
 
In the process of cost data scale-up for each level of government, this study did not 
take into account the economies of scale. Economies of scale refer to changes in 
average unit costs that are related to changes in scale or size of the firm or 
enterprise.  A relevant implication of this concept on economies of scale is that high-
cost firms (in this case, local government units especially the municipal level of 
government) cannot, or at least may have difficulty to, survive in a competitive 
economy (174).  Most of these lower levels of government are faced with high costs in 
delivering basic health services such as helminthesis programs, and thus, possibly 
confront with issues on sustainability of the program.  However, even without 
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considering the economies of scale in the scale-up calculations, the expected results 
(i.e., order of strategies in terms of costs) would remain the same across the three 
sub-national island groups. 
 
 
5.1.4. Cost Estimation for the other intervention strategies 
 
Cost estimates for the other intervention strategies (i.e., TA, MB, and TB) were based 
on extrapolating the scaled-up costs using assumptions from costing reports of other 
studies.  The 60% increase on non-financial costs from annual to biannual treatment 
was based on the estimated costs increase associated with biannual onchocerciasis 
control for Ghana(175) and with biannual MDA lymphatic filariasis control for Africa(176).  
The 60% estimated increases were higher than what was found in a school-based 
anthelmintic treatment programme in Lao PDR, wherein biannual treatment was 35% 
higher than annual treatment(20).  Nevertheless, it should be noted that direct 
comparison of the changes in treatment frequencies would be difficult since the study 
was conducted in a different setting (school-based vs. community-based) which 
would mean that programmes were implemented differently.  And although there was 
an effort in Uganda to estimate the cost of biannual treatment by simply doubling the 
estimated cost per year of the annual treatment(177), such could post a debate on 
issue as to whether the same amount of resource inputs were used when treatment 
frequency was increased to twice per year.  For treatment mode of delivery, 
percentage changes used to estimate non-financial costs from mass treatment to 
targeted treatment were based on the cost-effectiveness study of anthelmintic 
intervention for community control of STH in Nigeria(131).  Moreover, it is just proper 
that estimates of some cost inputs, such as training, remained constant whether 
mass or targeted treatment was adopted to acknowledge the fact that the same level 
of resources are needed to implement the programme.  Table 7 presents the 
assumptions used in estimating and predicting the cost for the other intervention 
strategies. 
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Table 7:  Assumptions Used in Estimating and Predicting the Cost for the Other 
Intervention Strategies 
Cost Variables Assumption References 
Total Economic Costs: 
 
MA treatment → MB treatment 
TA treatment → TB treatment 
60% approx. increase on 
economic costs from annual to 
biannual treatment 
Turner, HC, et.al. 
(2013); Stolk WA, 
et.al. (2013) 
Programme Running (i.e. 
Personnel, including volunteers) 
 
MA treatment → TA treatment 
MB treatment → TB treatment 
30-35% approx. decrease in 
total labor (personnel) costs in 
relation to programme 
administration and delivery 
from Mass treatment to 
Targeted treatment 
Holland, CV, et.al. 
(1996) 
Community Sensitization & 
Screening: 
 
MA treatment → TA treatment 
MB treatment → TB treatment 
3% approx. increase on cost 
(campaign phase, labor and 
transport) from Mass treatment 
to Targeted treatment 
Holland, CV, et.al. 
(1996) 
Drug Distribution and Treatment: 
 
MA treatment → TA treatment 
MB treatment → TB treatment 
43% approx. decrease on 
treatment cost from Mass 
treatment to Targeted 
treatment 
Holland, CV, et.al. 
(1996) 
Production and Distribution of 
IEC Materials: 
 
MA treatment → TA treatment 
MB treatment → TB treatment 
3% approx. increase on cost 
(campaign phase, labor and 
transport) from Mass treatment 
to Targeted treatment 
Holland, CV, et.al. 
(1996) 
Drug Supplies 
 
MA treatment → TA treatment 
MB treatment → TB treatment 
54% approx. decrease on drug 
costs from Mass treatment to 
Targeted treatment 
Holland, CV, et.al. 
(1996) 
 
 
5.2. Programme implementation structure set-up 
 
With the devolved set-up of the Philippine government, the role of the DOH shifted from 
being the sole provider of health services to provider of specific health services and technical 
assistance for health to LGUs. The DOH have carried out these functions through their 17 
regional offices (CHDs).  One of the factors that contribute to the costs incurred at the CHD 
level of administration is the role being played by their liaison officers.  They are group of 
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competent health workers who serve under the Provincial Health Team Office (PHTO),  an 
extension arm of the DOH-CHD to complement and augment LGUs’ efforts to provide better 
health care.  Members of the PHTO have been active in the conduct of orientation for the 
provincial and municipal health workers as well as in the monitoring of programme 
implementation for both Schistosomiasis and STH. 
 
On the other hand, LGUs (i.e., provincial, city, municipality) operate under different budgets 
and that they are allowed by the Constitution to explore avenues to attend to the needs of 
their populace.  Moreover, each LGU also differs in terms of socio-economic status and 
social services capacity.  The local chief executive (i.e., the governor under the province, the 
mayor under the city/municipality) has the power to determine which among the social 
services would get a bigger chunk of the budget. Some issues have been brought out during 
the interview including the issue that the delivery of intervention programmes have been 
hampered or limited because their local chief executive does not include health care on their 
priority list, leaving them a confined budget for the various health care 
programmes/activities.  These issues and other structural considerations as a result of the 
devolved set-up of health care in the country are evident on how each level of government 
spends or is proactively involved in the various phases of the programme intervention.  
 
The limited involvement of the Provincial Health Office (PHO) in the delivery of the 
programme is evident in having the least personnnel cost utilized during the intervention 
cycle.  The PHOs serve mainly as conduit in the delivery of drugs and supplies from CHDs 
to the municipalities in addition to its role of consolidating the accomplishment reports from 
the municipalities which will be submitted to the CHDs.  PHOs do not usually send 
representatives to monitor the intervention process being conducted at the lower levels of 
government.  Although one of their specified functions is to supervise the conduct of mass 
treatment and monitor the side effects  in all established mass treatment centers, they fall 
short of such expectation.  One of the reasons cited during the interview is the PHO’s limited 
number of health personnel to supervise the deworming administration at the lower levels of 
government. 
 
The municipal/city level of government, being the forefront in implementing the programme, 
has the highest total costs among the three levels of administration.  Barangay Health 
Workers (BHWs), together with the Barangay Nutrition Scholars (BNS), are the most notably 
utilized among the health workers.  They are the ones who do the house-to-house visit to 
update the masterlists or target population for the programme intervention and deliver the 
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anti-helmintic drugs to individuals who missed the usual center-based scheduled deworming 
treatment. These trained health workers are based and live in the barangays (villages) or 
communities they serve which give them better access, familiarity, and knowledge of their 
target population.  They are considered as volunteers, although they receive from their LGU 
some monetary remunerations for their personal expenses.  The amount varies depending 
on the Internal Revenue Allotment (IRA) share of their respective LGUs from the national 
government. 
 
The other type of health  workers that are mostly utilized at the municipal/city level during the 
intervention are the midwives and nurses.  These health workers personally supervise and 
monitor the efficient and on-time delivery of the drugs and supplies to be used in their 
respective communities. Aside from being active during the implementation of the 
intervention, they are also the ones in-charge of consolidating the accomplishment reports 
that will be submitted eventually to the PHO/CHD.  The Midwives receive and consolidate 
the accomplishment reports from the BHWs they supervise, while the Nurse 
Supervisors/Coordinator will come up with the consolidated accomplishment report for the 
municipality/city.    
 
The next section looks at the data collection tool that was used to capture the cost data from 
the three levels of government. 
 
 
5.3. Data Collected under the condition of MA treatment Strategy 
 
Table 8 presents both the financial and non-financial costs that have been collected by level 
of administration (i.e., regional/CHDs, provincial, and city/municipal).  Data from Luzon were 
collected from 8 regional offices of the DOH, 13 provincial health offices (PHOs), and 30 city 
and municipal health offices (C/MHO).  From Visayas, there were 3 CHDs, 4 PHOs, and 13 
C/MHOs and from  Mindanao, 5 CHDs, 10 PHOs, and 17 C/MHOs.   
 
The costs in each category (i.e., Programme running costs, community sensitization and 
screening, training, drug distribution and treatment, and production and distribution of IEC 
materials) were further itemized into resource inputs to have a better understanding as to the 
magnitude of resources inputs that are being utilized in each level of administration.  
Moreover, it  also served as a practical tool to identify and assess how the three levels of 
administration/government operate or perform with regard to this specific public health care 
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delivery.  Non-financial or imputed costs, which are mostly being left out in the equation in 
many costing exercises, turned out to have the biggest share in the cost of STH programme 
delivery.  And from the table, we can distinctively identify that most of these non-financial 
costs have been coming from the lower level of administration/government. 
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Table 8:  Financial and non-financial or imputed cost data  
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Table 8:  Financial and non-financial or imputed cost data  
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Table 9 shows the scaled-up non-financial and financial costs according to category for each 
of the three island groups per round of mass treatment. The largest proportion of the 
financial costs in terms of category was on ‘programme running’ with percentage share of 
79%, 74%, and 77%, for Luzon, Visayas, and Mindanao, respectively, and 77% at the 
national level.  Among the three island groups, Luzon, however, has the remaining 
categories in a different order in terms of its proportion to the financial cost.  ‘Production and 
distribution of IEC materials’ and ‘drug distribution and treatment’ were the next two 
categories with high proportion for Visayas (both with 10% share) and Mindanao (both with 
6% share).  On the contrary, these two categories were at the bottom 2 for Luzon (both with 
just 3% share).  Such result could be because Visayas and Mindanao have different physical 
characteristics from Luzon in terms of road conditions, community and population densities, 
availability of ethnolinguistic groups in the area, as well as distance from the DOH central 
office (situated in the heart of Manila in Luzon).     
 
The estimated scaled-up non-financial cost (i.e., volunteers’ time, donated supplies, 
resources provided free of charge) comprised the large chunk of the total costs in the 
deworming programme for Luzon (78%), Visayas (58%), and Mindanao (52%).  Thus, it is 
important not to neglect this aspect in any costing exercises to come up with the real picture 
of the programme intervention. Two of the resource inputs that largely contributed to the 
value of non-financial costs for Luzon, Visayas, and Mindanao were the volunteers’ time and 
donated deworming drugs.  
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Table 9:  Scaled-up financial and non-financial costs at national and subnational levels 
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Table 9:  Scaled-up financial and economic costs at national and subnational levels 
 
 
Table 10 further broke down the scaled-up financial and non-financial costs by level of 
administration in each island group.  In terms of ‘programme running’ category, it is evident 
that across the country majority of the labor and programme activities in the delivery of the 
deworming programme comes from the cities and municipalities.  This validates the fact that 
the point of delivery service happens in this unit level.  Moreover, costs related to building 
such as possible rent costs for office space and stockroom for keeping the deworming drugs 
and other STH related paraphernalia are high at the city and municipal levels.    
 
City and municipal levels also have the highest cost when it comes to ‘community 
sensitization and screening’ and ‘drug distribution and treatment’ among the three levels of 
administration across the country.  In addition, it is observed that both Visayas and 
Mindanao turned out to have high cost mainly due to their terrain and more dispersed 
populace.   
 
The national government through its regional offices (i.e., CHDs) is mainly providing funds 
related to training. However, some counterpart funds have to be shouldered by the 
respective LGUs such as allowances of the participants, location venues, and other training 
related expenses. 
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The regional offices mostly produced and supplied IEC materials to their respective LGU 
constituents. However, it is oftentimes a practice at the local units to come up with a local 
version of the IEC materials to communicate more effectively the health advisory message to 
the natives.  Moreover, cities and municipalities often purchase additional promotional 
materials such as shirts, umbrellas, caps and flyers to entice the locals to join the 
programme.  
 
In consideration of some assumptions from the literature, the cost data that have been 
collected and scaled-up to reflect one round of mass treatment were used to measure and 
generate the financial and non-financial costs for the other intervention strategies.    
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Table 10:  Scaled-up financial and non-financial cost data broken down into levels of administration in each subnational level 
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Table 10:  Scaled-up financial and non-financial cost data broken down into levels of administration in each subnational level 
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This chapter section has presented the results of the cost estimation and prediction of one 
strategy at both the national and island group levels.  The devolved set-up of the country’s 
health system has a large impact in the delivery and implementation of the programme.  The 
LGUs (i.e., provincial, city, municipality) have been operating under different budgets, socio-
economic status and social services capacity, not to mention how local chief executives 
prioritize funding of competing social services, the delivery of intervention programmes have 
been constrained.  Such issues are evident in the limited involvement of some LGUs in the 
various phases or aspects of the programme implementation.  Although considered only as 
part of the equation in the success of any health program implementation at the local level, 
the role being played by the frontline health workers (i.e., BHWs, BNs, Midwives and Public 
Health Nurses) and volunteers have been very critical.  
 
 
5.4. Predicted Cost for STH treatment strategies 
 
Table 11 shows the estimated financial and non-financial (or imputed) costs associated in 
each of the treatment intervention strategy at the national and subnational levels.  It is 
apparent that MB treatment strategy was the most ‘expensive’ among the 4 interventions, 
with estimated total economic costs per year in each island group of US$9.4M (Luzon), 
US$6.8M (Visayas), and US$6.6M (Mindanao), of which 73%, 60%, and 53% of the costs, 
respectively, were associated to non-financial costs.  This was followed  by the TB treatment 
strategy which is just 16%-17% lower than that of the MB treatment strategy. Non-financial 
costs for TB treatment strategy constituted 72%, 59%, and 52% of the TB total economic 
costs for Luzon, Visayas, and Mindanao, respectively. TA treatment strategy turned out to be 
the least ‘expensive’ among the strategies with total economic costs per year of 
approximately half of that of the MB treatment strategy.  Non-financial costs for TA treatment 
strategy also remained as substantial part of the TA total economic costs with 71% (Luzon), 
57% (Visayas), and 51% (Mindanao) proportions. Discounted total economic costs at a rate 
of 3% per annum over the 10-year period have been highlighted under each of the treatment 
strategies. 
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Table 11:  Predicted financial and non-financial or imputed costs discounted over 10-year 
period for each treatment strategy 
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5.5. Cost per person treated 
 
Using the predicted cost for each treatment strategy, together with the estimated target 
population presented in table 5, we can derive the cost per person treated for each of the 
four treatment strategies both at the national and subnational level (Table 12). 
 
 
Table 12:  Cost per person treated for each treatment strategy both at national and 
subnational levels 
 
 
 
At the national level, total cost per person treated is lowest in TA treatment with $0.97 
compared to $1.83, $1.16, and $1.53 for MB, MA, and TB treatment strategies.  The same 
pattern can be observed at the subnational level.   There is a significant reduction, average 
of 62%, in the cost per person treated when we look at just the financial aspect of the 
treatment.  The pattern, however, is not altered wherein TA treatment has the least cost per 
person treated ($0.38) and MB treatment the highest ($0.67). 
 
 
5.6. Summary 
 
The chapter has presented the methods and processes used to estimate and derive the cost 
data and the impact or health benefits of the respective treatment interventions have been 
presented.  Several assumptions from the published literature have been used in the 
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process to be able to come up with relevant estimates especially when local data or 
information are not available.   
 
The chapter also showed the results of the cost estimation and prediction of the four 
competing strategies at both the national and island group levels.  The devolved set-up of 
the country’s health system has a large impact in the delivery and implementation of the 
programme.  The LGUs (i.e., provincial, city, municipality) have been operating under 
different budgets, socio-economic status and social services capacity, not to mention how 
local chief executives prioritize funding of competing social services, the delivery of 
intervention programmes have been constrained.  Such issues are evident in the limited 
involvement of some LGUs in the various phases or aspects of the programme 
implementation.  Although considered only as part of the equation in the success of any 
health program implementation at the local level, the role being played by the frontline health 
workers (i.e., BHWs, BNs, Midwives and Public Health Nurses) and volunteers have been 
very critical.  
 
Results of the cost collected and estimated showed that most of the non-financial or imputed 
costs came from the lower level of administration/government (i.e., city/municipality).  In 
terms of financial costs, ‘programme running’ category has the largest cost proportion 
amongst the five financial cost categories for the 3 island groups.  However, for the 
remaining four cost categories, the 3 island groups came up with a different order of cost 
proportions. Such result could be because both Visayas and Mindanao have different 
physical characteristics from Luzon in terms of road conditions, community and population 
densities, availability of ethnolinguistic groups in the area, as well as distance from the DOH 
central office.  Moreover, the variations in costs among the different levels of government 
that have been observed across the 3 island groups reflect the extent of responsibilities that 
each LGU health office unit has in the programme implementation. 
 
Results of the predicted costs for the four intervention strategies showed that MB treatment 
strategy was the most ‘expensive’ while TA treatment strategy, the least ‘expensive.  Non-
financial costs remained to be substantial when we examined the total economic cost of 
delivering the intervention programmes. 
 
Lastly, the total cost per person treated is lowest in TA treatment with national level values of 
$0.97 compared to $1.83, $1.16, and $1.53 for MB, MA, and TB treatment strategies.  The 
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order/pattern of the strategies remains the same even if only the financial costs have been 
considered.  This result holds true also at the subnational level. 
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CHAPTER VI.   IMPACT TO HEALTH OUTCOMES 
 
This chapter starts with an overview of the results of the estimation and derivation of costs 
for each intervention strategy and the measures of effectiveness or health outcome that 
have been considered in this study (6.1). The predicted prevalence of STH infection (6.1.1), 
the methodologies of estimating the burden of disease due to STH infection (6.1.2) and the 
effectiveness for each of the intervention strategy (6.1.3) have been outlined. Also presented 
are the results of the estimated health outcome (6.2) and the health outcome measures per 
person treated (6.3) looking both in terms of DALYs averted and number of infections and 
reinfections averted. A summary (6.4) has been made to end the chapter.  
 
 
6.1. Estimating impact or health benefits 
 
This section deals with the processes and methods that were undertaken to estimate the 
impact or health benefits of each intervention control strategy.  It describes the 
metapopulation model for STH transmission and control in the Philippines that was utilized to 
derive the predicted/forecasted prevalence of STH infections given the current national 
control program and the 3 competing alternative programs.  It then presents the data 
assumptions and formula used to estimate what this prevalence means in terms of the 
burden of disease due to STH infection. 
 
 
6.1.1. Metapopulation model for STH transmission and control in the 
Philippines to estimate infection prevalence 
 
Estimates of the predicted/forecasted prevalence of STH infections by subnational 
levels (i.e., Luzon, Visayas, Mindanao) were obtained from the wider research team 
in which this project is based.  This complimentary team developed a mathematical 
model capable of modeling prevalence of STH infections in different regions in the 
Philippines.  The model was parameterized using local survey data to ensure that it 
reflected local transmission dynamics.  One of the surveys used stratified cluster 
sampling to select provinces in the three island groups in the Philippines wherein a 
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sample size of 3,600 participants, divided into 1,200 participants per island group, 
was targeted.(9) The other survey utilized a randomized, spatially stratified, multi-
stage clustered design, and with very large sample sizes, with approximately 20,000 
in Mindanao, 6,000 in the Visayas and 1,500 in Luzon.(178) 
 
Through a metapopulation model that simulated four different control strategies (i.e., 
combination in terms of mode of delivery and frequency) they produced estimates of 
the annual prevalence of three helminth infections under each category over a 10-
year period taking into account the corresponding cure efficacies of albendazole to 
the different STH infections.   
 
A more detailed description of the metapopulation model that the complimentary 
group used in deriving the predicted/forecasted prevalence of STH infections has 
been supplied earlier (Appendix B).  
 
To measure the transmission potential for a given pathogen, the group has derived 
the basic reproduction number (RO) which they calculated directly from infection data 
using equilibrial values of endemic diseases. One of the variables they used was the 
susceptible proportion of the population at disease equilibrium (a state that was 
assumed for STH infection in the Philippines given the low levels of nationwide 
control at the time of survey).  In addition, infection prevalence for both adult and 
children has also been estimated.  The estimated values for both groups have been 
weighted according to their proportional demographic representation, a necessary 
step to derive the population-level prevalence. Both the demographic information and 
the proportion of children to the total population have been sourced from the 
Philippine Statistics Authority. Table 13 presents the resulting population prevalence 
estimates and associated R0 values that the group has derived.  These estimates 
were used to infer the force of infection for the different parasites among the different 
regions which impacts the anticipated re-infection rate following drug administration.  
 
The splitting of the locations into: Luzon & Visayas; and Mindanao regions was done 
by the group since Matlab could not handle daily time steps connecting 200+ sub-
populations in the metapopulation model. 
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Table 13:  Resulting population prevalence estimates and associated R0 values 
Location Parasite Population 
Prevalence 
R0 
Luzon & Visayas 
Trichuris 47.5% 1.90 
Ascaris 33.1% 1.49 
Hookworms 12.9% 1.15 
Mindanao 
Trichuris 18.5% 1.23 
Ascaris 21.0% 1.27 
Hookworms 10.9% 1.12 
Source:  Yakob, L. et.al. Metapopulation model for STH transmission and control in the Philippines 
(unpublished work) 
 
Acknowledging transmission dynamics of the disease, the group explicitly 
incorporated the environmental contamination in an age-structured (children and 
adults) mathematical model of STH.  And although the same model was used to 
simulate transmission dynamics for all the STH species, parameters according to 
particular parasites were used in the process.  For instance, it was brought out that 
Ascaris and Trichuris eggs have a half-life of 2 months(179); whereas hookworms are 
more sensitive to external conditions and probably do not survive much beyond 40 
days(180).Moreover, within the host, Trichuris survives for approximately 1.5 
years(181),Ascaris for 1 year, and hookworm for 3 years(56). 
 
The group further assumed that all locations for which prevalence was measured in 
the Philippines (108 point estimates for Mindanao and 129 for Luzon and Visayas) 
were connected proportionally to their spatial autocorrelation. Each location is 
connected to all other locations according to a matrix which defines the transmission 
coefficient from contaminated environment to host apportioned across all locations. 
Equations used in the metapopulation model were implemented in Matlab with daily 
time-step output using the ode15s function over a time course of 10 years.  
 
Lastly, it was assumed that efficacies of the  deworming drug Albendazole differ 
according to the parasite species (clearance rate of 88% for Ascaris, 78% for 
hookworm and 28% for Trichuris)(182). 
 
The simulation output of the four control strategies for the three STH infections (i.e., 
Ascariasis, Trichuriasis, and Hookworms) for the three island groups was captured 
and appended in Appendix H.  Each line in the captured spreadsheets represents the 
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center of a barangay in various random locations covering the whole region and each 
column represents the predicted/forecasted prevalence under corresponding control 
strategy over a specified period of years.  The separation for Luzon and Visayas 
regions (129 sub-populations) and Mindanao regions (108 sub-populations) could 
also be considered as useful in comparing regional or intra-country variations of the 
CEA for the four control strategies.     
 
This study assumed that the output values of the complimentary group representing 
the center of a barangay under each subnational group were the same estimates that 
represented the spatial resolution for the corresponding regions where cost data 
were collected.  Moreover, prevalence estimates for the national level were assumed 
to follow the pattern from that of Luzon and Visayas.  The average (arithmetic mean) 
values of the predicted/forecasted prevalence (highlighted potion in the appendix) 
were used to represent the prevalence impact of the various intervention strategies 
for each STH infection.   
 
6.1.2. Estimation of burden of disease due to STH infection 
 
A standard measure of the health burden of a disease is the Disability-Adjusted Life 
Year (DALY) associated with a case of the disease.  Thus, converting the number of 
infections and reinfections into DALYs to serve as our health outcome enables us to 
make the results comparable across different diseases and causes. 
 
DALYs measure health loss by counting the years of healthy life that are lost due to 
death and non-fatal illness or impairment.  Thus, when we look at DALYs to measure 
health outcomes, two components should essentially be considered: the years of life 
lost due to premature mortality (YLLs) and the years lived with disability (YLDs).   
 
To estimate the respective YLLs and the YLDs caused by a particular STH infection 
for each intervention strategy,  a simple spreadsheet was developed incorporating 
findings from relevant studies as assumptions.  First, sex ratio specific to each 
infection was computed by dividing the derived prevalences of infection for female 
and male from the sampled population of published studies(52, 61, 62, 183-188).  The 
number of cases of infection at both the national level and the 3 island groups was 
then derived by multiplying the corresponding published/projected disease 
prevalence and the country or island region’s population(47).  The 10-year projected 
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disease prevalences  both at the national level and the three island groups were 
provided by the complementary team.  
 
Total cases of infection for male and female specific to the country and the three 
island regions were computed using the derived sex ratio from the published studies 
and the estimated number of cases of infections.  The derived female to male sex 
ratio from the published studies(52, 61, 62, 183-188) are as follows: Ascaris lumbricoides – 
1.23; Trichuris trichiura – 1.25; and hookworms – 0.93. 
 
Demographic data/group used (i.e. Under 5, SAC, Adult/Community) in this thesis is 
consistent with the US Census Bureau in calculating the fraction of total country 
populations in the infant class (0–1), pre-SAC class (2–4 years), SAC (5–14 years) 
and adults (15+ years)(109). 
 
YLDs are computed as the product of the prevalence of different disease-sequelae 
and injury-sequelae and their corresponding disability weights.  Disability weights are 
selected on the basis of surveys of the general population about the loss of health 
associated with the health state related to the disease sequela(79).  This thesis 
assumed that disease- and injury-sequelae associated with the STH infections were 
already captured in the age-pattern and sex prevalence estimates from the published 
studies(52, 61, 62, 183-188), from which the country’s sex ratio and age specific prevalence 
for the STH infections have been derived.  In addition, it is assumed that it has also 
been considered in the predicted/forecasted prevalence from the mathematical 
modeling/technique.   
 
Table 14 presents the description of disability weights for each STH infection that 
was used to estimate YLDs in a recent study looking at the global numbers of 
infections and disease burden of STH infections(30)  For each category of infection 
intensity to estimate YLDs, Pullan, et al. has applied the disability weights from the 
GBD Disability Weights Study(189).  It should be noted that the four major sequelae 
attributed to STH infection (i.e., abdominopelvic problems, symptomatic infection, 
wasting and anemia – the latter applying to hookworm only) have their corresponding 
disability weights assigned(30). 
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Table 14: Description of disability weights for eachsoil-transmitted helminth species 
Species 
 
Sequelae and disabling 
consequences 
 
Infection 
intensity 
Disabilty 
weighting 
A. lumbricoides 
Symptomatic infection Heavy 0.0296 
Wasting Heavy 0.1245 
Mild abdominopelvic problems Medium 0.0108 
T. trichiura 
Symptomatic infection Heavy 0.0296 
Wasting Heavy 0.1245 
Mild abdominopelvic problems Medium 0.0108 
Hookworm 
Mild anemia All 0.0041 
Moderate anemia All 0.0056 
Severe anemia All 0.1615 
Wasting Heavy 0.1245 
Mild abdominopelvic problems Medium 0.0108 
Source: Pullan RL,et.al. Global numbers of infection and disease burden of soil transmitted helminth 
infections in 2010. Parasit Vectors. 2014;7(1):37 
 
 
This study has utilized the following disability weights from the Global Burden of 
Disease (GBD) Study(189)to capture the conservative YLD values for the country:  A. 
lumbricoides – 0.0108; T. trichiura – 0.0108; and hookworms – 0.0041.  Furthermore, 
this thesis’ assumption that anemia due to hookworm attributes 60.72% of the total 
YLDs for hookworm disease is consistent with the YLD estimates for non-fatal health 
outcomes from diseases and injuries sequelae for the GBD Study 2010(151). 
 
Pullan, et. al. (2014)  presented global burden of STH infection estimates that differ 
from those produced previously due to a number of major methodological 
improvements that they introduced such as deriving disability weights from 
judgments of the general public about the health loss associated with the health state 
related to each sequela, rather than by health care professionals alone(190). 
Removing cognitive impairment as a sequela for STH has been justified by the 
perceived paucity of evidence of a cognitive impact of intestinal nematodes.  Such 
decision was made in recognition to a 2012 Cochrane review of available 
randomized controlled trials of deworming, finding contrasting evidence of nutritional 
benefits and little support for cognitive or education benefits(191). The review, 
however, was criticized for not only excluding studies that treated both STH and 
schistosomiasis, but also missing out a point that many underlying trials of 
deworming suffer from issues such as (i) methodological challenges, (ii) non-
assessment of treatment externalities, (iii) inadequate measurement of cognitive 
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outcomes and school attendance, and sample attrition, and (iv) better-designed 
studies are required (192). 
 
Table 15 provides the variables and assumptions/methods used in estimating the 
YLDs caused by a particular STH infection in each intervention strategy.  
 
 
 
Table 15: Variables and Assumptions/Methods Used in Estimating the YLDs 
Caused by a Particular STH Infection 
Variables Assumptions/methods References/Sources 
Prevalences of 
infection for 
female and male 
based on 
published 
studies 
Distribution prevalence of infection 
for female and male from the 
sampled population of published 
studies 
Baldo, et.al.(2004); 
Lumampao (2003); Kim, 
BJ., et al. (2003); 
Rayan, P. et.al.(2010); 
Chandrashekhar TS et. 
al. (2005); Alli JA, et.al. 
(2011); Awolaju and 
Morenikeji (2009); 
Choubisa, SL et.al. 
(2012); Abate, et.al. 
(2013) 
 
Sex ratio 
Derived by dividing the prevalences 
of infection for female and male 
 
n.a. 
National and 
Regional level 
(i.e., 3 Island 
Group): Based 
period Y0 and 
10-year 
projected 
disease 
prevalence 
 
Based on the projected/forecasted 
prevalence of STH infection 
Generated from a 
mathematical simulation 
model 
Number of cases 
of infection 
Derived by multiplying the 
corresponding infection prevalence 
and estimated population of the 
country or island region 
 
n.a. 
Cases of 
infection for 
male and female 
specific to the 
country and the 
3 island regions 
 
Computed using the corresponding 
derived sex ratio and the estimated 
total cases of infection 
n.a. 
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Table 15: Variables and Assumptions/Methods Used in Estimating the YLDs 
Caused by a Particular STH Infection 
Variables Assumptions/methods References/Sources 
Male and female 
prevalence 
specific to the 
Philippines both 
at the national 
and regional 
(i.e., island 
group) levels 
 
Derived from the proportion of the 
corresponding cases of infection 
and the given population for male 
and female 
 
n.a. 
Demographic 
data/group 
• Under 5 
• SAC (5-14 years old) 
• Adult/Community (15+ years old) 
 
US Census Bureau. 
2013 
Age pattern of 
disease for 
female and male 
Follows the proportion of 
corresponding cases of infection for 
each demographic group and the 
total number of cases for female 
and male 
Kim, BJ., et al. (2003) 
Age pattern case 
estimates for 
female and male 
specific to the 
Philippines 
Derived by multiplying the estimated 
total cases of infection for female 
and male and the age pattern of the 
disease for female and male 
n.a. 
Prevalence of 
different 
disease-
sequelae and 
injury-sequelae 
for each STH 
infection 
Already captured in the age-pattern 
and sex prevalence estimates from 
the published studies used to 
examine the country’s sex ratio and 
age specific prevalence. 
 
Moreover, it has been considered in 
the mathematical modeling 
technique. 
Baldo, et.al.(2004); 
Lumampao (2003); Kim, 
BJ., et al. (2003); 
Rayan, P. et.al.(2010); 
Chandrashekhar TS et. 
al. (2005); Alli JA, et.al. 
(2011); Awolaju and 
Morenikeji (2009); 
Choubisa, SL et.al. 
(2012); Abate, et.al. 
(2013) 
 
Disability 
weights 
Utilized the following disability 
weights to conservatively estimate 
the country’s YLD values in relation 
to STH: 
A. lumbricoides – 0.0108;  
T. trichiura – 0.0108; and 
hookworms – 0.0041. 
 
Pullan, et al. (2014) 
Anemia due to 
hookworm 
Attributes 60.72% of the total YLDs 
for hookworm disease 
 
Vos T., et.al. (2013) 
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On the other hand, YLLs are computed by getting the product of the number of deaths 
at each age x and the standard life expectancy at age x.  The reference standard life 
table aims to outline the aspiration for healthy lifespan for all individuals. Considering 
the improvements to extend life expectancy in the last 2 decades, it is necessary to 
also update the standard reference life table that was used in the GBD 1990.    In 
Japan, one of the countries with the lowest mortality, life expectancy has steadily 
improved for females from the previous 82.5 years to 85·9 years at birth(193).  This 
study adapted the new reference standard life table (Table 16) developed by Murray, 
et al.(193) in estimating the YLLs for the STH infections over the 10-year period for each 
of the intervention strategy.   
 
Table 16:  GBD 2010 Standard Abridged Life Table 
Used for Computing Years of Life Lost due 
to Deaths at Each Age 
Age Life Expectancy (years) 
0 86.02 
1 85.21 
5 81.25 
10 76.27 
15 71.29 
20 66.35 
25 61.40 
30 54.46 
35 51.53 
40 46.64 
45 41.80 
50 37.05 
55 32.38 
60 27.81 
65 23.29 
70 18.93 
75 14.80 
80 10.99 
85 7.64 
90 5.05 
95 3.31 
100 2.23 
105 1.63 
 
Source: Murray CJL, Ezzati M, Flaxman AD, et al. GBD 2010: 
design, definitions, and metrics. (Supplementary Appendix) 
Lancet 2012; 380: 2063–66. 
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The number of STH-related deaths in the Philippines at the national and regional 
levels was computed by multiplying the estimated population for each age-sex group 
and the corresponding percentage of STH-related death for female and male.  It is 
assumed that the percentage of STH-related death follows the same derived 
distribution pattern of death percentage as estimated by the Institute for Health 
Metrics and Evaluation (IHME)(66) specific to the three STH infections in the 
Philippines (Table 17).   Though it is unusual for STH to kill their human hosts(41) , 
death cases, if any, could occur only with Ascaris infection. 
 
 
Table 17:  Derived distribution pattern of STH-related death by 
age-sex group 
Age Group 
Estimated STH-related death (%) 
Male Female 
Under 5 0.000951 0.000827 
5 – 9 0.000154 0.000133 
10 – 14 0.000038 0.000033 
15 – 19 0.000016 0.000014 
20 – 24 0.000014 0.000012 
25 – 29 0.000011 0.000009 
30 – 34 0.000015 0.000013 
35 – 39 0.000011 0.000010 
40 – 44 0.000013 0.000012 
45 – 49 0.000012 0.000011 
50 – 54 0.000016 0.000015 
55 – 59 0.000023 0.000021 
60 – 64 0.000033 0.000029 
65 – 69 0.000040 0.000036 
70 – 74 0.000056 0.000051 
75 – 79 0.000111 0.000098 
80 – 84 0.000239 0.000166- 
85 and Over - - 
Note:  Values were derived from Institute for Health Metrics and Evaluation (IHME) estimates 
 
Table 18 presents the variables and assumptions/methods used in estimating the 
YLLs caused by a particular STH infection in each intervention strategy. 
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Table 18: Variables and Assumptions/Methods Used in Estimating the YLLs 
Variables Assumptions/Methods References/Sources 
Life expectancy 
(years) 
Adapted the new reference 
standard life table  
Murray,CJL,  et al 
(2012) 
 
Percentage of 
STH_related death 
for female and male 
Follows the same death 
distribution pattern as estimated 
by the Institute for Health Metrics 
and Evaluation (IHME) specific to 
the three STH infections in the 
Philippines 
 
Global Burden of 
Disease Study 2010 
(GBD 2010) Results 
1990-2010. IHME. 
Number of 
STH_related deaths 
for female and male 
specific in the 
Philippines 
Derived by multiplying the 
estimated population for each 
age-sex group at the national 
and regional levels and the 
percentage of death for female 
and male 
 
 
To  establish usability and reliability of the simple model that was developed to 
estimate the DALYs due to STH infections specific to the Philippines, generated 
DALYs from the model using baseline Y0 prevalence were compared with the country 
level DALYs figures as reported in the 2010 Global Burden of Disease (GBD) - 
Institute for Health Metrics and Evaluation(66).   To compare, table 19 shows the 
estimated YLL and YLD results of the two distinct reports for the STH infections 
specific to the Philippines: 
 
 
Table 19:  Comparison of YLL and YLD estimates of the developed model versus 
GBD-IHME report for the STH infections specific to the Philippines 
  Developed model GBD – IHME 
Ascariasis   YLL 9,796 9,557 (42.9061 - 45,451.7) 
YLD 140,147 60,277 (31,961.1 - 104,926) 
Trichuriasis   YLL - - 
YLD 345,743 141,360.77 (77,007 - 238,866) 
Hookworm   YLL - - 
YLD 11,555 148,045.29 (69,821 - 263,611) 
Total DALYs for STH 
infections 507,241 359,240.06 (195,714 - 597,197) 
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Although discrepancies were noted with the YLD estimates for Trichuriasis and 
hookworm infections, the derived total DALYs for all the STH infections were still 
within the CI values as reported in the 2010 GBD-IHME.  It should be noted that the 
total DALY estimates under the developed model fitted among the high range of CI 
values in the reported 2010 GBD-IHME, perhaps because the developed model used 
in this study had finer spatial resolution and better data for the underlying prevalence 
estimates.  This could mean that a country-based study would be necessary to 
capture unaccounted burden of the disease and reflect a finer health outcome 
brought by these infections. 
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Figure 11 presents the summary of the variables and their interconnections in 
estimating the burden of disease (*i.e., DALYs) due to STH infection.  
 
 
Figure 11:  Schematic Diagram of the Variables that were Used in the Estimation of 
Burden of Disease (i.e., DALYs) Due to STH Infection  
 
Note:  Highlighted boxes contain variables that have been calculated/ 
derived based on data/estimates from the literature while the remaining 
boxes show pieces of data/estimate from the literature. 
 
 
DALYs, together with information on the effectiveness and cost of different 
interventions, have served as guide in priority setting(108) by  providing a consistent 
measure of population health which can be used to evaluate the relative burden of 
different diseases and injuries and compare population health by geographic region 
and over time(194).  However, Pullan, et. al (2014) have also noted several limitations 
and implications on the use of DALYs for modelling the burden of  infectious diseases 
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like STH infections. In general, DALYs focus solely on health and do not capture the 
broader societal impact of diseases. This is especially true for STH, which have 
subtle, lasting impacts on child development and education.  Moreover, the indirect 
methods used to estimate the proportion of the infected population experiencing high 
intensity infections (and thus at risk of morbidity) are highly sensitive to the choice of 
model parameters used.  Mortality estimates could also be subjected to considerable 
ambiguity if data sources are unclear.   It was noted the need for future work to give 
attention on better quantifying these relationships, and incorporating uncertainty in 
resulting models(194). 
 
 
6.1.3. Effectiveness estimates per intervention strategy 
 
Estimated YLDs and YLLs for each STH infection under each intervention strategy 
have been subjected over a time course of 10 years consistent with the predicted 
prevalence output from the mathematical modeling.  To derive the DALYs averted over 
the 10-year period under each of the intervention strategy, computed total DALYs from 
Y1 to Y10 (period with intervention strategy) has been deducted from the computed 
total DALYs at baseline period,Y0  (period with no intervention) over the time course of 
10 years.  A 3% discounting rate was integrated in the computation to indicate the 
general preference for present consumption over future consumption(73) 
 
For each of the intervention strategy, DALYs at baseline period Y0 over the time 
course of 10 years have been computed as follows:  
 
 
 
 
On the other hand, DALYs from Y1 to Y10 (period with intervention strategy), have been 
computed as follows: 
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Aside from the DALYs averted, another health outcome effectiveness measure that this 
thesis looked at was the number of infections and reinfections averted as a result of 
the intervention strategy.  The process of deriving the number of infections and 
reinfections averted follows the same principle or process in estimating DALYs averted 
that has been described above.  We have also employed a 3% discounting rate and 
deducted the estimated total infections from Y1 to Y10 (period with intervention 
strategy) from the estimated total infections at baseline period Y0 (without intervention) 
for 10-year period.  The only difference was that we considered the number of 
infections rather than the YLLs and YLDs. 
 
To this point, we have so far presented the methods used in estimating and deriving 
the costs and impact (or health benefits) of the various treatment strategies. The other 
equally important component in conducting economic evaluation is to measure the 
impact of the intervention strategy in terms of health outcome. This study has 
considered two measures of effectiveness or health outcome, the DALYs averted and 
number of infections and reinfections averted.  These effectiveness measures have 
been discounted using 3% discount rate per annum over a 10-year period in order to 
place these effectiveness measures in the setting similar to what was applied during 
cost estimation.  
 
 
 
6.2. Estimated health outcome measures 
 
Table 20 presents the number of YLLs, YLDs, and DALYs averted for each treatment 
strategy both at the national and subnational levels.  A closer look at the table suggests that 
TA treatment strategy has the lowest DALYs averted while MB treatment has the highest 
health benefits.  This pattern can be observed at the national and across the subnational 
levels.  At the national level,  MB treatment has 6,295,180 DALYs averted, which is 47% 
higher than that of TA treatment (3,363,500).  While at the subnational level, MB treatment is 
higher by an average of 40% compared to TA treatment.  
 
Total DALYs averted across all treatment strategies are due to YLDs averted rather than 
YLLs averted.  For instance, MB treatment at the national level has estimated DALYs 
averted of 6,295,180, however, only 1.32% (83,046) of this is due to YLLs and the 98.68% is 
YLDs.  DALYs averted for all treatment strategies across subnational levels, has recorded 
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1.32% - 1.91% due to YLLs averted, the remaining is due to YLDs averted.  This would imply 
that treatment strategies on STH infections are geared towards saving years of disability 
rather than saving lives.   
 
 
Table 20:  Number of YLLs, YLDs, and DALYs averted over 10-year period for each 
treatment strategy both at the national and subnational levels 
Subnational/ 
National 
Groups 
TA treatment MA treatment TB treatment MB treatment 
YLL 
averted 
YLD 
averted 
YLL 
averted 
YLD 
averted 
YLL 
averted 
YLD 
averted 
YLL 
averted 
YLD 
averted 
DALYS averted DALYS averted DALYS averted DALYS averted 
Luzon 
30,475 1,846,488 46,179 2,822,825 38,953 2,616,047 47,211 3,531,757 
1,876,963 2,869,004 2,655,000 3,578,968 
Visayas 
10,478 634,877 15,878 970,570 13,393 899,474 16,232 1,214,265 
645,355 986,448 912,867 1,230,497 
Mindanao 
16,392 760,549 19,568 939,084 18,249 894,222 19,846 1,016,748 
776,941 958,653 912,471 1,036,594 
Philippines 
53,604 3,309,896 81,231 4,964,720 68,518 4,601,012 83,046 6,212,134 
3,363,500 5,045,950 4,669,530 6,295,180 
 
 
The estimated results of the other health outcome measures (i.e., number of infections and 
reinfections averted) are presented in Table 21.  The result supports the earlier findings 
when DALYs averted was examined wherein MB treatment strategy has the highest health 
outcome amongst the strategies and that TA strategy has the lowest.   
 
Looking at MB treatment, the number of infections and reinfections averted has been 
recorded to be at 374,035,602 for Luzon, 128,612,977 for Visayas, and 102,461,617 for 
Mindanao regions.   
 
On the other hand, TA treatment has it at 212,308,548 (Luzon), 72,997,940 (Visayas), and 
76,257,177 (Mindanao).   
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Table 21:  Number of infections and reinfections averted over 10-year period for each 
treatment strategy both at the national and subnational levels 
Subnational/National 
Groups 
Number of infection and reinfections averted 
TA treatment MA treatment TB treatment MB treatment 
Luzon 212,308,571 306,827,897 286,965,885 374,035,612 
Visayas 72,997,936 105,496,462 98,667,318 128,604,453 
Mindanao 76,254,112 94,908,695 89,930,787 102,461,617 
Philippines 379,175,146 539,644,594 504,707,537 657,455,484 
 
 
A breakdown of the estimated results for Table 20 is appended in Appendix I (Estimated 
Disability Adjusted Life Years (DALYs) averted for each intervention strategy for both 
national and subnational levels) and Table 21 in Appendix J (Estimated number of infections 
and reinfections averted for each intervention strategy for both national and subnational 
levels) 
 
 
6.3. Health outcome measures per person treated 
 
Table 22 presents some estimates on health outcome measures (i.e., DALYs averted, 
number of infections and reinfections averted) per person treated over a 10-year period. The 
table allows us to directly compare the island groups as they have different population sizes. 
 
Looking at the national level,  DALYs averted per person is highest under MB treatment 
strategy with 0.05 unit and lowest under TA treament with 0.03.  Within the island groups, 
under MB treatment, both Luzon and Visayas share the lead in terms of health benefit per 
person treated with 0.05 while Mindanao has it at 0.03.  The patterns are similar when we 
consider the number of infections and reinfections averted per person. 
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Table 22:  DALYs averted and number of infections & reinfections averted per person 
treated for each treatment strategy both at national and subnational levels over 
10 year period 
 
 
 
6.4. Summary 
 
This chapter outlined the overall methods, assumptions, and processes involved in 
examining the costs and impacts or health outcomes. The methods and processes used to 
estimate and derive the cost data and the impact or health benefits of the respective 
treatment interventions have been presented.  Several assumptions from the published 
literature have been used in the process to be able to come up with relevant estimates 
especially when local data or information are not available.   
 
 Subnational levels/island groups 
Philippines 
Estimated population Luzon Visayas Mindanao 
13.5% target population 52,362,998 18,003,940 21,968,174 92, 335,112 
DALYs averted 
TA tx 1,876,963 645,355 776,941 3,363,500 
MA tx 2,869,004 986,448 958,653 5,045,950 
TB tx 2,655,000 912,867 912,471 4,669,530 
MB tx 3,578,968 1,230,497 1,026,594 6,295,180 
DALYs averted per person treated 
TA tx 0.03 0.03 0.03 0.03 
MA tx 0.04 0.04 0.03 0.04 
TB tx 0.04 0.04 0.03 0.04 
MB tx 0.05 0.05 0.03 0.05 
Number of infecton and reinfections averted 
TA tx 212,308,571 72,997,936 76,254,112 379,175,146 
MA tx 306,827,897 105,496,462 94,908,695 539,644,594 
TB tx 286,965,885 98,667,318 89,930,787 504,707,537 
MB tx 374,035,612 128, 604,453 102,461,617 657,455,484 
Number of infection and reinfections averted per person treated 
TA tx 3.00 3.00 2.57 3.04 
MA tx 4.34 4.34 3.20 4.33 
TB tx 4.06 4.06 3.03 4.05 
MB tx 5.29 5.29 3.45 5.27 
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The chapter also presented the results of the impact to health outcomes of the four 
competing strategies over a 10-year period.  Two measures of effectiveness or health 
outcome have been examined - the DALYs averted and number of infections & reinfections 
averted.  Results on the estimated health outcome measures and health outcome measure 
per person treated show similar patterns both at the national and the subnational levels.  TA 
treatment strategy has the lowest DALYs averted, followed by TB and MA treatment 
strategies, respectively.  MB treatment has the highest health benefits.  The same 
sequence/pattern can also be observed when the number of infections and reinfections 
averted is examined. 
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CHAPTER VII.  ECONOMIC EVALUATION RESULTS 
 
This chapter starts with a brief overview of the economic evaluation results (7.1).  The 
results of the cost effectiveness ratio including the Cost Effectiveness (CE) frontier of both 
the outcome measures (i.e., cost per DALYs averted and cost per number of infections and 
reinfections averted) are presented (7.2).  This is followed by the presentation of the 
Incremental Cost Effectiveness Ratio (ICER) results (7.3).  To capture uncertainty in 
parameter estimates, sensitivity analyses have been carried out.  The results of such 
technique using scenario sensitivity analysis and probabilistic sensitivity analysis (PSA)  are 
presented under section 7.4 and 7.5, respectively.  Plotting the results of the sensitivity 
analyses, together with the willingness to pay thresholds is an effective technique to 
compare the alternative srategies and identify which among them is the most cost effective.  
The results of using the cost effectiveness plane and the cost effectiveness acceptability 
curve are presented under subsection 7.5.1 and 7.5.2, respectively.  After presenting the 
PSA model (i.e., parameter table) and decision tree (7.6), a summary conclusion on the cost 
effectiveness evaluation results (7.7) was given to end the chapter. 
 
 
7.1. Overview 
 
After examining the cost and health outcome impacts of the competing intervention 
strategies in the previous sections, we are now going to look at two cost effectiveness 
analysis measures – cost per DALYs averted and cost per number of infections and 
reinfections averted – for each of the control strategies both at the national and subnational 
(i.e., Luzon, Visayas, Mindanao) levels.  Scenario analysis was carried out looking at how 
the health outcome measures varied when only financial costs (i.e., disregarding economic 
costs) were considered in the analysis.  Probabilistic sensitivity analysis was undertaken to 
capture uncertainty in the underlying parameter estimates and the impact of this on decision 
uncertainty. 
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7.2. Cost Effectiveness ratio results and the CE frontier 
 
In a cost effectiveness analysis, treatment options are eliminated from the set of possible 
optimal choices based on their relative cost and effectiveness compared with another 
strategy. Strategy option is said to be dominated if it is both more costly and less effective 
than a comparator. Table 23 presents the summary of the cost effectiveness analysis for all 
the treatment strategies, on both effectiveness measures, over 10-year period per 
intervention strategy both at the national and the subnational levels.  After examining the 
result, TB treatment strategy (highlighted) is considered dominated and should be 
automatically eliminated from the possible choices for being both more costly and less 
effective than MA treatment.  This pattern where the TB treatment strategy is considered 
dominated is true when we look at DALYs averted and # of infection averted both at the 
national and the subnational levels 
 
 
Table 23:  CEA summary result on both effectiveness measures 
 
 
 
Among the remaining strategies, TA treatment has been considered as extendedly 
dominated in relation to MA treatment.  Although MA treatment has turned out to be more 
costly (with national cost estimate of $124M) compared to TA treatment ($104M), it offers 
cheaper  DALYs  than TA treatment does – paying $24.54 compared to $30.80 for a DALY.  
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This would mean choosing between MA treatment, wherein we buy more health for a lower 
cost per unit, or TA treatment, wherein we get less health for a higher cost per unit.  
 
Given such condition, one may opt to also remove TA treatment from the set of possible 
choices.  However, this study retains the TA treatment to be subjected to further analysis 
mainly for two reasons:  first, the presence of uncertainty might be such that this particular 
treatment strategy cannot truly be excluded from the frontier as cost effective acceptable, 
and second, extendedly dominated treatments that lie close to the frontier “might be 
considered a reasonable alternative…if there were non-economic reasons to prefer them, 
such as patient or physician acceptability, availability, or other factors”(195).  For the Philippine 
case, these factors can be related to the local’s low compliance with mass campaigns and 
some customs or traditional beliefs about the disease.  
 
The dominance condition from the CEA results presented in the table can be visually 
identified in a cost-effectiveness graph.  When effectiveness is plotted on the X-axis and cost 
on the Y-axis, a dominated strategy lies above and to the left of another alternative.  On the 
other hand, a strategy option situated below and to the right is referred to as dominant or 
dominating.  And since dominated options are often removed from the analysis, they are 
excluded from the cost-effective frontier. 
 
Figure 12 provides a visual summary of the national and subnational levels’ CEA results for 
all the intervention strategies with DALYs averted as effectiveness measure.  However, only 
those options which were not dominated were the ones connected by line segments defining 
the cost-effective frontier.   
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Figure 12:  Cost effectiveness graph showing the CE frontier with DALYs averted as 
effectiveness measure 
 
 
 
Plotting the values for the number of infections (including reinfections) averted in the cost-
effectiveness graph in Figure 13 has also resulted in a pretty much the same pattern of cost-
effectiveness frontier wherein TB treatment strategy has been eliminated in the set of 
possible optimal choices.  This pattern is also observed both at the national and subnational 
levels.   
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Figure 13: Cost effectiveness graph showing the CE frontier with number of infections and 
reinfections averted as effectiveness measure 
 
 
On the other hand, the intra-country variation of cost and effectiveness for each of the 
treatment options is also manifested from the tabulated CEA summary results.  Among the 
subnational groups, Mindanao, being the farthest to the DOH Central office (which is 
situated in Luzon), has the most costly (highest) CE ratio, 50%-61% higher than that of 
Luzon for all the treatment interventions.  On the other hand, Visayas recorded a slightly 
lower percentage increase of 52%-54% from that of Luzon across the four strategies. 
 
 
7.3. The Incremental Cost Effectiveness Ratio (ICER) results 
 
In a non-competing choice cost effectiveness, average cost effectiveness is used wherein 
one can simply divide the cost of the intervention by the effectiveness of the intervention.  
This means that one can have many possible options to choose from that are not mutually 
exclusive.  However, in most instances, we are faced with limited resources, putting us in a 
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situation where we have to choose the most cost effective (value for the money) option 
amongst several alternative interventions.  This is a situation wherein interventions are 
mutually exclusive (i.e., we can choose intervention A or B, but not both) and requires a 
different method of determining cost effectiveness called competing choice.  In choosing 
between or among different interventions, the competing choice method of CEA compels the 
use of Incremental Cost Effectiveness Ratio (ICER) to determine the marginal or incremental 
money spent for an additional unit of health benefit.   
 
Table 24 presents the incremental (change) costs and incremental health benefits, as well 
as the computed ICERs of the non-dominated intervention strategies, looking at both 
effectiveness measures both at the national and the subnational levels.  The estimated 
incremental changes for both cost and health benefits of a particular strategy were derived 
by subtracting its costs and health benefits from the respective costs and health benefits of 
the preceding non-dominated strategy.  So that the incremental costs and health benefits for 
TA treatment were computed with respect to the no intervention baseline; MA treatment with 
respect to TA treatment; and MB treatment with respect to MA treatment (since TB treatment 
has been eliminated from the possible choices).  Respective ICER of the non-dominated 
strategies is computed as the ratio of the change in cost and change in health benefits. 
 
Table 24: Incremental Cost Effectiveness Ratio (ICER) results on both effectiveness 
measures 
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ICER estimates with regard to DALYs averted at the national level were at $30.80, $12.01, 
and $56.65 for TA, MA, and MB strategy options, respectively. To determine the strategy 
with the best value for money, we have to move along the CE frontier until the ICER reaches 
the country’s WTP threshold level.  Given the country’s WTP threshold or threshold ICER 
(i.e., GDP per capita = $2,135), all the options turned out to be below the country’s ceiling 
ratio.  With this, we would end up choosing MB treatment as the most efficient choice.   
 
Moreover, in an undominated set of strategies, the ICERs will always increase as one moves 
to more costly option.  So that when the ICER goes down, this will indicate extended 
dominance.  Examining the respective ICER results from the table, TA treatment (vs. 
baseline) with ICER of $30.80 is higher than that of MA treatment (vs. TA treatment) with 
ICER of $12.01, thus eliminating TA treatment from the CE frontier for having been 
extendedly dominated.    
 
The pattern for choosing the MB treatment over the other strategies is the same for all the 
island groups.  The same pattern can also be examined for the other outcome measure (i.e., 
number of infections and reinfections averted), and that TA treatment has consistently been 
eliminated in all scenarios due to extended dominance.  
 
 
7.4. Scenario sensitivity analysis 
 
Scenario sensitivity analysis is the simplest form of sensitivity analysis wherein the value of a 
parameter in the model was simply varied to determine its impact to the model’s results.  
This study carried out a simple scenario analysis to examine ‘what ifs’ situations, in this 
case, what if we disregard volunteers time, donations, and other similar resource inputs (in 
short, we only considered the financial costs of programme implementation), ceteris paribus, 
how will this affect the ranking or list of choices which will be the basis of what intervention 
strategy to consider?   
 
Table 25 presents the result of the scenario analysis (i.e., considering just the financial cost) 
on ICER for both health outcome measures  over 10-year period for each of the intervention 
strategies both at the national and subnational levels.    Examining the result will show that 
there is a significant reduction in the respective ICERs for both national and subnational 
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levels.  ICERs at the national level has decreased significantly by 61%, 68%, and 65%, for 
TA, MA, and MB treatment strategies, respectively.   
 
 
Table 25:  Scenario sensitivity analysis result on Incremental Cost Effectiveness Ratio 
(ICER) for both effectiveness measures 
 
 
The results when plotted in the cost effectiveness graph would follow the same pattern when 
total cost was considered wherein TB treatment was considered dominated and TA 
treatment extendedly dominated in relation to MA treatment.  So that given the country’s 
WTP threshold, MB treatment would be chosen as the optimal treatment strategy for the 
country even if we just considered the financial cost of the programme.   
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7.5. Probabilistic Sensitivity Analysis 
 
The random results of the model at the national level over a 10-year period have been 
simulated for 1,000 trials from which the mean value of each parameter including the lower 
and upper credible intervals (C.I.) have been determined.  Macros commands were used to 
record the results of the Monte Carlo simulations for both the DALYs averted and the 
number of infections and reinfections averted (Appendix K). Table 26 presents the portion of 
the PSA worksheets showing the results of 1,000 simulations of this model examining two 
effectiveness measures – the DALYs averted (A) and the number of infections and 
reinfections averted (B).   
 
To determine which among the four intervention strategies gives the optimal value for 
money, some key parameters have been considered such as the mean ICERs (i.e., change 
to costs, and change to health benefits), net monetary benefits, and willingness to pay 
(WTP) thresholds.   
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Table 26:  Portion of the PSA derived by the results of 1,000 simulations with DALYs 
averted (A) and number of infections and reinfections averted (B) as 
effectiveness measures 
 
(A) DALYs averted as effectiveness measure 
 
(B) # of infections and reinfections averted as effectiveness measure 
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7.5.1. The cost effectiveness plane 
 
Figure 13 presents the results  of the PSA on the cost effectiveness plane with DALYs 
averted and number of infections and reinfections averted as effectiveness measures.  
The 1,000 bootstrapped results of incremental costs and incremental effectiveness per 
treatment strategy were used and plotted on the respective cost effectiveness planes.  
Each data point in the CE planes represents one simulated ICER of a particular 
treatment strategy.  Also presented in the CE planes are the respective mean ICERs 
(marked by asterisk) of each of the treatment strategy.  Among the four treatment 
interventions, TB treatment has been rejected on both effectiveness measures for 
being considered dominated (greater cost but lower health benefits) in relation to the 
other strategy (i.e., MA treatment).  The mean ICERs of the three non-dominated 
treatment strategies looking at DALYs averted as effectiveness measures (left) are 
estimated to be at $23.35, $30.41, and $27.56 for MA, MB, and TA treatment, 
respectively.  On the other hand, mean ICERs for treatment strategies with number of 
infections and reinfections averted as effectiveness measure (right) are recorded at 
$0.26, $0.33, and $0.31, following the same order of treatment strategies. The mean 
values, as well as the 95% upper and lower credible interval, of the bootstrapped 
ICERs  including other significant parameters are presented in the summary result in 
Table 26. 
 
Outlined also in the CE plane diagrams are the respective ceiling ratios or willingness 
to pay threshold levels.  On cost effectiveness grounds, treatment strategies situated 
above or to the left of the thresholds (i.e., ceiling ratios) are to be rejected and below it 
are to be accepted.  Examining the graphs, it is evident that there is a similar pattern 
for both health outcome measures (i.e., DALYs averted and number of infections and 
reinfections averted) as to how the strategies are situated in relation to the threshold 
levels.  All the strategies have been situated below or to the right of the WTP 
thresholds (note that TB treatment is already not a feasible option for being considered 
dominated).  In accordance with the criteria set by the WHO Choosing Interventions 
that are Cost–Effective project (WHO-CHOICE)(196), the three remaining treatment 
strategies are considered to be highly cost-effective interventions for having ICERs 
below the country’s GDP per capita threshold (i.e., Threshold 1) estimated to be at 
$2,135(197) .   
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Figure 14:  Cost effectiveness plane with the ceiling ratio on ICER considering 
effectiveness measures 
Note: DALYs averted (above) and number of infections and reinfections 
averted (below) as effectiveness measures 
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The use of threshold based on per capita GDP, which has been promoted by WHO-
CHOICE(198), has been the most common approach in evaluating health interventions.  
There have been a number of CEA of health interventions in low income countries that 
refer to this approach as the standard to determine whether an intervention is cost-
effective or not(152).   Marseille, E., et al. (2015), however, challenged the use of such 
thresholds based on per capita GDP in terms of its worthiness to guide policy-makers.  
One of the major limitations cited was that it reduces the value of CEA by making such 
analyses too blunt or obscure to be considered useful in public health decision making. 
An intervention could be classified as cost–effective under such thresholds; however 
there could be other needed interventions or activities with ICERs below the threshold 
that could represent the best use of a country’s health budget. It puts a little value in 
evaluating trade-offs that decision makers have to deal with. The other shortcomings 
that mentioned included the following: lacks theoretical justification, skirts the tedious 
yet important ranking of the relative values of locally-applicable interventions and 
disregards what is truly affordable(152).  
 
In view of the limitations in using thresholds based on per capita GDP, other 
alternative methods to evaluate cost–effectiveness of health interventions have been 
made and which can be adopted.   
 
One option that can be used as threshold for cost-effectiveness acceptability is the 
cost–effectiveness of benchmark interventions that have already been established and 
practiced in other countries (152, 199, 200).  This approach can address some issues with 
regard to local relevance that was seen in the use of GDP per capita threshold.  
However ICERs of the benchmark interventions can be high or low outliers and that 
benchmark results are just occasionally updated missing changes on opportunity costs 
resulting from new technologies or changes in the burden of disease(201). 
 
 
7.5.2. The Cost Effectiveness Acceptability Curve (CEAC) 
 
Figures 15 and 16 show the generated cost effectiveness acceptability curves 
(CEACs) of the four treatment strategies with effectiveness measures of DALYs 
averted and number of infections and reinfections averted, respectively.  Based on the 
distribution of the ICERs as plotted in the corresponding cost effectiveness planes, 
CEACs of each of the four treatment strategies have been outlined.  The CEACs 
presented on both figures depict how the probabilities of each of the treatment 
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strategies behave (i.e., increase or decrease) as regards their cost effectiveness as a 
function of the willingness to pay (WTP) for 1 additional unit of effect (i.e., DALYs 
averted and # of infection averted, respectively). 
 
For Figure 15, the CEACs demonstrate that by using the GDP per capital and total 
expenditure on health per capita thresholds to determine the probability that the 
intervention is CE acceptable, MB treatment has the highest probability on both 
occasions with 65.6% and 58.9%, respectively.  This has been followed by the MA 
treatment with just 21.9% and 27.4%, and TA treatment 0.7% and 1.4%, all 
probabilities in the same order of threshold level.  This clearly suggests that MB 
treatment would be chosen for having the optimal benefit given the country’s threshold 
considerations.   
 
 
Figure 15:  Cost effectiveness acceptability curve with DALYs averted as the 
effectiveness measure 
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However, public policy decisions are most of the time largely determined by political 
will/feasibility, some ideological and bureaucratic considerations, and even lobby 
groups.  These factors can affect the acceptability of programme interventions and 
merit the use of other alternative approaches that will be based on some acceptable 
level of cost-effectiveness.  Scenarios that reflect those conditions can be manifested 
in the CEAC graph wherein willingness to pay thresholds are at the lower threshold 
levels.  For instance, if the WTP threshold decreases to say, $60, $40 and $20, the 
probability of CE acceptability of MB treatment decreases to just 41.4%, 30.2%, and 
6.3%, respectively.  In fact, at these levels of WTP thresholds, MA treatment would 
rather be adopted with higher CE acceptability of 41.8%, 51.5%, and 62.0% 
probabilities, respectively.  In a WTP threshold of $60.5, an indifferent point between 
MA and MB treatments occurs wherein the decision maker can either choose between 
the two since both have 42% probability of CE acceptable.  
 
A similar pattern of result can be examined in Figure 16 wherein the MB treatment has 
the highest probability of being CE acceptable using the GDP per capital and total 
expenditure on health per capita thresholds (not shown in the figure). It has recorded a 
probability of 71.8% and 71.7%, respectively, compared to just 18.0% and 18.1% for 
MA treatment.  And at lower levels of WTP thresholds, say, $0.40 and $0.20, MA 
treatment would have the best value for money with 53.7%, and 59.9% probabilities, 
respectively.  Point of indifference between MA and MB treatments occur at $0.58 both 
with 42% probabilities. 
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Figure 16:  Cost effectiveness acceptability curve with # of infection averted as the 
effectiveness measure 
 
 
Table 27 presents the summary results of the PSA that were carried out comparing the 
four treatment strategies with effectiveness measures as DALYs averted and # of 
infection averted.  The table contains the mean, as well as the 97.5% lower and upper 
credible interval values, of selected parameters such as cost increases, cost savings, 
changes to costs and health benefits, and corresponding ICERs of the four treatment 
strategies.  The values presented in the table have been determined by simulating 
1,000 trials the result of the randomly drawn value from each parameter based on the 
set probability distribution. 
 
The table also consists of information as to the probability distribution that each of the 
four intervention strategies’ 1,000 bootstrapped ICERs would end up either in quadrant 
I, II, III, or IV.  Various scenarios of threshold levels including national thresholds (i.e., 
GDP per capita and Total expenditure on health per capita) to determine the 
probability of CE acceptability of the four intervention strategies have also been 
presented.    
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Table 27:  Summary result of the PSA carried out comparing the four treatment strategies 
with (A) DALYs averted and (B) number of infections and reinfections averted as 
the effectiveness measures 
(A) DALYs  averted as the effectiveness measures 
 
 
 
(B) Number of infections and reinfections averted as the effectiveness measures 
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7.6. PSA model and Decision Tree 
 
Using spreadsheet that follows a decision tree technique (please refer to previous Figure 6), 
a simple decision analytical model was developed to evaluate the expected cost-
effectiveness acceptability of the four treatment strategies.   
 
The decision tree that inspired this study’s decision analytical model aims to identify the 
optimal cost-effective parasite control strategies from among the four competing 
interventions (i.e., MB, MA, TB, and TA treatment).  Individuals living in a given locality, 
possibly, could either be infected with any of the STH infections (i.e., ascaris, trichuria, and 
hookworm) or no infection at all.  This study further looked at those hookworm-infected 
individuals because of the great risk of morbidity (i.e., YLDs) being attributed to people who 
suffer anemia due to hookworm infection(151).  At the end of each infection arm is the 
probability of staying alive or ending up dead.  It should be noted, however, that it is unusual 
for STH to kill their human hosts(41) and that death cases, if any, could occur only with 
Ascaris infection. 
 
The decision tree requires quality data on resources costs, impacts or health benefits, and 
chance events, to present the natural history of the competing options.  After attaching the 
respective values of all the structures, evaluation is then made by going back to the decision 
node (i.e., from endpoints to decision node).  However, it was noted that the available cost 
data collected from the Philippines did not specifically identify the STH infection that they 
had served.  The data have been recorded, in general, under the whole deworming 
programme and not disaggregated according to the type of infection.  In such case, 
estimated and derived cost data for STH have been considered to be the total cost under 
each of the intervention treatment/strategy.  A spreadsheet was developed eventually 
incorporating the techniques of a decision tree.   
 
Table 28 lists the parameters used in the PSA model with the respective middle value used 
and derived credible interval values. 
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Table 28:  Parameters used in the PSA model with the respective middle value used and derived credible interval values 
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In the PSA model that was used in this study, the DALYs averted, all the cost centers 
categories (i.e., programme running, community sensitization and screening, training, drug 
distribution and treatment, and production and distribution of IEC materials) as well as other 
economic costs were characterized as distributions to capture parameter uncertainty 
inherent in this captured data.  Specific consideration was given to volunteers’ time (i.e., 
BHWs and BNSs share to economic costs) since this cost item is considered as one of the 
‘big ones’ or largest component part in the cost of delivering STH intervention, yet it is often 
being missed-out in many economic evaluations of health services.  Aside from that, precise 
determination of the magnitude of time being spent by the volunteers in the conduct of their 
deworming tasks has become extremely difficult to carry out.   
 
The distribution type that was used in implementing the PSA was mostly normal distribution 
except for the volunteer’s time parameter.  All the cost parameters including DALYs averted 
parameter adopted the normal distribution to describe the mean value of the randomly cost 
variables.  It used a standard deviation (s.e) of 20% of the identified parameter’s middle 
value and set at CI=97.5. On the other hand, a uniform distribution was used in the 
volunteers’ time parameter to show that there is a continuous or constant probability within 
all the intervals or values (+/- 1M of the respective middle values) set in each treatment 
strategy.  The number of DALYs averted utilized gamma distribution while wage equivalent 
of the volunteers were set at constant value.  
 
 
7.7. Summary 
 
Economic evaluation results show that TB treatment strategy is considered dominated for 
being both more costly and less effective than MA treatment.  This pattern is true when we 
look at DALYs averted and number of infections and reinfections averted both at the national 
and the subnational levels.  The intra-country variation of cost and effectiveness for each of 
the treatment options is also manifested from the CEA summary results, wherein Mindanao, 
being the farthest to the DOH Central office (which is situated in Luzon), has the most costly 
(highest) CE ratio, 50%-61% higher than that of Luzon for all the treatment interventions. 
Visayas recorded a slightly lower percentage increase of 52%-54% from that of Luzon 
across the intervention strategies. 
 
Considering the country’s WTP thresholds (i.e., GDP per capita of $2,135 and the total 
expenditure on health per capita of $202) or threshold ICERs, all the undominated options 
turned out to be below the country’s WTP thresholds allowing them to be considered as CE 
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acceptable.  In such scenario, it would be practical and logical to select among the CE 
acceptable strategies the one that gives the highest health benefit. Probability Sensitivity 
Analyses that were carried out show that MB treatment has the highest probability on both 
thresholds (i.e., GDP per capital and total expenditure on health per capita) with 65.6% and 
58.9%, respectively.  This is followed by the MA treatment with just 21.9% and 27.4%, and 
TA treatment 0.7% and 1.4%, all probabilities in the same order of threshold level.  This 
clearly suggests that MB treatment would be chosen for having the optimal benefit given the 
country’s threshold considerations. The pattern for choosing the MB treatment over the other 
strategies is the same for all the island groups as well as on both outcome measures. 
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CHAPTER VIII.  DISCUSSION 
 
This chapter summarizes and discusses the key findings from this research.  The initial 
section provides an overview/brief dicussion (8.1) that answers the research questions that 
have been identified earlier. After which, synthesis and interpretation of the main results 
(8.2) was carried out focusing on the cost data collected, the impact to health outcome, and 
the economic evaluation of the program interventions.  The future research direction or 
potential to extend this research are examined and discussed (8.3) as well its effect on 
policy making.  The overall contributions, limitations, and weaknesses (8.4) of this research 
is given before the chapter summarizes/concludes (8.5). 
 
 
8.1. Overview 
 
This research provides estimates of the financial and economic delivery cost and health 
outcomes associated with 4 different and competing STH control strategies (i.e., Mass or 
community-wide and annual drugs (MA) treatment; Targetted and annual drugs (TA) 
treatment; Mass or community-wide and biannual drugs (MB) treatment; and Targetted and 
biannual drugs (TB) treatment) in the Philippines.  In terms of health outcomes measures, 
this research provides estimates in terms of DALYs averted and number of infections and 
reinfections averted. It demonstrates that the most efficient option is mass biannual (MB) 
although this conclusion is associated with some degree of uncertainty. This finding that MB 
treatment option is the optimal parasite control strategy in terms of frequency (ie. Annual vs. 
biannual) and mode of delivery (ie. Mass vs. targeted) is consistent across island groups 
suggests that a blanket national policy of MB treatment would be the most efficient control 
option in this context. 
 
8.2. Synthesis and interpretation of the results 
 
8.2.1. Cost Data Collected 
The cost of delivering the STH control program in the country is spread across the 
three levels of government (i.e., regional, provincial, city/municipal) as shown from 
the results, however, the funds for the program are mainly held at the national level.  
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This is despite the devolution of health service delivery in the country in 1991.   Most 
of the economic costs in relation to the country’s helminth programme delivery are 
being borne by the lower levels of government (i.e., LGUs). Moreover, unnecessary 
costs incurred include the additional purchase of anti-helminth drugs and the 
production of IEC materials by some LGUs when anti-helminth drugs and other 
related materials are already provided by the central office through the regional 
CHDs, which could imply some duplication of activities that are not efficient. 
 
 
Comparison of findings on cost per person treated 
 
Comparing the estimated cost per person treated as previously presented in Table 
19 to the findings of other studies that were presented in Chapter 3 (i.e., Systematic 
Review of Economic Evaluation Studies)  would reveal the following conclusions and 
interpretations:  
 
First, in terms of the total cost per person treated, the estimated cost per person is a 
bit higher in the Philippines, with $0.97 for Targeted Annual (TA) treatment, 
compared to school-based treatment reported in Uganda with $0.93(18).  Uganda’s 
$0.93 cost per person treated was derived by combining the financial cost ($0.93) 
and economic cost ($0.54).  It should be noted, however, that the Uganda study has 
evaluated STH together with Schistosomiasis and that a once a year delivery was 
assumed since there was no mention in the study about the frequency of the 
treatment delivery.  Comparison result of this study in terms of the total cost per 
person treated has turned out to be insignificant when compared with that of other 
country indicates some degree of generalizability of findings with other settings.  
 
Second, when just the financial cost of treatment delivery is considered, the 
Philippines has a comparable TA treatment cost per person treated of $0.38 per 
annum, compared to the school-based treatment delivery in Uganda, Burkina Faso, 
and Tanzania with $0.39(18), $0.32(129), and $0.23(130), respectively.  Uganda and 
Burkina Faso have considered STH and Schistosomiasis together, while the figure 
for Tanzania was separated for STH. 
 
Lastly, in terms of studies looking singly at STH, the Philippines’ cost per person 
treated (i.e., considering just the financial cost) is lower than that of Nigeria on both 
Targeted and Mass treatment strategies.  The Philippines has $0.38 and $ 0.44 
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compared to Nigeria’s $2.76 (approx: NGN 20.40) and $1.39 (approx: NGN 
10.30)(131) for Targeted and Mass chemotheraphy, respectively.  And even if we 
consider the biannual treatment delivery in the Philippines, it has still a lower 
(financial) cost per person treated ($0.58 and $0.67, respectively). 
 
Comparing the cost per person treated among the different island groups shows that 
both Visayas and Mindanao are more expensive than Luzon by average of 53% and 
41%, respectively.  Even when just financial cost is considered, both island groups 
are still more expensive than Luzon by 68% and 66%, respectively.  This is due to 
the more difficult terrain both Visayas and Mindanao island groups have and a wider 
dispersed populace compared to Luzon; thus, requiring the use of more resources to 
treat the people.  
 
Several studies(202-206)showed  that in general, average cost in rural areas with some 
covering mountainous areas similar to Nepal(207), is higher than in urban areas in 
terms of transport, supervision and training. The process of scaling up will be also 
problematic in the short run due to the lack of physical infrastructure in the usually 
underdeveloped rural areas. Lack of roads, supply chain and other basic 
infrastructure elements may be detrimental for a country to scale up, make 
communication and training more difficult, or otherwise substantially increase prices 
in new areas of coverage. Additionally, remote areas are more likely to have less 
highly trained personnel, requiring more supervision, support, and motivation. 
 
Given these conditions, possible implications when scale up/change in the 
intervention design could be that the Visayas and Mindanao regions need to attract 
more volunteers such as BHWs and BNS, including the assistance of barangay 
kagawad members, in order to reach and cover a wider population during the 
delivery of the programme. On the other hand, Luzon needs to step up and 
maximize its resources proportionate to the large population they serve. 
 
 
Impact of opportunity costs to sustainability and mode of programme delivery 
 
Opportunity (i.e., economic) cost comprises the majority of the cost of the 
programme for all the treatment strategies (Table 8).  Implementation of a particular 
programme could run smooth for as long as these resource inputs are being 
provided continuously.  However, uncertainties that hamper the sustainability of the 
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programme being implemented in this world are present.  One adverse situation is 
the lacking of volunteers and health care workers. Generally, in multiple studies(208-
212), it was shown that there is a higher absence rate of health workers in poorer 
regions and developing countries. This difference was seen to arise because health 
care workers have more opportunities to moonlight at other jobs, or because health 
workers receive smaller wages relative to what they would earn in the private sector. 
 
Moreover, another problem is when there is a slowdown or stoppage of drugs being 
donated.Geographic access is an important part of accessing health care in low to 
middle income countries. Good roads, which is rare in poor areas of developing 
countries most to be found in the Visayas and Mindanao, are required for easy 
access of both the drug suppliers and the people needed to treat.(213)The WHO-
CHOICE mentioned how the cost of expanding coverage increase due to the 
transportation costs especially in remote areas because the items needed have to 
be shipped greater distances.Further, there is an increase need for supervisory trips 
and drug re-supply. These circumstances result to the reassessment of the 
programme to contain the impact of such situations. 
 
Given the devolved setting of health services in the country, respective LGUs would 
eventually need to step-up to fill in the gaps in implementing the programme. These 
LGUs need to come up with necessary strategies and means to support the 
operationalization of the program.  However, not all LGUs have equal capacity to do 
so and local chief executives have the different ways of prioritizing various social 
health programmes within their jurisdictions.  In addition, switching to a targeted 
programme, may not be possible even if it costs the same in total as the current 
program if it relies on more financial costs e.g. laboratories that require an actual 
budget, rather than volunteers/donations.   
 
Moreover, other reasons that could affect the sustainabiltiy of the programme 
include the level of the government’s political will and international agendas where 
health intervention priorities are set.Although it is generally accepted that national 
policies and conditions influence economic growth, poverty, and other determinants 
of health status, there is relatively little systematic evidence about how national 
policies and conditions affect the different patterns of health services. An important 
exception are the studies of ‘good health at low cost’ cited for China, Costa Rica, 
Cuba, Kerala, and Sri Lanka. These studies demonstrated that long-term political 
commitment to equitable coverage both of education and health services and of high 
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levels of social participation led to high rates of health service use and better health 
status, even though these countries had diferent political and economic policies(214). 
 
Despite the importance attributed to pro-poor health policies, it was seen in several 
studies(215-217)that in practice, it has not yet been a clear priority for many national 
governments. Studies on benefit incidence in low to middle income countries 
revealed that for nearly all countries, public spending on health disproportionately 
benefits wealthier citizens. Health policymakers should also be aware that 
macroeconomic, labor, and social policies have the potential to limit or enhance 
health opportunities for different groups in the population. International aid agencies 
and governments in developing countries should be aware that the search of liberal 
macroeconomic pro-growth policies has the tendency to provide better opportunities 
to those without these assets are unlikely to benefit and may in fact become 
casualties of economic transition. Thus, it is the duty of health policymakers to signal 
when other policies may undermine efforts to promote health equity. Recognizing 
the political commitment with emphasis on public health to social and economic 
interventions would help in the sustainability of disease-focused models that are 
continued to be funded and promoted in developing countries(218). 
 
 
8.2.2. The Impact to Health Outcome 
Health outcome measure – DALYs averted 
 
The finding that majority of the DALYs averted are due to reduced disability rather 
than lives saved is primarily because STH infections does not usually kill the human 
hosts(41).  Worldwide burden of disease due to STH infections has been estimated to 
be at 5.2 million DALYs(79), wherein almost half of it is borne by children 5 to 14 years 
of age(7).  In the Philippines, the burden of these intestinal nematode infections in 
2010 has been estimated to be at 359 thousand DALYs and almost one-third of it 
came from children in that range of age(66) and comprise 22% of the country’s 
population. Micronutrient deprivation with peak worm burdens and increased 
nutritional requirements associated withpoor personal hygiene and frequent outdoor 
exposures explain why preschool-age children (1-4 years) and school-age children 
(5-14 years) are particularly vulnerable and at greater risk of morbidity due to 
STHs(219). 
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One of the limitations of the underlying model in estimating the health benefits is that 
it assumed that the programme has the same impact for localities in each 
subnational level.  Some issues have also been raised that multiple chronic sequelae 
of many infectious diseases were not taken into consideration in burden analyses 
such as the DALY measure(220).  Helminth infection sequelae are associated with 
both physical and cognitive well being such as anemia, malnutrition, stunted growth, 
and learning development delays(6).  In addition, the absence of data to analyze the 
impact of coinfections (e.g., STH and malaria contribute to anemia and low weight 
status) could underestimate the disease burden of STH infection.  It should, 
therefore, be recognized that DALYs may not properly capture the full range of long 
term potential benefits of the STH programme to the society, making the positive 
effect of the programme underestimated.   
 
Despite this, DALY is used in the Philippines by the health sector as recommended 
by the WHO and the World Bank who fund most implemented health programmes. 
Programmes such as the calculation of smoking-attributable burden of lung 
cancer(70), the return on investment of needle syringe programs in HIV infections(71),  
and the feasibility and cost-effectiveness study of DOTS-Plus for Multi-Drug 
Resistant Tuberculosis (MDR-TB) (72)use DALYs to consider mortality with age at 
death, incidence of various types of adverse health conditions with age at onset, 
prevalence of morbidities with severity, duration and sequelae, and remission rates. 
Accounted for the use of DALY in the study is its ability to infuse information about 
non-fatal health outcomes such as STHs into debates of health inequalities, the only 
measure to do so. The increasing popularity of DALYs and burden of disease 
estimates clarified that for STHs that mainly cause morbidity rather than mortality, the 
average disability incurred by a diseased individual is crucial for correctly compiling 
data to global burden estimates.  
 
Aside from permeating information of non-fatal health outcomes, DALYs also 
dissociate social and epidemiological assessment of health inequalities from 
advocacy. It allows comparison of efficiency to other disease programmes and is 
suggested to be used in generalized CEA(73).  It is an approach to evaluate a wide 
range of alternative strategies for chronic diseases and disabling health conditions to 
identify the optimal health care programme given only limited resources(88), a setting 
that is present in the Philippines.  In addition, it also measure the magnitude of 
premature death and non-fatal health outcomes attributable to proximal biological 
causes, including diseases and injuries or attributable to more distal causes such as 
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poor living standards as in the case of STHs, tobacco use or socio-economic 
determinants. Finally, DALYs is a reasonable measure since it can be used for 
purposes of comparisons either between different communities or between different 
points of time(74).  
 
Among the subnational groups, Luzon turned out to have the biggest impact in terms 
of health benefits (both on DALYs averted and number of infections and reinfections 
averted) compared to Visayas and Mindanao (Tables 20-22).  This might be the case 
since the initial prevalence of infection for the region was set higher compared to the 
other region, specifically in Mindanao.  The other reason could be attributed to the 
cost efficiency of the region in the management and delivery of the program. 
 
Possible reasons on the less efficient management and delivery of the program in the 
rural areas (mostly Visayas and Mindanao) include limited health facilities, 
professionals, and resources despite the devolved setting of health care system in 
the Philippines. There is currently more health facilities such as hospitals and 
hospital beds in Luzon. Autonomous Region in Muslim Mindanao (ARMM) has the 
least number of hospitals, whereas Southern Tagalog in Luzon has the most with 176 
private hospitals and 95 government hospitals as of 2004. In rural areas, healthcare 
facilities are limited to lay-in and barangay clinics. In terms of human resources for 
health, compared to most asian countries, the Philippines is producing more and are 
based in Metro Manila and other urban centers. Health care professionals in rural 
areas are typically social workers and midwives. Moreover, the proportion of 
household that visited a health facility is higher for urban (80 percent) compared to 
rural (72 percent) households with the largest number of visits made in Visayas 
followed by Mindanao. Possible explanations include poorer health status in the 
Visayas and Mindanao than in Luzon or less effective care necessitating many 
repeat visits. The situation is worsened by the fact that many provincial and district 
hospitals have inadequate budgetary support after devolution and have lost 
managerial autonomy(221);(222). 
 
The enormous relative impact of the program using the metric number of infections 
and reinfections averted over ten (10) years, is explained because the force of 
transmission at baseline is so high.  Given this condition, what happens is that a 
number of people clearly are infected and by the time the next round of treatment 
comes up, they are reinfected.  This would bring us back to issue on the trade-off 
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between drug resistance and the ability to actually break that transmission cycle and 
eliminate the infection. 
 
 
8.2.3. Economic evaluations of the program interventions 
 
Optimal choice and the most likely cost-effective strategy 
 
Results in the cost effectiveness analysis that was carried out show that TB 
treatment was considered dominated and was automatically eliminated from the 
possible choices.  TA treatment has been considered as extendedly dominated in 
relation to MA treatment which offers cheaper DALYs  thereby getting more health for 
a lower cost per unit.  Given such condition, one may opt to also remove TA 
treatment from the set of possible choices.  However, this study retains the TA 
treatment to be subjected for further analysis mainly for two reasons.  First, 
uncertainty might be such that this particular treatment strategy cannot truly be 
excluded from the frontier as cost effective acceptable.  Second, extendedly 
dominated treatments that lie close to the frontier “might be considered a reasonable 
alternative…if there were non-economic reasons to prefer them, such as patient or 
physician acceptability, availability, or other factors”(195).  In the case of the 
Philippines, these factors could be related to the local’s low compliance with mass 
campaigns and some customs or traditional beliefs about the disease.  
 
To determine which among the intervention strategies gives the optimal value for 
money, considerations were given to ICERs (i.e., change to costs, and change to 
health benefits), and willingness to pay (WTP) thresholds.  Subjecting the results to 
some form of sensitivity analysis would affirm the selection’s robustness to decision 
uncertainty. 
 
The use of GDP per capita threshold, threshold 1 
 
ICER estimates with regard to DALYs averted at the national level were at $30.80, 
$12.01, and $56.65 for TA, MA, and MB strategy options, respectively. To identify the 
strategy with the best value for money, we have to move along the CE frontier until 
the ICER reaches the country’s WTP threshold level.  Given the country’s WTP 
threshold or threshold ICER (i.e., GDP per capita = $2,135) as recommended by the 
WHO, all the undominated options turned out to be highly cost-effective interventions 
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for having ICERs below the country’s GDP per capita threshold(197).  Comparing 
treatment options, we would end up choosing MB treatment as the most efficient 
choice for having the highest health benefit compared to MA strategy.  This 
conclusion is considered robust taking into account the level of threshold and the 
number of health outcome we get by choosing MB treatment.   
 
The use of threshold based on per capita GDP, which has been promoted by WHO- 
Choosing Interventions that are Cost–Effective project (WHO-CHOICE)(198), has been 
the most common approach in evaluating health interventions.  There have been a 
number of CEA of health interventions in low income countries that refer to this 
approach as the standard to determine whether an intervention is cost-effective or 
not(201).   Marseille, E., et al. (2015), however, challenged the use of such thresholds 
based on per capita GDP in terms of its worthiness to guide policy-makers.  One of 
the major limitations cited was that it reduces the value of CEA by making such 
analyses too blunt or obscure to be considered useful in public health decision 
making. An intervention could be classified as cost–effective under such thresholds; 
however there could be other needed interventions or activities with ICERs below the 
threshold that could represent the best use of a co untry’s health budget. It puts a 
little value in evaluating trade-offs that decision makers have to be dealt with. The 
other shortcomings that have been mentioned include the lacking of theoretical 
justification, skirting the tedious yet important ranking of the relative values of locally-
applicable interventions and disregarding what is truly affordable(201).  
 
In view of the limitations in using thresholds based on per capita GDP, other 
alternative methods to evaluate cost–effectiveness of health interventions have been 
made and which could be adopted.   
 
One option that could be used as threshold for cost-effectiveness acceptability is the 
cost–effectiveness of benchmark interventions that had been established and 
practiced in other countries (201, 223, 224).  This approach could address some issues 
with regard to local relevance that was seen in the use of GDP per capita threshold.  
However, ICERs of the benchmark interventions could be high or low outliers and 
that benchmark results are just occasionally updated missing changes on opportunity 
costs resulting from new technologies or changes in the burden of disease(201). 
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The use of Total expenditure on health per capita threshold, threshold 2 
 
Another alternative approach is  to utilize the country’s total expenditure on health 
per capita as threshold level (marked in the graph as Threshold 2).  This study 
believes that the use of such threshold is more robust compared to the GDP per 
capita in determining an intervention’s acceptability and better value for money.  It 
primarily limits and focuses the analyses to what is only available in the realm of the 
health sector. For instance, out of the country’s GDP per capita of $2,135(197), the 
total expenditure on health per capita was at $202(225), a value which is more 
meaningful when we look at how much was spent on individual’s health. The 
country’s health spending level could depend on several factors such as the 
country’s income, overall government’s fiscal capacity, demographic structure, 
disease pattern, and time, among others(226). 
 
Using the new ceiling constraint (i.e., threshold 2), the remaining strategies were still 
able to qualify to be considered as CE acceptable.  Given the same scenario pattern 
in threshold 1, it would still be practical and logical to choose MB treatment for 
delivering the highest number of health benefits.   
 
We must also acknowledge however, that there is some uncertainty in this decision 
given that there is an approximately 40% chance of being wrong and that another 
option is preferred. This may make decision makers reluctant to act on the mentioned 
results since they may be very risk averse if this is a political area. Moreover, it is a 
big program considering its nationwide scope of delivery, that there is likely a high 
cost of getting it wrong, and that decision would be difficult to reverse.  Especially at 
the lower levels of government where various social services programs that needs to 
be prioritized compete to a pot of limited resources, making such decisions would be 
very difficult and sometimes unpleasant. 
 
 
Cost Effective ratio (i.e., cost per DALYs averted) compared 
 
Table 23 presents the subnational and national estimated cost per DALYs averted for 
all the intervention strategies.  The country’s cost per DALYs averted were estimated 
to be at $30.80, $24.54 and $30.91 for TA, MA, and MB treatment strategies, 
respectively.  Although the CE ratio estimates for the STH treatment strategy in the 
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Philippines could be considered as better buys in public health when compared to the 
cost per DALYs averted of US$257 – US$4,565 for measles vaccination(227)and 
US$48-US$303 for Lymphatic Filariasis vector control(2) , it is apparently more costly 
than estimates from other helminthiasis related studies.  For example, Hotez, et al., 
estimated that in low- and middle-income countries with just 1 million people and 
whose treatment is limited to school-age children treated 1.1 times per year with 
albendazole and taking into account some reinfections, the cost per DALY averted 
for STH infections is estimated only at US$3.41.   This estimate could increase when 
we looked at countries with bigger population, like the Philippines.  Costs increased 
to a range of US$8 - US$19 in combination treatment with praziquantel (PZQ) for 
schistosomiasis(41). On the other hand, cost per DALYs averted for Lymphatic 
Filariasis MDA programme have been estimated to be within the range of US$4 to 
US$29(2, 228).  
 
The derived costs per DALYs averted from the Philippines, however, turned out to be 
within the WHO’s second most cost-effective band of less than US$150 per DALY 
saved(229).  Moreover, the derived values from the Philippines are close to the 
estimated cost per DALYs averted when cost sharing was examined in relation to 
echinococcosis disease in humans and livestock.   A cost of less than US$25 per 
DALYs averted has been estimated for human health sector after responsibilities for 
control costs were divided proportionally between the public health sector (human 
health-related benefits) and the agricultural sector (livestock-associated benefits)(230). 
 
 
Incremental Cost Effective ratio (ICER) compared 
 
In a situation where we are faced with mutually exclusive alternatives, determining 
the marginal or incremental (rather than the average) money spent for an additional 
health benefit is very critical in identifying the alternative with the best value for 
money.  This is so because we are oftentimes faced with limited resources that we 
have to choose the most cost effective option among several alternative 
interventions.  This is very relevant in low to middle income countries like the 
Philippines.  
 
Given the estimated national ICERs with regards to DALYs averted at $30.80, 
$12.01, and $56.65 for TA, MA, and MB strategy options, respectively, as well as the 
country’s WTP threshold levels, all the undominated interventions turned out to be 
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cost effective following the criteria set by the WHO-CHOICE(196).   However, in 
determining the best value for the money, the strategy with ICER closest to and 
below the given threshold will be chosen. With this, we have ended up with MB 
treatment as the most efficient choice, which gives the highest health benefit.  The 
pattern for choosing the MB treatment over the other strategies is the same across 
the island groups, and the other outcome measure (i.e., number of infections and 
reinfections averted).  Such decision has also proven to be stable even after 
subjecting such result into the scenario analysis and PSA.  
 
In the Philippines, the results of this project can be adopted by the primary public 
health provider, the Department of Health (DOH), since it would be the one who will 
most likely benefit in terms of the economical aspect of policy making in the 
systematic approaches and strategies for the prevention and control of soil-
transmitted helminth (STH) infections and diarrheal diseases in support of their 
projects such as the Integrated Helminth Control Program (IHCP) and the Food and 
Waterborne Diseases Prevention and Control Program of the DOH. Together with its 
intersectoral alliances, the Department of Environment and Natural Resources 
(DENR) and the Department of Public Works and Highways (DPWH), Centers for 
Health Development (CHD), and the local government units (LGUs), the DOH can 
achieve the goal of enabling health service providers and other stakeholders to make 
provisions for early diagnosis, treatment, prevention, and control of these diseases 
consistent with existing diseases consistent with existing disease control 
programs(139). 
 
The World Health Assembly Resolution 54.19 in 2001 urged member countries to 
reduce STH infections through school-based mass drug administration among 
school-age children. The IHCP of the DOH aims to reduce the prevalence rates of 
STH infections among children, adolescent females, pregnant women, and other 
special occupational groups by MDA. From mass annual in 1999 to July 2003, the 
Philippines shifted to a mass biannual for high risk school-age children while only 
once in a year for the low-risk children(126, 139). This research has shown that, overall, 
it is more cost-effective in all three islands to cover a blanket national policy of 
administering control strategy intervention twice a year. This finding will help cut the 
screening of the community into high risks and low risks categories and instead treat 
all communities as high-risk by administering treatment biannually.  If there will be 
further shifting in the frequency of administration, it will eventually accomplish the 
goal of controllng STHs and proceed eventually with elimination. 
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The issue of drug resistance of the treatment has been recognized; nevertheless, it 
was not factored into the model because there was no available reliable data on what 
the level of resistance these drugs have.  Moreover, the prevalence estimates that 
were developed by the people in the team did not also take these issues into 
account.  It should be noted that MB treatment is probably the only one that actually 
has the capacity to eliminate these infections.  There have been a lot of papers and 
discussions about the shift in focus in the management of STH interventions 
away from just wanting to control the morbidity associated with STH infection to 
actually wanting to eliminate infection.  The aim is to break the transmission rather 
than just keep treating morbidity.  Probably, the optimum strategy in terms of meeting 
that goal, as well as to eliminate the infection and the issue of drug resistance, might 
actually be better strategy.  Although the treatment might be the one that has the 
most potential to create resistance, breaking the transmission early would actually 
lead to the elimination of the infection. 
 
 
8.3. Policymaking and Potentials to Extend this Research 
 
Although a number of economic evaluations of helminth control have been conducted in 
various parts of the world such as Cambodia(16), China(17), and Uganda(18), none has been 
done for the Philippines to our knowledge. This research can be considered as one of the 
pioneer studies in conducting full economic evaluation of multi-parasite control strategies for 
the Philippines. Evidenced-based policy making cannot solely rely on a single study thus, 
there is a need for policy makers and the researchers that support them to utilize all partially 
relevant studies that are already available and conduct further studies to add to the current 
body of knowledge.  
 
Due to the diverse need for various helminthic disease (e.g. schistosomiasis, soil-transmitted 
helminthiasis), strong district health systems that are nationally-owned serve as main 
requirements for a successful, cost-effective and sustainable control of these neglected 
diseases. In order to achieve true integration of disease control, the interventions must be 
adapted as local priorities using locally-owned resources and targeting those at greatest 
need. It is proposed to have a system of real-time and flexible monitoring to allow adaptation 
of strategies and targets for the control programmes. Aside from the environment, the 
demographic, health and social systems contextx need to be considered(231).  
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Since this study has only examined the perspective of the public healthcare provider, 
extending the research to consider other non-health sectors (i.e., society perspective) in the 
picture would somehow give more value to the equation.  The world is emerging and 
demanding wherein programmes are expected to be approached in a more holistic manner.  
Moreover, it has already been recognized that bringing non-health sector in the equation has 
significance in evaluating some disease or risk factors(140).  Conducting such a research 
would fill the vacuum that this study has set aside due to time and resource constraints.  
Some non-health components of the programme that could be considered include Water, 
Sanitation and Hygiene (WASH), specifically provision of safe, adequate and sustainable 
water supply, better infrastructure, and installation of low cost technology and culturally-
acceptable sanitation facilities. 
 
Evaluation studies on interventions among the neighboring countries is not comprehensive 
as cost-effectiveness and economic or opportunity costs of delivering the programme were 
not estimated(19-21). Presence of variation was also evident as in those with full evaluations, it 
was found out that the mass treatment strategy was more cost-effective compared to no 
control(16) and targeted treatment(17) strategies which is in contrast to the typically low in the 
Philippines(11).  Thus, the conduction of this economic evaluation (i.e. CEA) comparing mass 
versus targeted treatment was essential in guiding the country’s health sector 
policy/decision-makers come up with a solid basis for a parasite control policy in the 
Philippines.  
 
In addition, this research opens up multiple opportunities for the country’s health sector, both 
at the national and local levels, as well as challenges to revisit and reasses how programme 
planning and health intervention priorities are being done. Currently, CEA are being used by 
the national health agency (i.e., DOH) in the planning and priority setting, however, such 
technique is not available in the lower levels of government, wherein the setting varies 
accordingly. In addition to this, the devolved set-up of health services in the country should 
further warrant the use of CEA in setting priorities. Adopting more test-proven systems to 
evaluate the cost effectiveness of programmes and strategies would give more health 
benefit for every money and resources spent by the government.  
 
One of the issues in the Philippines is that majority of programs have been subjected to an 
economic evaluation in order to come up with the most effective path for investment.  
However, it is actually very difficult to rank or prioritize interventions in this manner because 
only partial evidence has been considered.  In addition, in terms of priority setting and policy, 
Chapter 8. Discussion 
 
 
Garcia, Fernando Jr., n8415790, School of Public Health and Social Work, QUT Page 176 
 
the Philippines have been exploring effective intervention techniques to implement STH 
programs.  As a matter of fact, the STH program has been on the Department of Health’s 
radar and the fact that the Department has recently moved to buy a new program indicates 
that it's actually quite high up in their agenda.  
 
Moreover, in the international context, the country is in a fitting situation at the moment 
wherein the grand scheme of things, not to mention its global commitment, is on the 
declaration to control and target STH infections.  There are also big collaborative 
arrangements with the drug companies through drug donations.  Such enabling components 
create a lot of momentum in implementing the STH program.  That would also kind of bump 
up the priority issue as compared to other health issues because if resource components do 
not capitalize on, say drug donation or subsidization, concerned agencies might faced 
challenging situations ten years down the track. 
 
Furthermore, this research has already came up with robust and spatial-based costs in 
implementing deworming programme from various levels of government (i.e., provincial, 
city/municipal levels), investigating and deriving the respective health benefits in these levels 
of government would be valuable.  Moreover, generating spatial maps and conducting the 
spatial analysis in relation to the programme’s cost-effectiveness would be very useful for 
decision makers to identify problematic areas that need to be monitored. 
 
 
8.4. Overall contributions, limitations and weaknesses 
 
This research has been approached in a very rigorous manner.  It has been innovative in 
that cost data have been collected in the field taking into account the devolved set-up of the 
country’s healthcare delivery systems.  A multi-levelled data collection method was 
developed and carried-out to collect and cram related non-financial and opportunity costs in 
the delivery of the STH program.  This is in addition to the usual methodology that a number 
of studies took wherein cost data were just based on project reports and just considered 
financial expenditure.  In a systematic review recently published by Turner, et. al. (2015), it 
was found that oftentimes works done were basically based on financial expenditure and it 
was not really set within a decision making framework(232).  This research is very innovative 
because a lot of the issues that were raised in that review have been avoided or addressed.  
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Taking a national approach to evaluation and breaking it down by islands groups also 
manifests innovativeness of this research.  This is essential to understand whether there is 
actually variation between the different settings especially in an archipelagic country like the 
Philippines.  This research has also been innovative in that different thresholds for cost 
effectiveness have been utilized.  Aside from the WHO recommendation of the country’s 
GDP per capita, a more stringent technique of using the country’s total expenditure on health 
per capita was applied.   The discussion on how the findings could actually be converted to 
policy on both national and local levels of government, taking into account the cost 
effectiveness and budgetary constraints, can also be considered as innovative of this study. 
 
The finding that MB is the optimal parasite control strategy in terms of frequency (ie. Annual 
vs. biannual) and mode of delivery (ie. Mass vs. targeted) is consistent across island groups 
suggests that a blanket national policy of MB would be the most efficient control option in 
this context. The study  adds to the currently limited body of knowledge of full economic 
evaluation studies on parasitic disease intervention strategies. It would be of great benefit to 
the national and local health planners in coming up with efficient decisions in the future using 
systematic approach to evaluate disease control strategies. As the STH Control Programme 
is still being improved in the Philippines to come-up with an integrated and coordinated 
approach to sustain delivery of services in a devolved environment(27), the findings and 
results of this research can be used to further improve the design and 
implementation/delivery of the programme in order to get the best value for money.  
Moreover, this research will further enrich the current discourses on the burden of diseases 
and on the economic evaluation of disease strategies, and thus, be able to influence future 
studies in these areas. 
 
The study examined the STH intervention strategies in terms of frequency and mode of 
delivery and eventually subjected the strategies to a cost effectiveness analysis that 
determined a national programme policy to be more appropriate in providing valuable 
information for decision and policy making at various levels of government in the Philippines. 
Moreover, it contributes in the international field as findings such as cost per person treated 
and cost per DALYs averted have shown to be generalizable to other countries with similar 
settings of goverment.  The methods and data collection tool used in this research has been 
patterned with the standards and practices identified in published literature.  The multitude 
processes used in this research can be applied as well in evaluating other parasitic 
diseases, such as schistosomiasis, looking at similar control programs. 
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As this study has worked on the estimates from a complimentary team that used 
mathematical modeling  in order to predict the prevalence of the STH infections in the 
Philippines, the study’s estimation of health benefits is bounded with the parameter output of 
the said team.  It should also be noted that the forecasted prevalence rates that were used in 
this study have been based at the barangay (village) level.  This study could have more 
precise estimation of health benefits should the forecasted prevalence rates have been at 
the same level of spatial resolution where cost data of this study have taken. Nevertheless, 
the forecasted prevalence used, which were sourced from the barangays, have been 
presented within the respected subnational regions (i.e., Luzon, Visayas, Mindanao) were 
cost data have also been examined.  In the absence of needed data specific to the situation 
being studied, several assumptions which were based from the published studies were used 
and have been properly acknowledged. 
 
Limitations in relation to costs could come from the assumptions used to scale-up the cost 
that has been collected in each level of administration/government.  Moreover, assumptions 
to estimate the cost in each of the remaining strategies based on the scaled-up cost have 
also been recognized as limitations.  These assumptions, however, were all based from 
published literature. 
 
Limitations in the calculation of health outcome measures (i.e., DALYs and number of 
infections and reinfections averted) could come from the used of assumptions that have 
been obtained from the literature.  This also includes issues and limitations that comes with 
the use of burden of disease measures such as DALYs.  
 
The selection process in identifying localities where data cost were collected could also be 
considered as a limitation of this study.  However, time constraints as well as safety and 
security during the period of data collection have been considered in the process.  
 
Lastly, this thesis has worked within the realm of disease control and prevention rather than 
elimination.  It should be noted that the parameters used in this study were taken on the 
perspective of controling the infection.  Bringing the elimination aspect would require a wider 
facet and other sectors of the society; thus, would skyrocket the cost component that has 
been estimated in this study. 
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8.5. Conclusions 
 
To answer the identified objectives set in this study, a decision analytical modeling was 
developed and used.  Both financial and economic cost of one mass treatment being 
implemented was collected and scaled-up. From this result, the remaining intervention 
strategies have been estimated/derived. Measures of health outcome such as DALYs 
averted and number of infections and reinfections averted were used to test treatment 
strategy whether it is most likely be cost-effective.  Several assumptions based on published 
literature were used to build the building blocks of this study (i.e., cost and the health 
outcomes measures).  Parameters and decision uncertainties have been addressed by 
employing several sensitivity analysis in the process.   
 
The findings that MB treatment is the optimal choice have proven to be robust to decision 
uncertainty after subjecting it to some probability sensitivity analysis and consideration of 
financial versus economic costs.  Moreover, the findings turned out to be stable across a 
wide range of willingness to pay thresholds (i.e., the country’s GDP per capita and Total 
expenditure on health per capita).  This all suggests, therefore, that there is a high level of 
confidence in the decisision to choice MB treatment as the optimal strategy with the best 
value for money.  And since the findings are also stable across the country’s island groups, a 
blanket national strategy is the most appropriate for the Philippines. 
 
In order to achieve the vision of IHCP, all sectors concerned must be committed considering 
that helminth infection is a multi-faceted problem. Aside from the LGUs which are primarily 
responsible in the control of the infection, the support of DOH, DepEd and other national 
government agencies including the private sector, civil society and the community is very 
important to the success of IHCP. 
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Appendix B:  Metapopulation model for STH transmission and control in the 
Philippines
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Appendix C:  List of DOH Regional Offices (CHDs) and LGUs where cost data have 
been collected 
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Appendix D:  Cost and Data Collection Tool 
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Appendix E: Memorandum from the Office of the Secretary, Department of Health 
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Appendix F: Copy of the Informed Consent Form 
 
INFORMED CONSENT FORM 
We are researchers from the College of Public Health, University of the Philippines 
Manila and the Queensland University of Technology, Australia who are conducting a 
research study entitled “An Economic Evaluation of Multi-Parasite Control Strategies in the 
Philippines”. 
The general objective of this research is to conduct a cost-effectiveness analysis 
(CEA) of multi-parasite (i.e., Schistosomiasis and Soil-Transmitted Helminthiasis) control 
strategies that are being implemented in the Philippines. In order to achieve this objective, 
we need to conduct field visits and interviews to key individuals who are directly involved in 
the management and delivery of the programmes (i.e., Regional Directors, Provincial Health 
Officers, Provincial Health Team Leaders, Municipal Health Officers, and 
Schistosomiasis/STH Coordinators).   This study will be conducted in all regions, 30 
provinces, and 60 municipalities in the country, including your good office.  Provinces and 
municipalities have been purposively selected to ensure a balance and well-represented 
disease prevalence rate levels (i.e., low, moderate, and high). 
Your voluntary participation is requested so we may learn more about the financial 
and economic costs of helminth control programme strategies being implemented in your 
locality.  Our questionnaire/interview will take 45-60 minutes to complete.  The information 
that you will provide will be a major input in the conduct of economic evaluation of 
helminth strategies that will be use to guide in crafting responsive parasite control policy 
and to improve the delivery of health services in the country. 
Again, your participation is voluntary and you may choose not to answer any of the 
questions or items on the data collection tool even after signing the consent form.  No 
penalty will be imposed even if you decide to end your participation at any time.  Moreover, 
you are assured that all information related to your personal identity will be kept 
completely confidential.  Personal information will only be revealed when you provide 
permission or being summoned by legal authorities. 
This research study will not involve direct reward or payment to you as participants.  
However, the information that you’re going to share will be of great help to the 
government, particularly the health sector, to effectively design helminth control 
programme interventions.  
If you have any questions about this research study, you may contact Prof. Fernando 
Garcia Jr. at mobile number 0921-4660422 or email address nuj_garcia@yahoo.com 
/ fernandojr.garcia@student.qut.edu.au. 
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An Economic Evaluation of Multi-Parasite Control Strategies in 
the Philippines 
 
INFORMED CONSENT FORM 
I have read and understood the information provided in this consent form.  I was 
given the opportunity to ask questions about the research study and discern the 
answers given. 
I understand that the procedures contained in this study involve minimal/low risks. 
With this in mind and with the above description of the research study, I agree to 
take part in the study.  I have received a copy of this consent form to keep for myself 
and have read and understand all of it. The researcher/s have explained the things 
that I did not understand.  Therefore, I voluntary agree to participate in the study. 
  
          Printed Name      Signature   Date 
__________________________      ________________     ______________ 
__________________________      ________________     ______________ 
__________________________      ________________     ______________ 
 
Witness: 
          Printed Name      Signature   Date 
__________________________       ________________     ______________ 
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Appendix G: Summary of Current Regional Daily Minimum Wage Rates 
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Appendix H:  Mathematical Modeling’s Predicted/Forecasted Prevalence of the Four Control Strategies 
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Appendix I: Estimated Disability Adjusted Life Years (DALYs) averted for each 
intervention strategy for both national and subnational levels 
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Appendix J: Estimated number of infections and reinfections averted for each 
intervention strategy for both national and subnational levels 
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Appendix K: Macros used to record the results of the Monte Carlo simulations 
 
1. Probabilistic Sensitivity Analysis – DALYs averted 
 
2. Probabilistic Sensitivity Analysis – Number of infection and reinfections averted 
 
 
 
Sub Simulation_PSA_Jun() 
Index = 0 
Trials = 1000 
Do 
    Range("B6:Y6").Select 
    Selection.Copy 
    Range("B8").Select 
    ActiveCell.Offset(Index, 0).Range("A1").Select 
    Selection.PasteSpecial Paste:=xlPasteValues, Operation:=xlNone, SkipBlanks _ 
        :=False, Transpose:=False 
        Index = Index + 1 
        Loop While Index < Trials 
End Sub 
 
Sub Simulation_PSA_Jun() 
Index = 0 
Trials = 1000 
Do 
    Range("B6:Y6").Select 
    Selection.Copy 
    Range("B8").Select 
    ActiveCell.Offset(Index, 0).Range("A1").Select 
    Selection.PasteSpecial Paste:=xlPasteValues, Operation:=xlNone, SkipBlanks _ 
        :=False, Transpose:=False 
        Index = Index + 1  
        Loop While Index < Trials 
End Sub 
 
